

**UNIVERSIDADE FEDERAL DE PERNAMBUCO
CENTRO DE BIOCÊNCIAS
PÓS-GRADUAÇÃO EM BIOQUÍMICA E FISIOLOGIA**

Cnidoscolus sp DA CAATINGA: FITOQUÍMICA E ATIVIDADES BIOLÓGICAS

PÂMELLA GRASIELLE VITAL DIAS DE SOUZA

**Recife - Brasil
2017**

PÂMELLA GRASIELLE VITAL DIAS DE SOUZA

Cnidoscolus sp **DA CAATINGA: FITOQUÍMICA E ATIVIDADES BIOLÓGICAS**

Tese apresentada ao Programa de Pós-Graduação em Bioquímica e Fisiologia do Centro de Biociências da Universidade Federal de Pernambuco como parte dos requisitos, para obtenção do título de Doutora em Bioquímica e Fisiologia.

ORIENTADOR: Prof. Dr. Nicácio Henrique da Silva

**Recife - Brasil
2017**

Catálogo na fonte

Elaine Barroso

CRB 1728

Souza, Pâmella Grasielle Vital Dias de
***Cnidoscolus urens* da Caatinga: fitoquímica e atividades biológicas./**

Recife: O Autor, 2016.

214 folhas: il., fig., tab.

Orientador: Nicácio Henrique da Silva

Tese (doutorado) – Universidade Federal de Pernambuco. Centro de Biociências. Bioquímica e Fisiologia, Recife, 2016.

Inclui referências e anexos

1. Fitoquímicos 2. Euphorbiaceae 3. Caatinga I. Silva, Nicácio Henrique da (orient.) II. Título

572.2

CDD (22.ed.)

UFPE/CCB-2017- 561

PÂMELLA GRASIELLE VITAL DIAS DE SOUZA

***Cnidoscolus sp* DA CAATINGA: FITOQUÍMICA E ATIVIDADES BIOLÓGICAS**

Tese apresentada ao Programa de Pós-Graduação em Bioquímica e Fisiologia do Centro de Biociências da Universidade Federal de Pernambuco como parte dos requisitos, para obtenção do título de Doutora em Bioquímica e Fisiologia.

Banca Examinadora:

Profo. Dr. Nicácio Herique da Silva (Presidente)

Profa. Dra. Vera Lúcia de Menezes Lima (Membro Interno)

Profa. Dra. Maria da Paz Carvalho da Silva (Membro Interno)

Profa. Dra. Mônica Cristina Barroso Martins (Membro Externo)

Profo. Dr. Antônio Fernando Moraes de Oliveira (Membro Externo)

DATA: 17 / 02 / 2017

Dedico esta tese a todos que torceram para que tudo que eu buscava nesta fase de minha vida, desse certo. Em especial e com amor aos meus pais Valdilene e Waldecio, ao meu irmão Khayo, ao meu noivo Emanuel. Com muito carinho aos meus avós Vonício (*In Memoriam*) e Marlene, M^a Ivonilde e Valdecio, aos meus tios Walberlene, Valdenilson, Vonicio, Waldenio e Waldson e por fim, porém extremamente importante, ao meu orientador Dr. Nicácio.

AGRADECIMENTOS

À Deus que sempre caminhou ao meu lado, segurando minha mão e que sempre mostrou a mim e minha família uma janela;

À minha amada mãe Valdilene, que com a força do seu amor, me proporcionou a maior riqueza que um ser humano pode ter, através do seu árduo trabalho, os estudos e ao meu pai amado Waldecio que sempre batalhou com toda sua força para me proporcionar uma vida digna com muito amor, juntos dedicaram suas vidas para fazer de mim a pessoa que sou hoje;

Ao meu irmão querido Khayo pelo companheirismo, carinho de nossa infância até hoje e pelo empenho para ajudar a realizar um sonho dos nossos pais, muito obrigada;

Ao meu companheiro Emanuel, pelo incentivo de ir sempre à luta, pela sua dedicação e admiração;

Aos meus avós Vonicio (*In Memoriam*) e Marlene, Ivonilde e Valdecio pelo amor e carinho dedicado;

Aos meus tios Bela, Nilson, Vonicio, Waldênio, Waldson, Lúcia, Iram que torceram para que eu pudesse vencer mais esta fase;

Aos meus primos Pablo e Pedro que são como irmãos, pelo seu carinho e consideração;

A meu primo Tiago que me ajudou com seu entendimento científico;

A todos os meus familiares que um pouco mais distantes, mas, desejaram-me todo sucesso;

À minha sogra Lucinha que com a sua fé, torceu por mim;

Aos meus amigos Ewerton, Nathalie, Pamella, Rafael, Raquel pelo companheirismo e amizade verdadeira que dura até hoje, juntos sempre;

Ao meu amigo Tiago pela sua imensa disposição em estar comigo na finalização deste trabalho;

A minha amiga Janaína, companheira de experimentos;

À Mônica amiga de Laboratório, que me ajudou com suas orientações e sua experiência;

A todos os meus amigos do Laboratório de Produtos Naturais; Bruna, Alexsandra, Ana Paula, Amanda, Joelma;

Aos técnicos amigos de laboratório João e Albérico que sempre estiveram dispostos a ajudar;

A Prof^a. Dr^a. Vera por acolher-me em seu laboratório;

Ao meu orientador Prof. Dr. Nicácio por ser tão dedicado e empenhado a pesquisa, por ter acreditado no meu objetivo e me acolhido em seu laboratório;

A todos que de forma direta ou indireta, contribuíram para a realização deste trabalho;

A todos que sempre torceram pela minha vitória.

A todos, muito obrigada!

RESUMO

Conhecida popularmente por “urtiga” ou “cansação”, *Cnidoscolus urens* é uma espécie pertencente a família Euphorbiaceae, endêmica da Caatinga. Bastante conhecida pela presença de pelos urticantes. Segundo conhecimentos populares, esta espécie é utilizada como fitoterápico, utilizando-se principalmente raiz e caule para o tratamento de muitas enfermidades, tais como inflamação da próstata e cistos ovarianos. Em estudos fitoquímicos, metabólitos secundários como flavonóides, antraquinonas, terpenos, taninos, antocianinas, esteróides e xantinas, foram detectados em extratos orgânicos de *C. urens*. O presente estudo objetivou investigar o perfil fitoquímico e avaliar o potencial antitumoral, antidiarreico e inseticida dos extratos aquoso e orgânico de *C. urens* coletadas em Caruaru/ área de Caatinga-PE. Para tanto, foi investigado por cromatografia de camada delgada (CCD), os metabólitos secundários produzidos por *C. urens* presente em extratos aquoso, acetato de etila e n-butanólico. A toxicidade foi verificada seguindo o guideline OECD. Para a atividade antitumoral, utilizou-se ensaios antiproliferativo *in vitro* sobre células de linhagem HELA e *in vivo*, em animais com carcinoma de Ehrlich induzido, sendo tratados com extrato aquoso e etanólico, administrados numa concentração igual a 200mg/kg. A atividade antidiarreica foi averiguada pelas metodologias sobre o efeito nas fezes normais, diarreia induzida por óleo de rícino, ensaio de enteropooling e trânsito intestinal por carvão ativado, para tal, os animais foram tratados com extrato etanólico de partes aéreas (folha, semente e flor) de *C. urens*. Quanto a atividade inseticida, o extrato metanólico e também suas frações: éter, clorofórmio, acetona e metanol, foram avaliados quanto a sua toxicidade por ingestão e contato, além do índice de deterência alimentar. Os testes fitoquímicos demonstraram a presença de taninos, flavonoides, açúcares redutores, terpenos e cumarinas. No modelo de atividade *in vitro* o extrato aquoso e etanólico (Aq200 e EtOH200) demonstraram moderada ação citotóxica para as metodologias testadas para os modelos *in vitro* (MTT e Vemelho neutro). Para a atividade *in vivo*, os extratos Aq200 e EtOH200 produziram um percentual de redução do crescimento tumoral igual a 84.4% e 79.2%, além de causar uma melhora representativa do perfil bioquímico e hematológico. Todos os extratos de *C. urens* foram avaliados quanto a sua toxicidade e não mostrou ação tóxica na dose máxima testada (2000mg/kg). Quanto a avaliação antidiarreica o extrato etanólico de partes aérea de *C. urens* nas doses de 200 e 400mg/kg, mostraram excelentes resultados. Para o ensaio de diarreia induzida por óleo de rícino foi observado uma redução no número total de fezes (7.0 e 7.2), respectivamente, para o ensaio que avalia o acúmulo de fluido,

a redução foi de 23.4 e 20.8 para as concentrações de 200 e 400 mg/kg, respectivamente. Já a avaliação do trânsito intestinal os resultados encontrados foram iguais a 36.3% para EtOH200 e 25.5% para EtOH400. Os extratos de *C. urens* também foram testados quanto sua ação inseticida e mostrou-se ser um potente agente. Para os testes inseticida, duas metodologias diferentes foram utilizadas, avaliando a ação inseticida por ingestão e contato. Quando espécies de *Sitophylos zeamais* foram expostos a uma dieta contendo MeOH (0.18; 0.25; 0.5 mg/g) e MeOHFrac (0.25- 0.5 mg/g) foi observado uma indução de 27 a 90% e 33 a 91% de mortalidade por ingestão, respectivamente. O percentual de mortalidade por contato foi avaliado para os mesmos extratos nas concentrações de 50 e 100 µg/mL e apresentou 45 a 75% e 77 a 87% de mortalidade respectivamente. A LC_{50} também foi determinada, tanto por ingestão para MeOH e MeOHFrac (LC_{50} = 0.241 mg/g e LC_{50} = 0.11 mg/g, respectivamente), quanto por contato para os mesmos extratos (LC_{50} =0,012 µg/inseto e LC_{50} = 0.026 µg/inseto), também respectivamente. Essas metodologias também nos permitiram avaliar que os extratos induziram mudanças significativas nos índices nutricional, além de induzir rejeição do alimento disponibilizado durante o ensaio. Todos estes resultados contribuem para confirmar a hipótese popular de que *C. urens* possui ação antitumoral, antidiarreica e inseticida. Estes resultados corroboram com o enriquecimento bibliográfico científico e contribuem para uma perspectiva na produção de novos fármacos e agentes inseticidas mais eficazes e com menor efeitos adversos.

Palavras-chave: *Cnidoscolus urens* (Euphorbiaceae). Antitumoral. Antidiarréia. Atividade inseticida.

ABSTRACT

Popularly known as "nettle" or "cansação" *Cnidoscolus urens* is a species belonging to the family Euphorbiaceae, endemic to the Caatinga. Well known for the presence of stinging. According to popular knowledge, this species is applied as fitoterápico, using mainly the root and stalk for the treatment of many diseases, such as inflammation of the prostate and ovarian cysts. In phytochemical studies, secondary metabolites such as flavonoids, anthraquinones, terpenes, tannins, anthocyanins, steroids and xanthines were detected in extraneous organs of *C. urens*. The present study aimed to investigate the phytochemical profile and evaluation of the antitumor, antidiarrheal and insecticidal potential of the aqueous and organic extracts of *C. urens* collected Caatinga area in Caruaru - PE area. Therefore, it was investigated by thin layer chromatography (TLC), secondary metabolites produced by *C. urens*. The toxicity was observed following the OECD guideline. or antitumor activity, *in vitro* antiproliferative assays on HELA lineage cells and *in vivo* in animals with induced Ehrlich carcinoma were treated with aqueous and ethanolic extract, administered in a concentration equal to 200mg / kg. The antidiarrheal activity was investigated by the methodologies on the effect on normal feces, castor oil-induced diarrhea, enteropooling test and activated carbon intestinal transit. The animals were treated with ethanolic extract of aerial parts (leaf, seed and flower) of *C. urens*. Regarding the insecticidal activity, the methanolic extract and also its fractions: ether, chloroform, acetone and methanol, were evaluated for their toxicity by ingestion and contact, besides the food deterrence index. Phytochemicals tests showed the presence of tannins, flavonoids, açúrcos reducers, terpenes and coumarins. In the model of activity *in vitro* the aqueous extracts and ethanol (Aq200 and EtOH200) showed moderate cytotoxic action for the methodologies. For the *in vivo* activity, and Aq200 EtOH200 produced a reduction of percentage of tumor growth equal to 84.4 and 79.2%, and cause a representative improved biochemical and haematological profile. All *C. urens* extract was evaluated for toxicity and showed no toxic action at the maximum tested dose (2000mg / kg). The evaluation antidiarrheal ethanol extract of aerial parts of *C. urens* in doses of 200 and 400 mg / kg, showed excellent results. For diarrhea assay induced by castor oil has been observed a reduction in the total number of stools (7.0 and 7.2), respectively, to test that evaluates the accumulation of fluid, the reduction was 23.4 and 20.8 for concentrations of 200 and 400 mg / kg, respectively. Since the

evaluation of the intestinal transit the results were equal to 36.3% for EtOH200, and 25.5% for EtOH400. The extracts of *C. urens* were also tested for their insecticidal action and proved to be a potent agent. For the insecticide tests, two different methodologies were used, evaluating the insecticide action by ingestion and contact. When *S. zeamais* species were exposed to a diet containing MeOHC.*urens* (0.18, 0.25, 0.5 mg / g) and MeOHFrac (0.25- 0.5 mg / g) an induction of 27 to 90% and 33 to 91% of Mortality on ingestion, respectively. The percentage of contact mortality was evaluated for the same extracts at concentrations of 50 and 100 µg / mL and presented 45 to 75% and 77 to 87% of Mortality, respectively. LC₅₀ was also determined, both by ingestion for MeOHC.*urens* and MeOHFrac (LC₅₀ = 0.24 and LC₅₀ = 0.11, respectively), and by contact for the same extracts (LC₅₀ = 0.012 and LC₅₀ = 0.026, respectively). Allowed to evaluate that the extracts induced significant changes in the nutritional indices, in addition to inducing rejection of the food available during the test. All these results contribute to confirm the popular hypothesis that *C. urens* has antitumor, antidiarrheal and insecticide action. These results corroborate with the scientific bibliographic enrichment and contribute to a perspective on the production of new drugs and insecticides more effective and with less adverse effects.

Key words: *Cnidoscolus urens* (Euphorbiaceae). Antitumor. Antidiarrhea. Insecticidal activity.

LISTA DE FIGURAS

CAPÍTULO I:

REVISÃO DE LITERATURA

Figura 1: Distribuição geográfica do gênero <i>Cnidoscolus sp</i> no Brasil.	38
Figura 2: Distribuição geográfica da espécie de <i>C. urens</i> no Brasil.	39
Figura 3: Aspectos gerais de partes de <i>C. urens</i> .	41
Figura 4: Incidência de diferentes tipos de câncer no Brasil.	44
Figura 5: Etapas de instalação do câncer.	45
Figura 6: Desenvolvimento e modificações genéticas para o surgimento da carcinogênese	46
Figura 7: Esquema simplificado da patogênese do câncer.	46
Figura 8: Estrutura química da uracila, à esquerda e do 5- fluorouracil, à direita.	48
Figura 9: Esquema do mecanismo de ação do 5- Fluorouracil. Reação anabólica e catabólica	48
Figura 10: Via alternativa envolvendo a timidina sintetase, resultando em dano ao DNA.	49
Figura 11: Lúmen do trato gastrointestinal.	50
Figura 12: Proporção de óbitos por doenças diarreica aguda em > de 5 anos de idade.	52
Figura 13: Espécies de insetos pragas que estão associados com os prejuízos e perdas da produção de grãos e frutas no Brasil.	58
Figura 14: Características das fases do <i>Sitophilus zeamais</i> .	59
Figura 15: (A) Exemplar de inseticida de origem vegetal, (B) <i>Azadirachta indica</i> , (C) Estrutura química da azadiractina	61

CAPÍTULO II:

Figure 1. Antiproliferative activity of extracts of <i>Cnidoscolus urens</i> in HELA cells by MTT method (A) and Neutral Red method (B). P< 0.05 for all analysis as compared with Aq group.	108
Figure 2. Effect of <i>C. urens</i> extracts on footpad thickness (A) and EC solid tumor weight (B).	109

Figure 3. Radical scavenging activity of *Cnidoscolus urens* extracts by DPPH method. *P < 0.05 for all analysis as compared with Aq group. _____ **110**

CAPÍTULO III:

Figure 1: Effect of MeOHC. *urens* (200 and 400 mg/ kg) extract of *C. urens* on enteropooling induced by castor oil in mice. P < 0.001 vs. Control _____ **137**

CAPÍTULO IV:

Figure 1: Diagram of production of raw extracts and partitioning of extracts of *C. urens*. ____ **146**

Figure 2. Percentage of mortality by ingestion of *S. zeamais* exposed to different concentrations of MeOHC.*ures* and MeOHFrac of *C. urens*. P < 0.05 for all groups compared to control ____ **151**

Figure 3. Evaluation of the anti-feeding action of *S. zeamais* grown in artificial diets (0.18 - 0.5 mg / g of wheat flour). (A) Rate relative to biomass gain (RBGR) indicates a biomass (mg) gained every day per mg of initial body weight. (B) The percentage of conversion of ingested food (ECI%) indicates the amount of food consumed and converted to insect mass. (C) A relative consumption rate (RCR) indicates an amount of food consumed by *S. zeamais* (mg) per mg of body weight per day. _____ **154**

Figure 4. Percentage of mortality by contact of *S. zeamais* exposed to different concentrations of extracts of MeOHC.*ures* and MeOHFrac of *C. urens*. * P < 0.05 for all groups compared to control . _____ **156**

LISTA DE TABELAS

CAPÍTULO I:

INTRODUÇÃO

Tabela 1: Lista de espécies de Euphorbiaceae registradas em uma região de Caatinga. _____ **19**

REVISÃO DE LITERATURA

Tabela 2: Relação nacional de plantas medicinais de interesse ao SUS _____ **24**

Tabela 3: Vinte e uma unidades federativas pactuaram a disponibilização de fitoterápicos com recurso tripartite, conforme a portaria GM/ MS nº 1.555/ 2013. _____ **27**

Tabela 4: Lista de espécies da família Euphorbiaceae que foram citadas em estudos etnobotânicos e suas respectivas aplicações. _____ **36**

Tabela 5: Tipos de agentes etiológicos desencadeadores de diarreia. _____ **53**

CAPÍTULO II:

Table 1. Biological parameters in mice bearing EC solid tumor treated with *Cnidoscolus urens* extracts . _____ **111**

Table 2. Hematologic parameters in mice bearing EC solid tumor treated with *Cnidoscolus urens* extracts. _____ **112**

CAPÍTULO III:

Table 1. Effect of the MeOHC. urens (200 and 400 mg/kg) extract of *C. urens* on castor oil induced diarrhea. _____ **136**

Table 2. Effect of MeOHC. urens (200 and 400 mg/kg) extract of *C. urens* on small intestinal transit in mice. _____ **138**

CAPÍTULO IV

Table 1: Effect the feed-deterrence index of extracts of <i>C. urens</i> against <i>S. zeamais</i> .	154
Table 2: Determination of the lethal dose (LC50) of extracts of <i>C. urens</i> , capable of inducing mortality in 50% of the population of <i>S. zeamais</i> by ingestion.	155
Table 3: Determination of the lethal dose (LC50) of extracts of <i>C. urens</i> , capable of inducing mortality in 50% of the population of <i>S. zeamais</i> by contact.	156

LISTA DE ABREVIATURAS

5-FU- 5- fluorouracil

ACh- acetilcolina

AMPC- 3,5 monofosfato cíclico de adenosina

Ca²⁺- ion de cálcio

CaM- proteína ligadora de cálcio

Cav- canais de Ca⁺ dependentes de voltagem

Aq- Extrato aquoso

CFTR- regulador transmembrana de fibrose cística

Cl⁻- íon de cloro

DA- doença de Alzheimer

DAG- diacilglicerol

DDA- doença diarreica aguda

DMEM- dulbecco's modified Eagle

DPPH- 2,2-difenil-1-picrilhidrazil

EA- Extrato de acetato de etila

EC- Carcinoma de Herlich

GMPC- monofosfato cíclico de guanosina

GTP- trifosfato de guanosina

HCO³⁻- íon de bicarbonato

INCA- instituto nacional de câncer

IP3- 1,4,5- trifosfato de inositol

MLCK- cinase de cadeia leve de miosina

MLCP- fosfatase de cadeia leve de miosina

MTT- 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide

Na⁺- íon de sódio

N- bu- butanol

OMS- organização mundial de saúde

PIP2- 4,5- difosfato de fosfatidil inositol

PKC- proteína cinase C

PLC β 1- fosfolipase C β -1

PMCA- troca do sódio- cálcio da membrana plasmática

RN- Vermelho neutro

SBCO- sociedade brasileira de cirurgia oncológica

SERCA- Ca^{2+} - ATPase do retículo sarcoplasmático

SNC- sistema nervoso central

SNE- sistema nervoso entérico

TGI- trato gastrointestinal

SUMÁRIO

CAPÍTULO I

1 INTRODUÇÃO	18
---------------------	-----------

2 REVISÃO DE LITERATURA	21
--------------------------------	-----------

2.1 Plantas Medicinais	21
------------------------	----

2.1.1 Características do Bioma Caatinga	28
---	----

2.2 Plantas Medicinais da Caatinga	31
------------------------------------	----

2.3 Família Euphorbiaceae	34
---------------------------	----

2.3.1 O Gênero <i>Cnidoscolus</i> Phol	37
--	----

2.3.2 Espécie <i>Cnidoscolus urens</i> (L) Arthur	39
---	----

2.4 Atividades Biológicas	42
---------------------------	----

2.4.1 Atividade Antitumoral	42
-----------------------------	----

2.4.2 Anatomia, Fisiologia, Motilidade, Secreção do TGI e a Diarreia	49
--	----

2.4.3 Controle de Insetos Pragas	54
----------------------------------	----

2.4.3.1 O Gorgulho do Milho (<i>Sitophilus zeamais</i>), Insetos Pragas de Grãos Armazenados.	57
---	----

3 OBJETIVOS	62
--------------------	-----------

3.1 Geral	62
-----------	----

3.2 Específicos	62
-----------------	----

REFERENCIAS BIBLIOGRÁFICAS	63
-----------------------------------	-----------

CAPÍTULO II

<i>In vitro</i> and <i>in vivo</i> antineoplastic activity of <i>Cnidoscolus urens</i> (L). Arthur extracts	78
---	----

CAPÍTULO III

Effects of methanoliic extract of aerial parts of *Cnidoscolus urens* (Euphorbeaceae) on the spontaneous contractile activity and induced castor oil in an animal model. _____ 113

CAPÍTULO IV

Potential effect of extracts of *Cnidoscolus urens* on *Sitophilus zeamais*, insects Prague Biology Biology. _____ 139

4 CONCLUSÃO _____ 168

ANEXOS _____ 170

Anexo A - Carta de Aprovação do Comitê de Ética (01) _____ 170

Anexo B - Carta de Aprovação do Comitê de Ética (02) _____ 171

Anexo C - Guide for Authors- JOURNAL OF ETHNOPHARMACOLOGY _____ 172

Anexo D - Guide for Authors- PESTICIDE BIOCHEMISTRY AND PHYSIOLOGY _190

Anexo E: Ficha de identificação botânica (IPA) _____ 206

CAPÍTULO I

1 INTRODUÇÃO

Organização Mundial de Saúde (OMS), identificou que nos países em desenvolvimento, aproximadamente 80- 85% da população, utilizam práticas tradicionais para os cuidados com a saúde (OMS, 2002; CRUZ et al., 2015). Na atualidade, tem-se falado muito em produtos de origem natural, porém, sabemos que desde as mais antigas civilizações, as plantas são utilizadas para tratar diversas enfermidades, e esta prática, durante muito tempo foi a única alternativa de cuidados e prevenção que os indivíduos praticavam (BATTISTI et al., 2013; CRUZ et al., 2015).

Sendo o Brasil detentor da maior biodiversidade, cerca de 55 mil espécies já catalogada, sendo estimado um total de 550 mil espécies. Por isso, é tradição da população brasileira, utilizar recursos naturais como as plantas medicinais, sendo uma cultura transmitida entre as gerações (FONSECA, 2012). Outro fator que contribui para a continuidade desta cultura, é atribuído aos fatores socioeconômicos, principalmente pela falta de assistência médica (ROQUE; LOIOLA, 2013; MARREIROS et al., 2015). O quantitativo de novas pesquisas em torno das plantas medicinais tem crescido nos últimos anos, porém esse crescimento é muito pequeno, apenas 8% ao ano (FONSECA, 2012).

A Caatinga tem uma vegetação seca, e nem todas as partes das plantas (folhas, frutos e flores) estão disponíveis o ano inteiro, principalmente pela pequena duração do período chuvoso e por essas características, a maioria dos fitoquímicos retirados desta vegetação é produzido através da casca dos vegetais (PINTO; AMOROZO; FURLAN, 2006). A explicação para a ampla utilização da casca, pode ser justificada pelo fato de estarem disponíveis o ano inteiro independente da estação (ALBUQUERQUE; ANDRADE, 2002). Porém, essa prática pode colocar esse ecossistema em risco de extinção (ALBUQUERQUE et al., 2007).

Os jornais científicos revelam muitos exemplares de vegetais da Caatinga que são aplicados na medicina popular (MARQUES, 2008; ROQUE et al., 2010; PEDROSA et al., 2012; LUCENA et al., 2012). Como as plantas são amplamente utilizadas e muitas vezes de forma indiscriminada, é de grande valia que seja dada uma atenção maior a respeito desta causa.

A ciência revela e esclarece muitas informações, o semiárido brasileiro disponibiliza recursos fitoterápicos com ações e mecanismos diversificados: anti-inflamatória, tônico, analgésica, antidiabético, adstringente, entre outras ações (SANTOS; ARAÚJO; ALBUQUERQUE, 2008; MACENA et al., 2012). Desta forma, a região do nordeste brasileiro é considerada, um centro de diversidade de famílias, com aproximadamente 50 gêneros e 240 espécies, com muitas espécies endêmicas, que se distribuem, a maior parte, em áreas de Caatinga (LUCENA; ALVES, 2010; OLIVEIRA, 2013).

As Euphorbiaceae são uma das mais importantes famílias vegetais encontradas em áreas de Caatinga (Tabela 1). Espécies desta família pode ser facilmente encontrada em regiões tropicais e subtropicais dos continentes americano e africano (LUCENA; AMORIM; ALVES, 2009). As angiospermas, são uma das mais extensas e complexa família. Espécimes de Euphorbiaceae são bem representadas por cerca de 254 gêneros e 6.300 espécies (HEYWOOD et al., 2007), só no Brasil, já foram registradas ocorrências de 72 gêneros distribuídos em 1.100 espécies, essa informação pode ser confirmada na tabela 1, onde foram registradas algumas das espécies de Euphorbiaceae encontrada em uma região do semiárido (WEBSTER, 1994; GOVAERTS; FRODIN; RADCLIFFESMITH, 2000; RADCLIFFE- SMITH, 2001; BARROSO, 2002; SOUZA; LORENZI, 2008).

Tabela 1: Lista de espécies de Euphorbiaceae registradas em uma região de Caatinga. A tabela demonstra a riqueza e diversidade de espécies da família Euphorbiaceae

Espécies	Nome comum	Hábito	Vocher
<i>Acalypha multicaulis</i> Müll. Arg	Velaminho	Arbustiva	20577
<i>Acalypha poiretii</i> Spreng.	-	Herbácea	20830
<i>Astraea lobata</i> (L.) Klotzch	-	Herbácea	20573
<i>Cnidoscolus urens</i> (L.) Arthur	Cansanção	Subarbustiva	20378
<i>Croton adenocalix</i> Baill.	Marmeleiro-branco	Arbustiva	20355
<i>Croton blanchetianus</i> Baill.	Marmeleiro	Arbórea	20384
<i>Croton heliotropiifolius</i> Kunth	Velame	Arbustiva	20382
<i>Croton hirtus</i> L' Her	-	Herbácea	25128

<i>Dalechampia scandens</i> L.	Cipó-de-caboclo	Trepadeira	21068
<i>Ditaxis malpighiacea</i> (Ule) Pax & K. Hoffm	Pelo-de-raposa	Arbustiva	20567
<i>Euphorbia heterophylla</i> L.	-	Herbácea	21342
<i>Euphorbia hyssopifolia</i> L	Erva-de-leite	Herbácea	21072
<i>Euphorbia insulana</i> Vell	Maleiteira	Herbácea	20829
<i>Euphorbia prostrata</i> Aiton	-	Herbácea	21357
<i>Euphorbia</i> sp	-	Herbácea	20831
<i>Jatropha molissima</i> (Pohl) Baill	Pinhão	Arbórea	20347
<i>Mabea</i> sp	Pau-de-estralo	Arbórea	20832
<i>Manihot dichotoma</i> Ule	Maniçoba	Arbórea	20346
<i>Sapium glandulosum</i> (L.) Morong	Burra-leiteira	Arbórea	20358
<i>Tragia volubilis</i> L	Urera	Trepadeira	20374

Fonte: OLIVEIRA, 2013, com modificações.

As Euphorbiaceas destacam-se por ser uma família de importância econômica, essa importância torna-se ainda maior quando avaliado a participação em setores industriais, ornamentais, alimentício e farmacológico (ALVES, 1998). Espécies como *Manihot esculenta* Crantz, utilizada para a produção de farinha, no setor da indústria podemos destacar a *Hevea Aubl*, conhecida por seringueira, foi bastante explorada durante o período do ciclo da borracha (CORRÊA et al., 2002).

Espécies como: *Croton blanchetianus* Baill (marmeleiro), *Phyllanthus niruri* L. (quebra pedra) (CORRÊA et al., 2002), *Ricinus communis* L. (mamona) utilizado para extração de óleo aplicado como lubrificantes e compostos biodegradáveis (SILVA, 1998), *Cnidoscolus urens* (L.) Arthur (urtiga), entre outras tantas (CORRÊA et al., 2002). Atualmente muitas dessas espécies são alvo de diferentes estudos, acerca de suas propriedades química e biológicas, importância etnobotânica, contribuindo para melhor compreensão sobre as espécies (SECCO, 2005).

O gênero *Cnidoscolus* Phol é nativo do Brasil e 50-70 espécies com alastramento neotropical (ARAÚJO; LEAL; QUIRINO, 2012). A espécie *Cnidoscolus urens*, pertencente à família Euphorbiaceae, com importância econômica, apresenta distribuição no semiárido (FERREIRA, 2011). Muitas são as causas, as quais espécies do gênero *Cnidoscolus* Phol, são aplicadas pela medicina popular, entre as formas populares de utilização podemos citar a preparação de chás de raízes com efeito cicatrizante, tônico, diurético e até diarreico (BRAGA, 1976).

Conhecida como urtiga, de ocorrência comum na Caatinga, porém também apresenta ocorrência no México e Argentina (ARAÚJO; LEAL; QUIRINO, 2012). Estas plantas apresentam pelos urticantes distribuídos pelo seu caule, nas pesquisas etnobotânicas (PEIXOTO SOBRINHO, 2011), esta espécie é a mais relatada, segundo Albuquerque et al., (2007). Estudos realizados por Alves et al., (2007), identificaram que entra as espécies citadas sendo utilizadas como medicinais, em uma feira livre no estado da Paraíba, a espécie *C. urens*, estava entre as mais relatadas. Na maioria das vezes são administradas por via oral utilizando-se da raiz para tratar diversas enfermidades: Inflamação da próstata, cisto de ovário e útero.

Entre tanto, ainda se torna escasso a bibliografia científica que informem as propriedades presentes em diferentes extratos desta espécie, corroborando com a necessidade de iniciar estudos e avaliar os potenciais efeitos biológicos que podem ser atribuídos aos produtos sintetizados pelo *C. urens*, a fim de investigar seus metabólitos secundários para que suas atividades sejam comprovadas, até que possam ser utilizados como terapêuticos seguros.

2 REVISÃO DE LITERATURA

2.1 Plantas Medicinais

A evolução da humanidade apresenta uma relação muito íntima com o mundo dos vegetais. A espécie humana iniciou a domesticação de espécies vegetais e animais quando processos evolutivos da ciência biológica, cultural e técnicas, tiveram início, acerca de 200 mil anos. Os povos mais antigos passaram a reconhecer os produtos naturais, inicialmente, como fonte alimentícia. Com o passar dos anos, a humanidade começou a despertar outros tipos de

interesse a esses produtos e reconhecer que as plantas tinham propriedades curativas E a partir desta prática, cada localidade desenvolveu e criou sua própria cultura, tradição e crenças (MAZOYER; ROUDART, 2010; MINISTÉRIO DA SAÚDE, 2006).

A fitoterapia, que tem como base uma variedade inesgotável de produtos farmacológicos para fins terapêuticos sem isolamento de substâncias ativas. (CARTAXO et al., 2010; TAN et al., 2010; OLIVEIRA et al., 2012). Os fitoterápicos são produzidos de plantas frescas ou secas, processadas por destilação, maceração, percolação, entre outras metodologias. Por tanto a procura por fitoterápicos a nível mundial, tem crescido abundantemente. Esse crescimento dá-se pelo conhecimento acerca das plantas medicinais as quais apresentam um alto valor econômico e são principais fontes para a retirada de recursos voltados para a produção de fármacos (OLIVEIRA et al., 2012).

O conhecimento sobre a ação terapêutica das plantas, tem sido acumulado, aperfeiçoado e reproduzido, passado de geração em geração. Sendo assim, à sabedoria é passada entre pessoas de uma mesma família. Esta prática garante a imortalidade do reconhecimento dessas espécies com ação terapêutica e que é influenciada pela idade, onde os mais antigos de uma determinada comunidade eram o portador de maior conhecimento, capaz de identificar a planta indicada para determinada doença, a parte da planta (raízes, cascas, folhas, frutos e sementes) que podem ser utilizada e a melhor forma de preparo como chás (onde a plantas é fervida junto com a água), decocção ou infusão (o qual a água é fervida e depois colocada sobre a planta, com agitação) (REZENDE; COCCO, 2002).

A utilização de plantas como tratamento de enfermidades ocorreu nas civilizações chinesas, assíricas, egípcias e hebreus desde 2.300 a.C, e que ainda hoje fazem uso desta prática. A fitoterapia cruzou toda a existência das mais antigas civilizações, iniciando na antiguidade seguindo até à idade média, prosseguindo pela idade moderna e contemporânea, sendo utilizada até hoje em todo o mundo. No Brasil não poderia ser diferente. A origem da medicina popular com a utilização de plantas foi influenciada de maneiras diferentes: (i) Os conhecimentos deixados pelos índios que habitaram os territórios brasileiros; (ii) A introdução de tratamentos alternativos foram deixadas pelos negros escravos trazidos para o Brasil e europeus; (iii) Durante o período que o Brasil foi colonizado e seguiu como colônia de Portugal (BIESKI, 2005).

O Brasil encontra-se entre os 10 maiores consumidores de fitoterápicos, onde 91,9% dos brasileiros utilizam ou já utilizaram plantas para algum tipo de tratamento e quase 50% desses possuem um cultivo medicinal caseiro, sendo 30% dos medicamentos, disponíveis e registrados, de origem natural (OLIVEIRA et al., 2012).

A prática da medicina caseira, além do incentivo realizado pelo exercício político, é estimulada entre as comunidades e sem supervisão médica, a procura pela medicina tradicional, nestes casos, só acontece se os sintomas persistirem. Outra causa que leva a escolha do tratamento por métodos alternativos da-se quando a medicação tradicional não se encontra acessível ou é muito cara (RIBEIRO; LEITE; DANTAS- BARROS, 2005).

Diante da grande importância mundial, nota-se a necessidade de incorporar a associação entre a medicina tradicional e a medicina alternativa, visto que nem sempre é possível atingir um potencial terapêutico ideal utilizando somente a medicina tradicional. Por isso, cada vez mais vem sendo estimulado programas de saúde adaptados especificamente para cada localidade de acordo com o perfil socioeconômico (OLIVEIRA et al., 2012).

Deste modo, políticas governamentais estimulam a divulgação de plantas com potencial terapêutico e que poderão ser utilizadas como fitoterápicos e implementadas no cotidiano do Sistema Único de Saúde (SUS), com a finalidade de ampliar o número de fitoterápicos financiados por verbas federal, a fim de torná-los acessíveis à população. (PINHO; PICHONELLI, 2009). Também foram incluídos a criação de leis como o Decreto n 5.813, que regula o programa de Política Nacional de Plantas Medicinais e Fitoterápicos (PNPMF) (BRASIL, 2007).

A fim de concretizar a utilização de fitoterápicos, o governo brasileiro criou em 2006, a Política Nacional de Práticas Integrativas e Complementares do SUS, a qual aprova o uso de medicamentos fitoterápicos. Mais tarde, em 2008, o Programa Nacional de Plantas Medicinais e Fitoterápicos foi implantado, garantindo a população brasileira, o acesso seguro aos fitoterápicos (Instituto Ethos, 2016). Em 2009, o Ministério da Saúde do Brasil divulgou uma relação de 71 plantas (Tabela 2), as quais podem ser utilizadas como fitoterápicos (Ministério da Saúde, 2014).

Tabela 2: Relação Nacional de Plantas Medicinais de Interesse ao SUS.

Nome científico	Nome popular	Utilidade
<i>Achillea millefolium</i>	Mil-folhas, Dipirona	Combate úlceras, feridas e é analgésico.
<i>Allium sativum</i>	Alho	anti-séptico, antiinflamatório e anti-hipertensivo.
<i>Aloe</i> spp (A. vera ou A. barbadensis)	Babosa, áloes	Combate a caspa, calvície e é antisséptico. Retira lendia de piolhos e é cicatrizante .
<i>Alpinia</i> spp (A. zerumbet ou A. speciosa)	Colônia	Anti-hipertensivo.
<i>Anacardium occidentale</i>	Caju	Antisséptico e cicatrizante .
<i>Ananas comosus</i>	Abacaxi	Mucolítica e fluidificante das secreções e das vias aéreas superiores.
<i>Apuleia ferrea</i> = <i>Caesalpinia ferrea</i>	Jucá, pau-ferro-verdadeiro, Ibirá-obi	Infecção catarral, garganta, gota, cicatrizante
<i>Arrabidaea chica</i>	Craijirú, carajiru	Afeções da pele em geral (impigens), feridas, Antimicrobiano
<i>Artemisia absinthium</i>	Artemísia	Estômago, fígado, rins, verme (lombriga e oxiúru, giárdia e ameba)
<i>Baccharis trimera</i>	Carqueja, carquejaamargosa	Combate feridas e estomáquico
<i>Bauhinia</i> spp (B. affinis, B. forficata ou variegata)	Pata de vaca	
<i>Bidens pilosa</i>	Picão	Combate úlceras
<i>Calendula officinalis</i>	Bonina, calêndula, flor-de-todos-osmales, malmequer	Feridas, úlceras, micoses
<i>Carapa guianensis</i>	Andiroba, angiroba, nandiroba	Combate úlceras, dermatoses e feridas
<i>Casearia sylvestris</i>	Guaçatonga, apiáacanoçu,bugre branco, café-bravo	Combate úlceras, feridas, aftas, feridas na boca
<i>Chamomilla recutita</i> = <i>Matricaria chamomilla</i> = <i>Matricaria recutita</i>	Camomila	Combate dermatites, feridas banais
<i>Chenopodium ambrosioides</i>	Mastruz, erva-de-santa- maria, ambrosia, erva-debicho, mastruço, menstrus	Corrimento vaginal, antisseptico local
<i>Copaifera</i> spp	Copaíba	Antiinflamação
<i>Cordia</i> spp (C. curassavica ou	Erva baleeira	Antiinflamatorio

<i>C. verbenacea</i>)		
<i>Costus</i> spp (<i>C. scaber</i> ou <i>C. spicatus</i>)	Cana-do-brejo	Combate leucorréia e inflamação renal
<i>Croton</i> spp (<i>C. cajucara</i> ou <i>C. zehntneri</i>)	Alcanforeira, herba-mular, péde-perdiz	Combate feridas, úlceras
<i>Curcuma longa</i>	Açafrão	
<i>Cynara scolymus</i>	Alcachofra	Combate ácido úrico
<i>Dalbergia subcymosa</i>	Verônica	Auxilia no tratamento de inflamações uterinas e da anemia
<i>Eleutherine plicata</i>	Marupa, palmeirinha	Hemorróida, vermífugo
<i>Equisetum arvense</i>	Cavalinha	Diurético
<i>Erythrina mulungu</i>	Mulungu	Sistema nervoso em geral
<i>Eucalyptus globulus</i>	Eucalipto	Combate leucorréia
<i>Eugenia uniflora</i> ou <i>Myrtus brasiliana</i>	Pitanga	Diarréia
<i>Foeniculum vulgare</i>	Funcho	Anti-séptico
<i>Glycine max</i>	Soja	Sintomas da menopausa e osteoporose
<i>Harpagophytum procumbens</i>	Garra-do-diabo	Artrite reumatóide
<i>Jatropha gossypifolia</i>	Peão-roxo, jalopão, batata-de-téu	Antisséptico e feridas
<i>Justicia pectoralis</i>	Anador	Cortes, afecções nervosas, catarro bronquial
<i>Kalanchoe pinnata</i> = <i>Bryophyllum calycinum</i>	Folha-da-fortuna	Furúnculos
<i>Lamium album</i>	Urtiga-branca	Leucorréia
<i>Lippia sidoides</i>	Estrepa cavalo, alecrim, alecrim-pimenta	
<i>Malva sylvestris</i>	Malva, malva-alta, malva-silvestre	Furúnculos
<i>Maytenus</i> spp (<i>M. aquifolium</i> ou <i>M. ilicifolia</i>)	Concorosa, combra-de-touro, espinheira-santa, concerosa	Antiséptico em feridas e úlceras
<i>Mentha pulegium</i>	Poejo	
<i>Mentha</i> spp (<i>M. crispa</i> , <i>M. piperita</i> ou <i>M. villosa</i>)	Hortelã-pimenta, hortelã, menta	
<i>Mikania</i> spp (<i>M. glomerata</i> ou <i>M. laevigata</i>)	Guaco	Broncodilatador
<i>Momordica charantia</i>	Melão de São Caetano	
<i>Morus</i> sp	Amora	
<i>Ocimum gratissimum</i>	Alfavacão, alfavaca-cravo	

<i>Orbignya speciosa</i>	Babaçu	
<i>Passiflora</i> spp (<i>P. alata</i> , <i>P. edulis</i> ou <i>P. incarnata</i>)	Maracujá	Calmante
<i>Persea</i> spp (<i>P. gratissima</i> ou <i>P. americana</i>)	Abacate	ácido úrico, prevenir queda de cabelo, anti-caspa
<i>Petroselinum sativum</i>	Falsa	
<i>Phyllanthus</i> spp (<i>P. amarus</i> , <i>P. niruri</i> , <i>P. tenellus</i> e <i>P. urinaria</i>)	Erva-pombinha, quebra-pedra	
<i>Plantago major</i>	Eanchagem, tanchás	Feridas
<i>Plectranthus barbatus</i> = <i>Coleus barbatus</i>	Boldo	
<i>Polygonum</i> spp (<i>P. acre</i> ou <i>P. hydropiperoides</i>)	Erva-de-bicho	Corrimentos
<i>Portulaca pilosa</i>	Amor-crescido	Feridas e úlcera
<i>Psidium guajava</i>	Goiaba	Leucorréia, aftas, úlcera, irritação vaginal
<i>Punica granatum</i>	Romeira	Leucorréia
<i>Rhamnus purshiana</i>	Cáscara sagrada	
<i>Ruta graveolens</i>	Arruda	
<i>Salix alba</i>	Salgueiro branco	
<i>Schinus terebinthifolius</i> = <i>Schinus aroeira</i>	Araguaíba, aroeira, aroeira-do-rio-grande-do-sul	Feridas e úlceras
<i>Solanum paniculatum</i>	Jurubeba	
<i>Solidago microglossa</i>	Arnica	Contusões
<i>Stryphnodendron adstringens</i> = <i>Stryphnodendron barbatimam</i>	Barbatimão, abaremotemo, casca-da-virgindade	Leucorréia, feridas, úlceras, corrimento vaginal
<i>Syzygium</i> spp (<i>S. jambolanum</i> ou <i>S. cumini</i>)	Jambolão	
<i>Tabebuia avellanedae</i>	Ipê-roxo	
<i>Tagetes minuta</i>	Cravo-de-defunto	
<i>Trifolium pratense</i>	Trevo vermelho	
<i>Uncaria tomentosa</i>	Unha-de-gato	Imunoestimulante e antiinflamatório
<i>Vernonia condensata</i>	Boldo da Bahia	
<i>Vernonia</i> spp (<i>V. ruficoma</i> ou <i>V. polyanthes</i>)	Assa-peixe	
<i>Zingiber officinale</i>	Gengibre	Tosse

Fonte: MINISTÉRIO DA SAÚDE, 2014. Modificada.

Em decorrência da implementação desses programas, o MS iniciou convênios com a indústria e pequenos agricultores, além de selecionar 12 municípios distribuídos entre Pernambuco, Paraná, Minas Gerais, Pará, Goiás, Rio de Janeiro e São Paulo, objetivando estimular a produtividade desses produtos, sendo esta a primeira vez em que recursos federais foram investidos nesta área (Instituto Ethos, 2016). Hoje 21 unidades federativas (Tabela 3) já disponibilizam fitoterápicos assegurados por recursos do governo, estado e município (Ministério da Saúde, 2015).

Tabela 3: Vinte e uma unidades federativas pactuaram a disponibilização de fitoterápicos com recurso tripartite, conforme a Portaria GM/MS nº 1.555/2013:

UNIDADES DA FEDERAÇÃO		
ACRE (AC)	ESPIRITO SANTO (ES)	PARANÁ (PR)
ALAGOAS (AL)	GOIÁS (GO)	RIO DE JANEIRO (RJ)
AMAZONAS (AM)	MATO GROSSO DO SUL (MS)	RONDÔNIA (RO)
BAHIA (BA)	MINAS GERAIS (MG)	RIO GRANDE DO NORTE (RN)
CEARÁ (CE)	PARÁ (PA)	RIO GRANDE DO SUL (RS)
DISTRITO FEDERAL (DF)	PERNAMBUCO (PE)	SANTA CATARINA (SC)
SÃO PAULO (SP)	SERGIPE (SE)	TOCANTINS (TO)

Fonte: MINISTÉRIO DA SAÚDE, 2015.

Os ramos de fitoterápicos movimentam cerca de US\$ 22 bilhões de dólares, no mundo, com um crescimento anual de 12%. No Brasil, a fitoterapia é detentora de uma parcela de 5% do mercado farmacêutico (MINISTÉRIO DA SAÚDE, 2003). Os fitoterápicos apresentam uma potencialidade inesgotável, baseados nos recursos retornáveis. E através dos conhecimentos obtidos por estudos realizados com matéria prima vegetal e levantamentos etnobotânicos, novas descobertas, e desenvolvimento de novas moléculas com aplicabilidade tecnológica, poderão fazer parte do leque para a busca de terapêuticos com maior eficiência e com menor ou nenhum efeito adverso (MINISTÉRIO DA SAÚDE, 2006b).

No Brasil encontramos uma ampla biodiversidade e vinculada a essa biodiversidade, temos a riqueza do conhecimento popular acumulado por pessoas que têm acesso direto a natureza. Portanto, é um país que somou seus conhecimentos sobre a medicina popular de uma mistura cultural entre os indígenas, europeus e africanos, sendo, hoje uma nação que é dita

como base para o desenvolvimento de novas pesquisas para descoberta de novas fontes de medicamentos utilizando plantas medicinais como ponto de partida (SANTOS et al., 2012). Os altos custos e o potencial adverso com efeitos colaterais que fármacos industriais apresentam e incentiva a tendência para a procura de plantas que apresentam alto potencial biológico (HALBERSTEIN, 2005).

O Brasil abriga a diversidade química vegetal. Sendo o país que aloca a maior floresta úmida. Com seis Biomas bem distribuídos por todo o seu território. No território brasileiro, estão localizados seis Biomas ricos em fauna e flora: Amazônia, Caatinga, Cerrado, Pantanal, Pampa e Mata Atlântica, dentre eles destacamos o Bioma Caatinga, que atinge cerca de 70% do Nordeste (PINTO et al., 2002; SANTOS; JUNIOR; PRATA, 2012). Plantas nativas da Caatinga são vastamente utilizadas como medicinais e algumas espécies são comercializadas como fitoterápico. Este cenário é bem representado pela *Amburana cearenses* e *Erythrina velutina*, referendadas por Albuquerque e seus colaboradores em 2007.

2.1.1 Características do Bioma Caatinga

Entre 1801 a 1900, século XIX, marcado por muitos conflitos militares, foi também, um período marcado pelo aumento desenfreado de interesses em explorar áreas inexploradas ou pouco conhecidas, como o Cerrado, a Floresta Amazônica e a nossa inestimada Caatinga. Os desbravadores que aqui chegaram, alimentavam uma expectativa de deparar-se com uma vegetação verde e florida, quando na verdade, encontraram uma vegetação seca, cheia de galhos espinhos e sem folhas e nem flores (CARRARA, 1996).

Sendo assim, a Caatinga se destaca dos outros Biomas, por apresentar uma vegetação arbustiva e grandes árvores, repletas de espinhos (Ministério do Meio Ambiente, 2016). De aparência seca, mas com grande capacidade auto renovável, basicamente localizado no Nordeste do Brasil. Toda a extensão territorial da Caatinga, encontra-se bem distribuída em 09 estados brasileiros: Piauí, Ceará, Rio Grande do Norte, Paraíba, Pernambuco, Alagoas, Bahia e Sergipe, além de atingir uma parte de Minas Gerais (TRENTIN et al., 2011; PINHEIRO et al., 2013).

Para atribuir a real importância da vegetação do semiárido brasileiro, tornou-se necessário que pesquisadores em suas minuciosas observações, notassem o perfil adaptativo que esses vegetais exibiam. Num dia de sol ardente incidindo sobre aquela terra seca, com árvores quase morta, fixadas em baixo da terra por raízes que se estendiam por quilômetros em busca d'água, bastava um rápido contato com a umidade para que esta vegetação desenvolvesse folhas e frutos (MARTIU, 1996).

Provavelmente, hoje, a Caatinga é uma área que tem sofrido com as intervenções do homem, com sua atuação explorativa. Com 844.453 Km² de extensão pelo território nacional, rico em biodiversidade, o Bioma ampara 178 espécies de mamíferos, 591 de aves, 177 de répteis, 79 espécies de anfíbios, 241 de peixes e 221 de abelhas. Milhares de pessoas carentes dependem deste Bioma para sua sobrevivência (MINISTÉRIO DO MEIO AMBIENTE, 2016).

Cartaxo et al. (2010) e Pinheiro et al., em 2013, observaram e relataram a existência de muitos estudos em torno do Bioma, Caatinga, os quais comprovam uma potente capacidade terapêutica, com competência para ampliar o arsenal de moléculas bioativa. Em conjunto a este Bioma está a importância do conhecimento popular que pode auxiliar nesta busca. Vários estudos populacionais relatam que muitas espécies são utilizadas para tratar diversas enfermidades, incluindo doenças de pele, gastrointestinais, infecciosas, entre outras (CARTAXO et al., 2010; PINHEIRO et al., 2013).

Em pesquisa realizada por Agra, Freitas e Barbosa- Filho, em 2007, retratam informações onde a vegetação espinhosa da Caatinga, abriga em média, 483 espécies que tem suas propriedades bioativas reveladas. Em contrapartida, muitas dessas espécies ainda não foram estudadas a nível de composição de seus constituintes e de suas atividades biológicas.

Enxergando a relevância dessa vegetação rica e com baixíssima reserva de água, passamos a compreender o seu importantíssimo papel, pois é altamente vulnerável a ação do homem sobre o mesmo e as modificações dela resultante, esse Bioma que hospeda mais de 20 milhões de habitantes, que sofrem com as mudanças drásticas de estação, principalmente com o período da seca (CARTAXO et al., 2010; PINHEIRO et al., 2013).

A Caatinga não é um Bioma que serve de alojamento para apenas espécies animais e vegetais, servindo também de abrigo para famílias. Aproximadamente 27 milhões de pessoas vivem em regiões de Caatinga, e a maior parte dessas pessoas, são pessoas carente e dependente dos recursos do Bioma para sobrevivência. Essa mata seca tem um imenso potencial para a conservação de serviços ambientais, uso sustentável e bioprospecção. Condições estas que, se bem dirigidas e exploradas de forma conservativa, poderão contribuir para o desenvolvimento da região e do país. Já é sabido que, essas regiões (Ministério do Meio Ambiente, 2016).

A Caatinga dá suporte para vários tipos de atividades econômicas voltadas para fins agrosilvopastoris (Sistema integrativo de lavouras, com espécies florestais e pastagens) e industriais, especialmente nos ramos farmacêutico, de cosméticos, químico e de alimentos. Entretanto, o Bioma de importância inestimada, tem sido devastado de forma acelerada. Uma das principais causas do rápido desmatamento pode ser atribuída ao consumo de lenha nativa de forma ilegal e insustentável, para fins domésticos e indústrias, ao pastoreio e a conversão da vegetação nativa para pastagens e agricultura (ALMEIDA ET AL, 2010; MINISTÉRIO DO MEIO AMBIENTE, 2016).

Na tentativa de cessar esse desmatamento que já atinge 46% da área do Bioma, conforme informações fornecidas pelo Ministério do Meio Ambiente (MMA), o governo luta pela criação de mais unidades de conservação federais e estaduais e promove alternativas para o uso sustentável da sua biodiversidade. Parcerias também são seladas entre o governo e os estados, para garantir a integridade e preservação, além da promoção de ações para a utilização sustentável de espécies nativas, manejo florestal e eficiência energética nas indústrias (Ministério do Meio Ambiente, 2016). Mesmo com todas essas parcerias, a Caatinga continua sendo um dos Biomas menos protegidos do país (Ministério do Meio Ambiente, 20016).

Diante desta vasta biodiversidade, inúmeras espécies têm uma representatividade de valor inestimado, outras dessas espécies são comercializadas em feiras livres como fitoterápicos, mas algumas poucas destas têm propriedades medicinais conhecidas (ALBUQUERQUE et al., 2007; CARTAXO et al., 2010).

Dentre todas as classes e espécies de vegetais já conhecidas podemos destacar a notável contribuição das plantas superiores (CALIXTO, 2003). São cerca de 60 mil espécies de plantas

superiores, onde somente 8% já foram alvo de pesquisa quanto as ações de seus produtos e pouco mais de 1000 espécies tiveram suas propriedades medicinais avaliadas. O Programa das Nações Unidas para o Desenvolvimento (2010) estima que no Bioma Caatinga, possam existir mais de 1500 exemplares de plantas superiores (entre Angiospermas e Gimnospermas) (BRASIL, 2006).

As plantas superiores desempenham um papel fundamental para o desenvolvimento de novas drogas, embora só se tenha 10% da biodiversidade mundial estudada. Aproximadamente 140 mil metabólitos intermediários são derivados em sua maioria, de plantas superiores (CALIXTO, 2003). Esse grupo vegetal, que é composto por 55.000 espécies (SEVERIANO et al., 2010; DUARTE et al., 2004), que apresentam uma heterogeneidade de tipos estruturais como, por exemplo, os flavonóides, os terpenóides e os alcalóides, os quais podem exercer atividades biológicas (GOTTLIEB; BORIN, 2012; DUARTE et al., 2004).

Estima-se que 520 novos fármacos aprovados pela Food and Drug Administration (FDA), aproximadamente 39% tenha partido de recursos naturais. Demonstrando um pouco mais da importância desses derivados, 33% dos medicamentos mais prescritos e vendidos no mundo são de origem vegetal. Este percentual atinge a margem de 70% quando essas drogas são direcionadas para o combate contra o câncer e infecções (CALIXTO, 2003).

2.2 Caatinga e plantas medicinais

A maior responsável pela produção das substâncias orgânicas é a natureza e o reino dos vegetais sendo o produtor da maior parte desta fração. Seja oriundo de qual quer fonte, os produtos de origem natural, podem servir como base para estudos de novos padrões de moléculas benfeitoras para a descoberta de novos fármacos (VIEGAS-JUNIOR; BOLZANI; BARREIRO, 2006).

Apresentando-se como um dos mais importantes Biomas do Brasil, a Caatinga, tem se tornado alvo de grandes pesquisas. É neste lugar onde muitas pesquisas são iniciadas. A fauna e flora que compõem esta reserva instiga muita curiosidade, em especial as plantas. Esta constatação pode ser confirmada pelo grande número de estudos já existente na literatura científica, que correlacionam a utilização dessas plantas como terapêuticos e a elas tem sido

reportada muitas ações: anticolinesterásica, gastroprotetora, analgésica, anti-inflamatória, anticoagulante, ansiolítica, antiplasmodica, antitumoral, antidiarreica, atividade inseticida, entre outras numerosos potenciais (CARVALHO et al., 1996; DINIZ, 2013; PEREIRA et al., 2012; TREVISAN; MACEDO, 2003).

Trevisan e Macedo (2003) em seus estudos, puderam comprovar que ao utilizar a casca de *Amburana cearenses*, conhecida por umburana, e extraíndo da casca os princípios ativos com etanol, aplicando a uma atividade de inibição enzimática por teste de microplaca, poderiam obter excelentes resultados. Sendo assim, o extrato da umburana é um potente inibidor de acetilcolinesterase. Agentes que atuem neste sentido são bastante utilizados para o tratamento de pacientes portadores da doença de Alzheimer (DA).

A indução de úlcera crônica por ácido acético, em roedores, é uma metodologia utilizada a fim de se verificar a ação gastroprotetora dos fármacos. E foi através deste método que Pereira et al (2012) identificaram que *Handroanthus impetiginosus* (ipê roxo), quando utilizou-se extrato hidroalcoólico da casca do caule para tratar animais induzidos por ácido acético, obteve resultados significativos quanto a proteção da mucosa gástrica e ainda pode sugerir que o mecanismo de ação esteja envolvido com a manutenção da integridade da mucosa e estímulo de proliferação celular.

O extrato aquoso de *Libidibia ferrea* (pau-ferro), foi testado quanto sua ação analgésica e anti-inflamatória. Nos modelos testes, o extrato apresentou resultados significantes quando comparados ao controle negativo tanto para os modelos de edema de pata, contorção abdominal e placa quente, entre tanto os melhores resultados foram obtidos para os modelos que avaliaram a ação analgésica do extrato (CARVALHO et al., 1996).

Em 2011, Araújo e colaboradores, conseguiram isolar uma lectina da casca de trapiá (*Crataeva tapia*), a qual foi testada com relação a sua atividade anticoagulante. Existe indicativo de que a lectina isolada tem ação direta nos fatores VIII, IX, X e XI da coagulação. Este mesmo estudo ainda identificou que este composto isolado da trapiá desempenha dupla ação: inibição e anticoagulação.

Testes que avaliam a utilização de plantas da Caatinga, com ação sobre o sistema nervo central (SNC) também foram testadas. O extrato etanólico de folhas de *Annona vepretorum*, mais popularmente conhecida como “pinha da Caatinga”, foi empregado para avaliar a atuação sedativa do SNC em camundongos. Segundo resultados obtidos pelo estudo, a pinha da Caatinga apresenta ação sedativa, sem afeta a coordenação motora dos indivíduos testados (DINIZ, 2013).

Quando testado frente a *Plasmodium falciparum*, os compostos extraídos do caule de *Hymenaea coubaril* (jatobá) demonstrou ter atividade. Segundo Köhler et al, 2002, uma concentração de aproximadamente 11 µg/mL, foi a dose encontrada e necessária para induzir a inibição do crescimento desta população em 50%.

Peixoto (2011), conseguiu identificar e comprovar que algumas espécies de *Cnidoscolus*, entre elas: *C. infestus* e *C. quercifolius*, desempenharam potencial citotóxico e apresentaram a capacidade de inibir o crescimento celular. Extratos produzidos com a utilização de partes aéreas e raiz de *C. infestus*, apresentaram atividade antiproliferativa contra as linhagens Hep-2 e NCI- H292, numa concentração de 50µg/ mL. Quanto ao extrato da casca de *C. quercifolius*, demonstrou-se ativo frente as linhagens celulares HT-29 e Hep-2, também na mesma concentração. Ainda segundo Peixoto, estas espécies são amplamente utilizadas popularmente para o tratamento de processos inflamatórios e tumorais.

Segundo Beserra, 2014 extratos de *Cissus sicyoides*, já conhecida pela sua ação hipoglicemiante, também chamada de insulina vegetal, foi capaz de inibir a diarreia provocada por óleo de rícino, tanto no que refere- se a frequência de evacuações quanto ao percentual de fezes liquefeitas, quando realizado o pré-tratamento com doses iguais a 250 e 500 mg/Kg. Na visão do autor, o extrato pode apresentar a ação antidiarreica, estando envolvido com a indução de uma alteração na motilidade intestinal, em consequência, inibição do trânsito e aumento da absorção de água, contribuindo para menor secreção do TGI.

Extratos da *Myracrodruon urundeuva* (Anacardiaceae), *Ziziphus joazeiro* (Rhamnaceae) e *Croton blanchetianus* (Euphorbiaceae), foram testados quanto sua atividade de repelência contra *Tetranychus bastosi*. Ao fim do experimento, verificou- se que os extratos

das folhas das três espécies em teste, desempenharam além da atividade repelente, apresentaram também um índice de mortalidade significativa (XAVIER et al., 2015).

Durante muito tempo as plantas medicinais foram negligenciadas e só na década de 80 esse cenário começou a mudar. Na atualidade, como pode ser comprovado pelos estudos realizados por Xavier et al. (2015) são constantes as descobertas e as publicações na literatura científica, sobre plantas como produto terapêutico. A importância da medicina alternativa, baseada na utilização de plantas, tradicionalmente, assume que esses vegetais devem ser empregados para finalidades curativas, ao ser utilizado qualquer parte do vegetal (FONTE, 2004).

2.3 Família Euphorbiaceae

A família Euphorbiaceae é composta por 5 subfamílias, 49 tribos, 300 gêneros e 8000 espécies. Entre as famílias de plantas com flores, é uma das maiores, de alta complexidade e diversificada. (SECCO et al., 2012; WMINE; DAMME, 2011). Essa família está entre as mais importantes por apresentar valor econômico histórico, como por exemplo, o gênero *Hevea brasiliensis* (seringueira), o qual economicamente fez parte do ciclo da borracha, que aconteceu no Brasil, por volta do século XX e a *Manihot esculenta* (macaxeira) que está entre os mais importantes alimentos (SECCO et al., 2012). E mais recentemente a *Jatropha curcas* (pinhão-mansão), matéria prima utilizada para a produção do biodiesel (GARG; KHATRI; GANDHI, 2011).

No Brasil, a família é representada por mais de 1000 espécies, dentro de 80 gêneros (SÁTIRO; ROQUE, 2008). No Nordeste a família é registrada com uma das mais importantes do semiárido e se distribui em 211 espécies e 45 gêneros (LUCENA; ALVES, 2010). A Caatinga possui 17 espécies endêmicas como representante das Euphorbias (SÁTIRO; ROQUE, 2008).

As Euphorbiaceae exibem importância terapêutica e características peculiares que atribuem a esta família uma excelente atividade medicinal. Por apresentarem ampla distribuição em todas as regiões tropicais de todos os continentes, a família apresenta características de sobrevivência excepcional, como adaptações climáticas, altas cargas de mutações,

além dos estímulos ambientais. A disposição para sofrer adaptações, confere a esta família a capacidade de produzir diversos metabólitos secundários (WMINE; DAMME, 2011). Compostos tais como fenóis, ésteres, ricina, flavonoides, saponinas, terpenos, alcalóides e taninos foram encontrados em espécies desta família e relatados por Kiem et al. (2009); Duarte; Lage; Ferreira (2008); Gressler et al. (2008); Goel et al. (2007); Liu et al. (2007); Yang et al. (2007) e Rossi et al. (2003) respectivamente.

Os achados de inúmeros pesquisadores em nível de moléculas derivadas do metabolismo das Euphorbiaceae demonstram a alta eficiência desses derivados, ao desempenhar função medicinal, já que esses metabólitos são produzidos pelas plantas para desempenharem papel protetor contra as adversidades encontradas no ambiente em que vivem. (WMINE; DAMME, 2011). Assinalando assim, um bom ponto de partida para uma pesquisa de novos fitoterápicos os quais possam ser utilizados na medicina humana e veterinária ou ainda na agricultura contra pragas.

Muitas espécies de Euphorbiaceae são alvos de muitos estudos científicos e são designadas para numerosas finalidades como alimentação, ornamentação, predecessor de compostos químicos, lubrificantes, resinas, além das utilidades medicinais. O látex que essas espécies produzem apresentam grandes concentrações de diterpenos de caráter complexo, estes apresentam atividades biológicas diversas como citotóxica, anti-inflamatória, analgésica, antiespasmódica, antitumoral, etc. Outras substâncias bem características desta família são os esteróides, lectinas, as hemaglutininas e compostos cianogênicos (FELIU, 2011).

Trindade e Lameira (2014), puderam comprovar que a maioria das espécies da Euphorbiaceae, que foram citadas por populares em estudos etnobotânicos, das 149 espécies, a grande parte foram indicadas com potencial medicinal. Sabe-se que a utilização dessa família é descrita por civilizações orientais e ocidentais. A tabela 4 abaixo destaca algumas das 149 espécies citadas por Trindade e Lameira e suas respectivas indicações de utilização.

Tabela 4: Lista de espécies da família Euphorbiaceae que foram citadas em estudo etnobotânicos e suas respectivas aplicações.

Nome Científico	Nome comum	Utilização/ propriedade
<i>Acalypha accedens</i> Müll.Arg.	Acalifa	Medicinal, ornamental
<i>Acalypha amblyodonta</i> (Müll. Arg.) Müll. Arg.	Pêlo-vermelho	Medicinal
<i>Acalypha arvensis</i> Poepp.	Rabo-de-macaco	Medicinal, ornamental
<i>Alchornea discolor</i> Poepp.	Supiarana	Madeira (embalagem), ornamentação
<i>Alchornea sidifolia</i> Müll. Arg.	Urucurana	Reflorestamento, madeira (tabuás)
<i>Alchornea triplinervia</i> (Spreng.) Müll.Arg.	Tapiá	Reflorestamento, madeira (tabuás), medicinal
<i>Aleurites moluccanus</i> (L.) Willd.	Nogueira-da Índia,	Ornamental
<i>Aparisthium cordatum</i> (A.Juss.) Baill	Marmeleiro	Medicinal, paisagismo
<i>Bernardia pulchella</i> (Baill.) Müll. Arg	Canela-de-virá	Medicinal
<i>Caryodendron amazonicum</i> Ducke	Mamaluco	Medicinal
<i>Caryodendron orinocense</i> H. Karst.	Tacai	Alimento, perfumaria, madeira, medicinal, fertilizante
<i>Cnidoscolus phyllacanthus</i> (Müll. Arg.) Pax & L. Hoffm.	Favela, faveleiro, quimadeira	Alimento gado, medicinal, forrageira
<i>Cnidoscolus quercifolius</i> Pohl	Favela-de-cachorro	Medicinal
<i>Cnidoscolus urens</i> (L.) Arthur	Cansação	Medicinal
<i>Croton heliotropiifolius</i> KUNTE	Velame	Medicinal e reflorestamento
<i>Croton hirtus</i> L'Hér.	Croton	Medicinal
<i>Euphorbia heterophylla</i> L.	Erva-de-leite	Medicinal
<i>Jatropha curcas</i> L.	Pião-branco	Ornamental
<i>Jatropha gossypifolia</i> L	Pinhao-roxo	Medicinal, cosmético, alimento animal, combustível, ornamental
<i>Manihot esculenta</i> Crantz	Mandioca	Alimento
<i>Ricinus communis</i> L.	Mamona	Codimento, óleo, biocombustível, medicinal
<i>Sebastiania jacobinensis</i> (Müll. Arg.) Müll. Arg.	Leiteiro	Combustível

Fonte: TRINDADE; LAMARIA, 2014.

A família Euphorbiaceae tem um amplo espectro na sua utilização na medicina alternativa, bem como o gênero que também está compreendido nesta família, *Cnidoscolus*, gênero este que é bastante citado em estudos etnofarmacológicos, em contrapartida, pouca são as comprovações e estudos científicos que revelem suas propriedades biológicas.

2.3.1 O Gênero *Cnidoscolus* Pohl

Este gênero proposto por Pohl (MELO; SALES, 2008), apresenta uma distribuição por todo o território brasileiro no Norte (Pará, Tocantins), Nordeste (Maranhão, Piauí, Ceará, Rio Grande do Norte, Paraíba, Pernambuco, Bahia, Alagoas, Sergipe), Centro-Oeste (Mato Grosso, Goiás, Distrito Federal, Mato Grosso do Sul), Sudeste (Minas Gerais, Espírito Santo, São Paulo, Rio de Janeiro) e no Sul (Paraná) (Figura 1) (CORDEIRO; SECCO, 2012).

Cnidoscolus, do grego: knide = urtiga, skolos = ponta, são popularmente conhecidos como “urtiga”, uma das características peculiares deste gênero é a presença de tricomas urticantes, os quais provocam irritações severas, na área de contato, severas. Seus representantes são encontrados principalmente na América Tropical, e praticamente predominantes no México e no Nordeste Brasileiro. Para este gênero são relatados cerca de 50 a 75 espécies, em toda América tropical (PEIXOTO SOBRINHO et al., 2012).

No estado de Pernambuco o gênero *Cnidoscolus* é representado por oito espécies, segundo Melo; Sales (2008), *C. bahianus* (Ule) Pax & K. Hoffm., *C. loefgrenii* (Pax & K. Hoffm.) Pax & K. Hoffm., *C. obtusifolius* Pohl, *C. oligandrus* (Müll. Arg.) Pax, *C. quercifolius* Pohl, *C. urens* (L.) Arthur, *C. urnigerus* (Pax) Pax e *C. vitifolius* (Mill.) Pohl. *C. urens* ocorre praticamente em todos os Biomas. *C. loefgrenii* pode ser encontrado na Zona da Mata e Caatinga, *C. quercifolius*, *C. obtusifolius*, *C. vitifolius*, *C. bahianus* e *C. urnigerus*, com registro na Caatinga e *C. oligandrus* presente somente na Zona da Mata (MELO; SALES, 2008). No entanto, Peixoto Sobrinho et al. (2011), traz a informação que na Caatinga, o gênero é representado por quatro espécies que se destacam por apresentar uma imensurável diversificação quanto a sua utilização, entre elas, *C. infestus* Pax & K. Hoffm., *C. pubescens* Pohl, *C. quercifolius* Pohl e *C. urens* (L.) Arthur.




Figura 1. Distribuição geográfica do gênero *Cnidoscolus* sp no Brasil. Áreas coloridas nas cinco regiões (Norte, Nordeste, Centro- Oeste, Sudeste e Sul) do Brasil demonstram a presença do gênero.

Fonte: CORDEIRO; SECCO, 2012. *Cnidoscolus* in Lista de Espécies da flora do Brasil. Disponível em: <http://floradobrasil.jbrj.gov.br/2012/index?mode=dp&tid=17491>.

Estudos sobre o perfil fitoquímico, a partir de extratos metanólicos, deste gênero revelaram a presença de cumarinas, flavonóides, taninos, fenóis e terpenóides como metabólitos secundários (PEIXOTO SOBRINHO et al., 2012). Várias são as doenças em que os *Cnidoscolus* são indicados através dos conhecimentos populares. Essas indicações incluem atividades anti-inflamatória (ALBUQUERQUE, 2006), antitumoral, para tratamento do sistema genito-urinário, como anti-séptico e no tratamento de infecções renais, lesões dermatológicas e oftálmicas, contusões, fraturas, ferimentos, verrugas, disenteria, hemorragia, apendicite, reumatismo (PEIXOTO SOBRINHO et al., 2012; ALMEIDA et al., 2005) e contra micoses (ALBUQUERQUE et al., 2007). Além da empregabilidade que o gênero apresenta na medicina caseira, este ainda pode ser utilizado como forrageiras, oleífera, laticífero e ornamental (MELO; SALES, 2008).

Por ser utilizada na medicina popular, de uso comum no Nordeste e em outras regiões do mundo e sempre citada em levantamentos etnobotânicos, a espécie *C. urens* se destaca dentro do gênero.

2.3.2 Espécie *Cnidoscolus urens* (L.) Arthur

Largamente distribuída em todo território brasileiro, chamada popularmente por cansanção, arrediabo, cansanção de leite, pinha queimadeira, urtiga de mamão, urtiga cansanção ou simplesmente urtiga, o *C. urens* é uma planta invasora (SÁTIRO; ROQUE, 2008).

Esta espécie pode variar de subarbustos a arbustos, medindo entre 0,5- 2,5 m de altura (SÁTIRO; ROQUE, 2008). É uma espécie nativa do Brasil e apresenta distribuição geográfica nas regiões do Nordeste (Piauí, Rio Grande do Norte, Paraíba, Pernambuco, Bahia, Ceará, Alagoas, Sergipe), Centro-Oeste (Mato Grosso, Goiás, Distrito Federal), Sudeste (Minas Gerais, Espírito Santo, São Paulo, Rio de Janeiro) e Sul (Paraná) (**Figura 2**) (CORDEIRO; SECCO, 2012).




Figura 2: Distribuição geográfica da espécie de *C. urens* no Brasil. Áreas coloridas nas quatro regiões (Nordeste, Centro- Oeste, Sudeste e Sul) do Brasil demonstram a presença da espécie.

Fonte: Cordeiro; Secco, 2012. *Cnidoscolus* in Lista de Espécies da Flora do Brasil. Disponível em: <http://floradobrasil.jbrj.gov.br/2012/index?mode=dp&tid=17495>.

A espécie é bastante conhecida pela presença de pêlos urticantes chamados de tricomas urticantes, que são quebradiços e quando o tricoma é quebrado ocorre uma liberação instantânea de cristais de oxalato de cálcio os quais provocam irritações quando em contato com a pele (MALHEIROS, 2012).

O *C. urens* tem como característica que auxilia no seu reconhecimento, numerosas glândulas papiliformes na junção do pecíolo com a lâmina, perianto das flores pistiladas com segmentos livres ou raramente unidos (MELO; SALES, 2008). As folhas da espécie são membranáceas, lâmina foliar lobada, ovada, com lobos centrais e laterais, da ápice agudo e margens serradas, estípulas triangulares. A inflorescência com 16 dicásios, brácteas, ápice agudo e bubescente. Suas flores estaminadas e pistiladas, sésseis, cálice tubular-hipocrateriforme, lobos elípticos a oblongos, glabros, não urticantes, com disco nectarífero proeminente, estames em 10 e desprovidas de odor (ARAÚJO; LEAL; QUIRINO, 2012; SÁTIRO; ROQUE, 2008). Quanto às sementes, são ditas oblongas, do tipo cápsula que se abrem para dispersão das sementes odor (ARAÚJO; LEAL; QUIRINO, 2012) (**Figura 3**).




Figura 3: Aspectos gerais de partes de *Cnidoscolus urens*. (A) Planta inteira, (B). Folha, (C) Semente, (D) Flor.

Fonte: SOUZA, P.G.V.D., 2016.

A ocorrência de *C. urens* se dá durante todo o ano e as maiores florações juntamente com a frutificação ocorrem durante os meses de abril e julho, mas durante os outros meses podem-se encontrar arbustos floridos, essa constante floração atribui a espécie importantes recursos alimentares. Assim sendo, espécies com este tipo de característica de floração, atribuem importantes fontes alimentares, já que ofertam estes recursos durante todo o ano (ARAÚJO; LEAL; QUIRINO, 2012).

Estudos prévios de Peixoto Sobrinho et al. (2012) identificaram a presença de antocianinas, derivados de antraquinonas, antraquinonas, cumarinas, flavonóides, taninos, triterpenos, esteróides, mono e diterpenos, xantinas pela extração com metanol de partes aéreas

de *C. urens* e na extração da raiz, pelo mesmo processo foram identificados derivados de antraquinonas, cumarinas, lignanas, mono, di e triterpenos, saponinas e esteróides.

Esta espécie nativa revela-se de grande acuidade, sendo a mais relatada em estudos etnofarmacológicos, onde populares utilizam suas raízes e cascas do caule para tratamento das mais diversas doenças, pois acreditam que esta espécie tem um potencial terapêutico contra cânceres, processos inflamatórios variados, dores generalizadas, problemas renais, disenteria, hemorragias, apendicite e reumatismo (AGRA et al., 2007b; ALBUQUERQUE, 2006; ALBUQUERQUE et al., 2007). Porém, até o momento não foram encontrados registros de sua utilização na agricultura, com ação inseticida.

Os conhecimentos populares são estímulos que incentivam a ampliação dos conhecimentos sobre as ações biológicas e mecanismos, apontando o potencial terapêutico que *C. urens* desempenha. Assim faz-se importante à realização de novos estudos não só sobre a espécie, mas também sobre a família, pois sua presença é notada em estudos etnobotânicos realizado por todo o Nordeste.

2.4 Atividade Biológicas

2.4.1 Atividade Antitumoral

Por haver muitas referências à neoplasia, na literatura médica da Grécia Antiga, a palavra “neoplasia”, significa novo crescimento, Hipócrates criou os termos *Karkinos* e *Karkinôma*, derivados de *Karkinos* que denotam úlceras não cicatrizadas e tumores malignos sólidos, respectivamente. (PASCOAL et al., 2010; CERDEIRA FILHO, 2008). Outros relatos existentes, também da Grécia Antiga entre 138 e 201 d.C. aproximadamente, Galeno, médico de origem grega, tenha feito analogia entre o tumor e o caranguejo. (PASCOAL et al., 2010). A palavra neoplasia é a definição científica empregada para referendar o “câncer”. (ALMEIDA et al., 2005; CERDEIRA FILHO, 2008). A expressão câncer surgiu um pouco mais tarde, advinda do latim da palavra *cancrum* que quer dizer “caranguejo”, essa designação foi atribuída ao câncer por apresentar-se com veias intumescidas e profundas, sendo comparadas as patas de um crustáceo quando firmasse na areia prendendo-se e dificultando sua remoção. (MINISTÉRIO DA SAÚDE, 1971; ALMEIDA et al., 2005).

Entretanto, podemos definir a palavra neoplasia como sendo, o crescimento descontrolado de uma nova massa celular/ tecido onde sua origem pode ser benigna ou maligna, já o câncer está relacionado ao crescimento desordenado de uma massa celular/ tecido de ascendência maligna (BOGLIOLO, 1998; MOURA et al., 2001).

Com a falta de conhecimento, sobre o comportamento desta doença, somente no final do século XVIII, o câncer iria começar a ser entendido, a cerca de como ele poderia progredir e destruir órgãos. Sua ação invasiva, agressiva e progressiva atribuiu ao câncer um protótipo estigmatizado segundo o qual, de fato, pessoa que estivesse acometida com tal doença, na certa teria uma morte precoce e seriam rejeitadas pelo seu grupo de convivência. Essa rejeição dar-se-ia devido à crença de caráter contagioso do câncer incentivada pela ciência, que perdurou até as duas primeiras décadas do século XX (CARVALHO, 2006).

O termo câncer/neoplasia tornou-se generalizado e agora é utilizado para identificar mais de uma centena de doenças. É definido e caracterizado por um histórico clínico-patológico de uma enfermidade multifatorial crônica, com perda de peso (cerca de 30% dos pacientes com câncer, apresentam perda de peso superior a 10%) e desnutrição, além do crescimento desordenado, proliferativo e difuso de células transformadas, as quais podem invadir tecidos e órgãos levando a formação de um novo tecido atípico: o tumor. Células de um tumor primário podem disseminar-se para diversas partes do corpo e diferentes órgãos levando ao surgimento de tumores secundários, assinalando-se como metástase. (MINISTÉRIO DA SAÚDE, 1971; ALMEIDA et al., 2005; GARÓFOLO et al., 2004; GARÓFOLO; PETRILLI, 2006; KOWATA et al., 2009).

O câncer ganha relevância pelo perfil epidemiológico que apresenta, até os dias atuais por ser considerada uma das doenças que mais causa mortes no mundo. Segundo a Organização Mundial de Saúde (OMS) em 2012 houve um total de 8,2 milhões de mortes por câncer e 14,1 milhões de novos casos de câncer. De acordo com essa estimativa o percentual de câncer continuará aumentando em países em desenvolvimento e também crescerá ainda mais em países já desenvolvidos. No Brasil, para o ano de 2014 e 2015 existiram aproximadamente 576 mil novos casos de câncer (INCA, 2014). Os tipos de câncer mais incidentes na população brasileira para o ano de 2014, são demonstrados na figura 4.




Figura 4: Incidência de diferentes tipos de câncer no Brasil.

Fonte: INCA (2014).

O processo complexo da formação e desenvolvimento das neoplasias, denominado carcinogênese, surge de uma série de alterações genéticas (alterações de genes ou cromossomo) e epigenéticas (expressão ou não de um determinado gene) (Figura 5) e ocorre em três etapas: iniciação, promoção e progressão. A iniciação é provocada por uma desregulação genômica, devido a um agente carcinogênico que incita modificações permanentes em alguns de seus genes, transformando a célula (BOGLIOLO; BRASILEIRO FILHO, 2006).

Esta, agora iniciada, se apresenta menos responsiva a fatores que interfira no crescimento celular ou aos indutores de diferenciação celular ou à apoptose (BOGLIOLO; BRASILEIRO FILHO, 2006). A etapa de promoção consiste na proliferação ou expansão das células devido a uma série de interações entre citocinas, fatores de crescimento e seus receptores. Para que o processo de transformação em célula maligna ocorra é necessário a exposição longa e continuada com o agente cancerígeno promotor.




Figura 5: Etapas de instalação do câncer.

Fonte: ABEL et al, 2009.

Os promotores são substâncias que apresentam uma propriedade em comum, de provocar irritação dos tecidos desencadeando reações inflamatórias e proliferativas, como por exemplo o promotor mais conhecido, o 12-O-tetradecanoilforbol-13-acetato (TPA) (BOGLIOLO & BRASILEIRO FILHO, 2006).

Sendo complexo processo, a carcinogênese inicia-se e se estabelece por danos genéticos induzidos por agentes carcinogênicos como: a radiação, vírus ou agente químicos (Figura 6). Os danos ocorrem nos genes conhecidos como, proto-oncogenes, que são promotores do crescimento celular, e genes supressores de crescimento celular e ainda alterações em genes que controlam o processo de morte programada das células (Figura 7). Por fim, o tumor após seu surgimento sofre modificações biológicas que o tornam mais agressivo e maligno, este processo é designado progressão tumoral e é caracterizado pela multiplicação descontrolada irreversível (ONCOGUIA, 2014).




Figura 6: Desenvolvimento e modificações genéticas para o surgimento da carcinogênese.

Fonte: SOUZA, P. G. V. D., 2016.



Figura 7: Esquema simplificado da patogênese do câncer. Demonstração dos genes que podem sofrer mutações e que estão envolvidos com o surgimento do câncer.

Fonte: GOMES, 2008.


As neoplasias podem ser divididas de acordo com vários critérios: comportamento clínico (benignas e malignas), aspectos microscópicos (histomorfológico) e pela origem do tumor (histogenético). As neoplasias benignas possuem suas células bem diferenciadas, discretas atipias celulares, baixo índice mitótico, com crescimento lento e expansivo,

delimitação e geralmente não recidivam após cirurgia de remoção. Já as malignas apresentam alterações na expressão gênica com tendências à síntese de isoformas de enzimas predominantes na fase embrionária, rápida captação de aminoácidos, resistência a hipóxia, são indiferenciadas e provocam metástase (BRASILEIRO-FILHO et al., 2000). Têm como componentes básicos todas as neoplasias, o parênquima constituído de células tumorais e estroma, composto principalmente de vasos neoformados e células inflamatórias e de tecido conjuntivo (DVORAK, 1986).

Inúmeras são as razões que levam a perda de função dos genes que regulam o ciclo celular, podendo ser por múltiplos fatores. A predisposição genética, fatores físicos, químicos e biológicos são exemplos. E os riscos envolvidos com a predisposição para o desenvolvimento de um câncer podem ser identificados por alterações moleculares. A carcinogênese se instala lentamente, levando anos, até que o primeiro sinal seja percebido, sendo mais comum em pessoas de idade avançada, devido ao acúmulo de mutações, danos oxidativos e diminuição da resposta imune (GOMES, 2008).


Existem hoje várias formas de tratamento para o câncer com maior eficácia, como esquemas terapêuticos associados a cirurgia, radioterapia e quimioterapia (RAINER et al, 2009). A remoção do tumor com intuito curativo pela cirurgia oncológica, realiza uma drenagem linfática dos linfonodos locais e do tecido normal em quantidades suficientes mantendo uma margem de segurança adequada (TEICH; FRANKS, 1990). A radioterapia é um método no qual aplica-se feixes de radiações ionizantes a um determinado tempo e volume de tecido que engloba o tumor com o intuito de destruí-lo, porém não age de forma específica e resulta também na lesão de células saudáveis. A quimioterapia emprega a utilização de medicamentos com o objetivo de destruir as células cancerosas bloqueando o seu desenvolvimento.

Um dos principais fármacos utilizados no tratamento de diversos tipos de câncer é o 5-Fluorouracil (5-FU) (Figura 8), é um análogo da uracila, contendo um átomo de flúor na posição 5 ao invés de um hidrogênio, amplamente usado a mais de 50 anos para tratar câncer de cólon, de mama, de cabeça e de pescoço. Ele age incorporando Fluoronucleotídeos ao DNA ou RNA, bem como inibindo a ação enzimática da Timidilato sintetase (responsável pela síntese de DNA) (LONGLEY; HARKIN; JOHNSTON, 2003).



Fonte: GREM, 2000.

Após sua administração, 80% do fármaco é catabolizado no fígado por ações enzimáticas, a massa biodisponível é transportada para o interior da célula convertida em três metabólitos ativos: Fluorodesoxiuridina-monofasfato (FdUMP), trifosfato de fluorodesoxiuridina (FdUTP) e fluorouridina trifosfato (FUTP). Após a conversão dos metabólitos, sua ação pode ser direta pela incorporação causando danos celulares ou irá ainda ativar a via alternativa pela inibição da timidilato sintetase (Figura 9 e 10). (LONGLEY, HARKIN; JOHNSTON, 2003). Os diferentes medicamentos anticancerígenos agem por diversos mecanismos e podem ser derivados também de organismos marinhos, microrganismo e plantas.



Fonte: LONGLEY; HARKIN; JOHNSTON, 2003.




Figura 10: Via alternativa envolvendo a timidina sintetase, resultando em dano ao DNA.

Fonte: LONGLEY; HARKIN; JOHNSTON, 2003. 5-Fluorouracil: Mechanisms of Action and Clinical Strategies.

Os produtos naturais têm se destacado entre outros recursos, como sendo um dos mais utilizados na busca de novos componentes antineoplásicos. E segundo Lima (2006), das 250.000 espécies de plantas existentes em todo mundo, aproximadamente cerca de 1000 espécies diferentes de vegetais apresentam ação antitumoral.

E muitas espécies e compostos isolados dos vegetais já foram testados quanto a sua ação antitumoral: terpenos, alcalóides, cumarinas, lignanas, flavonóides, taninos, stilbenos, curcuminóides, polissacarídeos (PEI-WEN et al, 2005, GOMES, 2008). Segundo Gullo et al. (2006) das novas drogas utilizadas para o tratamento dos tumores, 60% desses novos tratamentos são de origem natural. Um exemplo são os alcaloides (vinblastina e vincristina) extraídos da *Catharanthus roseus* e paclitaxel, extraído de *Taxus brevifolia*.

2.4.2 Anatomia, Fisiologia, Motilidade, Secreção do trato gastrointestinal e a Diarreia

Em seu pleno funcionamento, por sua ação contrátil e secretora, o TGI tem sua função relacionada com a absorção, secreção e motilidade (SILVERTHORN, 2010; CHEN et al., 2010). Em sua fisiologia, o TGI é formado por 4 camadas (Figura 11): mucosa, submucosa, camada muscular circular e longitudinal e por último a camada serosa, sendo coordenadas por uma rede de nervos do sistema nervoso entérico (SNE) (SILVERTHORN, 2010). O estímulo da motilidade do intestino é iniciado em decorrência do esvaziamento do estômago, sendo

modulada por fatores nervosos e humorais, sendo a acetilcolina (ACh) o principal neurotransmissor (GUYTON; HALL, 2006).




Figura 11: Lúmen do trato gastrointestinal. O trato gastrointestinal possui quatro camadas que auxiliam a desempenhar as funções durante o processo digestivo.

Fonte: <<http://magicnumbers-parussolo.blogspot.com.br/2011/05/sistema-digestorio.html>>, traduzido por Souza, P. G. V., 2016.

Atuando nos receptores muscarínicos (M3), a ACh liga-se a proteína G, provocando mudanças conformacionais e causando fosforilação por uma molécula de GTP, a qual induzirá uma dissociação da proteína G. A proteína G que foi subdividida, liberará a subunidade alfa-GTP, e ativará a fosfolipase C- $\beta 1$ (PLC $\beta 1$) e que atuará hidrolisando o fosfatidilinositol bifosfato (PIP2) em inositol trifosfato (IP3) e diacilglicerol (DAG). O IP3 se liga aos seus receptores que estão localizados no retículo sarcoplasmático das células e induz a liberação de Ca^{2+} , o qual irá atuar liberando mais Ca^{2+} . O aumento da concentração de Ca^{2+} intracelular mais o DAG ativa proteinocnase C (PKC) que contribuirá para a inativação dos canais de potássio (SILVERTHORN, 2010; BRUNTON et al., 2011).

A concentração de K^+ aumentada conduz a uma despolarização da membrana e abertura dos canais de cálcio dependentes de voltagem (Ca_v), levando ao influxo de cálcio na célula muscular lisa. O Ca^{2+} se liga a proteína ligadora de cálcio (CaM) ativando MLCK que por sua vez estimula a contração muscular (SILVERTHORN, 2010; BRUNTON et al., 2011).

Por ação da SERCA, que bombeia o Ca^{2+} do citosol para dentro do retículo, diminuindo a concentração de Ca^{2+} , assim como, a ativação da PMCA que empurraram sódio para o interior da célula e retira o cálcio, bem como a atividade da MLCP, ocorre o relaxamento do tecido musculares liso intersticial (SILVERTHORN, 2010; BRUNTON et al., 2011). Processo ritmado e executado por células chamadas de células de Cajal, localizadas na camada muscular (TACK, 2007).

Na luz intersticial, se dá o controle da secreção. Neste processo estão envolvidos o Ca^{2+} , Cl^- , e HCO_3^- , o controle da secreção desses íons é realizado por vários transportadores transmembranares e a secreção do Cl^- ocorre pela abertura dos canais iônicos, que é regulado pelo AMPc ou CMPc, por ativação de proteínas cinases, a qual estimula o bombeamento dos íons através dos canais. Assim, qualquer processo patológico que resulte no aumento de AMPc, promove abertura dos canais com secreção de Cl^- , Na^+ e H_2O para o lúmen intestinal (VANNUCCI; GUEDES, 2009; DONOWITZ et al., 2012).

Processos patológicos como, infecção bacteriana, toxinas, antibióticos, antiácidos contendo magnésio, produtos contendo lactose, análogos de prostaglandinas, colchicina, antineoplásicos, gastrina, serotonina, bem como inibidores, a noradrenalina, colecistocinina, NO, peptídio YY, prostaglandinas, dopamina e peptídeo intestinal vasoativo e agentes colinérgicos, provocam a diarreia (CHASSANY et al., 2000; KOEPPEN; STANTON, 2009; CHEN et al., 2010).

Estes agentes contribuem para o aumento de AMPc ou GMPc que estão envolvidos com a ativação de PKA, PKG e por sequencia fosforilação dos reguladores de bombeamento de íons transmembrana. Havendo abertura dos canais de reguladores transmembrana de fibrose cística (CFTR), um aumento o bombeamento de íons (Cl^- e Na^+) e água para o lúmen intestinal, acontecerá, induzindo alterações na motilidade e secreção intestinal, causando a diarreia (VANNUCCI; GUEDES, 2009; DONOWITZ et al., 2012).

A primeira estimativa da grandeza do problema das doenças diarreicas agudas, foi realizado por Snyder e Merson, em 1982 (SNYDER; MERSON, 1982). Infecções gastrointestinais, tem como principal sintoma, a diarreia, que mata cerca de 1,5 milhões de crianças todos os anos. Ainda que existam tratamentos baratos e eficazes, o quantitativo de

casos e internações com doenças diarreicas ainda é muito alto e apenas 39% das crianças com diarreia, recebem tratamento adequado. Embora a maioria dos casos não apresentem evolução mais grave, alguns agentes etiológicos podem contribuir para evolução grave, podendo chegar até o óbito. Mundialmente, os números de óbitos por diarreia, podem ser atribuídos à má qualidade da água, inadequação de saneamento e falta de higiene, contribuindo para um percentual de 88% da totalidade (UNITED NATIONS CHILDREN’S FUND e WORLD HEALTH ORGANIZATION, 2009).

Uma das doenças mais comum em quase todos os países de clima tropical do mundo, apresentando fases de agravamento, a diarreia é uma das principais causas de mortalidade nos países em processo de desenvolvimento socioeconômico (SATISH; RANJANA, 2015). O maior índice de mortalidade pode ser encontrado entre crianças de até cinco anos de idade, esses resultados podem ser comprovados na figura 12.




Figura 12: Proporção de óbitos por doenças diarreica aguda em > de 5 anos de idade.

Fonte: DATASUS (2012) modificado por Souza, P.G.V.D., 20016.

As afecções que levam a uma alteração intestinal, evoluindo para um quadro aumentado de números de evacuações, é uma das causas mais comum de morte nos países como a Nigéria e a segunda causa de morte entre crianças no mundo. Só na Europa, em 2001, foram constatados 1.793,000 casos de morte. A diarreia infecciosa é considerada uma doença fatal e grave, com o resultado de 4 a 6 milhões de óbitos/ano no mundo (BAMISAYE et al, 2013).

A diarreia pode ser desencadeada, na maioria das ocasiões por infecções gastrointestinais, podendo ser causadas por várias etiologias Tabela 5 (MINISTÉRIO DE SAÚDE, 2014).

Tabela 5: Tipos de agentes etiológicos desencadeadores de diarreia.

INFECCIOSA	NÃO INFECCIOSA
Bactérias e suas toxinas	Intolerância a lactose e glúten
	Ingestão de grandes quantidades de adoçantes
Vírus	Ingestão demasiada de alguns alimentos
	Sais mal absorvidos (Ex: laxantes e antiácidos)
Toxinas naturais	Ácidos biliares (após ressecção ileal)
	Gorduras não absorvidas
Parasitas	Algumas drogas (Ex.: catárticos, óleo de rícino, prostaglandinas)
	Hormônios peptídicos produzidos por tumores pancreáticos.

Fonte: Portal Saúde, MINISTÉRIO DA SAÚDE (2014), modificado por Souza, P. G. V. D., 2016.

A síndrome diarreica é caracterizada clinicamente, por uma alteração no volume, consistência e frequência, associada a uma liquidez das fezes. Podendo ainda estar acompanhada por intensas dores abdominais, febre e ainda vômito. Por tanto, caracterizando-se por uma quantidade anormal de fezes malformadas, aumento do número de evacuações, podendo durar até 14 dias. O comprometimento no equilíbrio do bom funcionamento do sistema digestivo, equilíbrio entre a reabsorção e secreção da mucosa intestinal, leva a um aumento da perda de água e de eletrólitos, pela liquefação, malformação das fezes e uma massa fecal superior a 200g/ dia (WGO, 2012; THIELMAN; GUERRANT, 2004).

Sendo chamados de antidiarreicos, esses fármacos atuam reduzindo os sinais da diarreia, melhorando a frequência, o volume e a consistência das fezes. Desta forma, os antidiarreicos exercem seus efeitos sobre a regulação da motilidade intestinal e da secreção de água e íons (BRUNTON et al., 2011). A terapêutica abordada para as doenças diarreicas deve ser iniciada pela hidratação oral, alimentação adequada e medicamentos que auxiliam na regulação da reabsorção de nutrientes, como a loperamida e o difenoxilato. A exemplo, a loperamida atua

diminuindo a motilidade e a secreção do fluido gastrointestinal (WANG et al., 2005; MARCOS; DUPONT, 2007). Fármacos com ação no retardamento do trânsito intestinal devem ser evitados em casos de infecções bacterianas, a fim de evitar a evolução da doença, com riscos de infecções sistêmicas (BRUNTON et al., 2011).

Os medicamentos utilizados para a terapêutica das DDA, são de classes diversas, desde antibióticos, opiáceos até antagonista de receptores muscarínicos. Entretanto, alguns desses fármacos, como a loperamida, podem desenvolver efeitos não desejados: constipação e distensão abdominal (RANG et al., 2011).

A Organização Mundial de Saúde, estimular a pesquisa com produtos naturais a serem utilizados como possível e potentes terapêuticos para diversas patologias, a fim de proporcionar tratamento eficaz, de baixo custo e com menor ou até mesmo nenhum efeito adverso. Assim, fica exposta a necessidade de novas pesquisas que possam comprovar os conhecimentos populares, tencionando a produção de novos fármacos com ação otimizada e mais acessível.

2.4.3 Controle de Insetos Praga

A guerra que o homem travou para habituar-se a natureza, faz parte da história da botânica e para tal adaptação o homem utiliza-se dos recursos naturais, em diversas áreas, como na medicina, na indústria e na agricultura. E desde da antiguidade a defesa contra pragas agrícolas, que se caracteriza por um surto de determinada espécie nociva ao desenvolvimento agrícola, é realizada com a utilização de plantas e mais recentemente, aplicação de substâncias sintetizadas, como os agrotóxicos (GALLUN, KHUSH, 1984; VIEGAS-JÚNIOR, 2003). A etimologia aplicada, remete desde os tempos mais remotos, estudos que retratam esta realidade além de apresentar a resistência de plantas a insetos (ORTMAN; PETERS, 1984)

A prática de controle de insetos é realizada pela aplicação de uma substância conhecida como inseticida, substâncias assim chamadas por ter ação letal, inibidora ou repelente contra essas pragas. Esses agentes são utilizados para controlar infestações de pragas que atacam tanto na zona rural e quanto na zona urbana (ADDOR, 1994) e começaram a ser utilizados após a Segunda Guerra Mundial e assim muitos desses compostos orgânicos passaram a ser sintetizados (LIU et al., 2011).

Organoclorados, organofosforados e carbamatos são inseticidas sintéticos e são bastante utilizados para o controle de inseto- pragas. A grande questão se dá pelo emprego desta prática em larga escala. O uso indiscriminado contribui para o aparecimento de populações de insetos resistentes, prejuízo ao meio ambiente, efeitos sobre outras populações que não são alvo, além de danos à saúde humana, em específico para aqueles que trabalham diretamente com esses produtos (BARROS et al., 2006; LEITE et al., 2007).

Inicialmente, dosado pela sua eficiência quanto ao controle de pragas em associação aos custos, eram considerados os melhores defensivos, mais posteriormente, a busca acontece de forma diferente, e a eficiência e economia, já não eram mais o padrão. Os interesses estavam em alternativas que não apresentassem prejuízo à saúde humana e ambiental. Recentemente, mais exigências, é preciso avaliar mais propriedades, tais como: mecanismo de ação, especificidades, degradação ao ambiente e segurança à saúde e ao ambiente (SALAZAR, 1997).

Com o interesse crescente pela agricultura, o homem desenvolveu maiores preocupações acerca das pragas com potencial em atacar suas plantações ou ainda causar qualquer outro tipo de dano e por isto passou a compreender melhor o que representa as pragas. As infestações por insetos, ameaça as culturas trazendo consigo ameaças devastadoras, como a fome e ameaçando também a saúde humana e ambiental. E isto tem levantado uma certa inquietação e têm sido acompanhadas pela criação de estratégias mais adequadas. Neste cenário atual, tem- se percebido a busca por novos métodos, que envolve a aplicação de biocidas (CASIDA; QUISTAD, 1998; BESTETE et al., 2011).

Fatalmente o emprego de inseticidas convencionais acarreta em desequilíbrio biológico, como por exemplo, a morte ou repelência de espécies polinizadoras (AZEVEDO, 1998; KNAAK et al., 2012). A alternativa seria a substituição de técnicas convencionais, por técnicas de origem biológica a qual, seria uma alternativa para diminuir tais danos (SALAZAR, 1997). E talvez por isso, o controle biológico de pragas, seja uma área promissora.

A matéria prima vegetal se constitui uma nova fonte e praticamente inesgotável para a pesquisa de novas moléculas biologicamente ativas e com potencial toxicológico a serem aplicadas ao manejo e controle de pragas (SIMÕES et al., 2004; GRZESIUK, CATELAN,

GEBARA, 2013). E o Brasil detêm uma das maiores biodiversidades em espécies (COSTA, 2001). Algumas dessas espécies já foram investigadas quanto ao seu mecanismo de ação, com relação a reguladores do crescimento ou inseticida.

Em 2003, Junior, verificou que isolados de *Croton cajucara*, apresentou potencial inibidor de crescimento em *Heliothis virescens* e neurotóxico em *Cylas formicarius*. O potencial inseticida do extrato etanólico do caule de *Croton linearifolius* contra *Cochliomya macellaria* foi evidenciado por Cunha et al, em 2010. Segundo Grzesiu, Catelan e Gebara (2013), relataram que os extratos de folhas e galhos de *Croton florinbundus*, podem ser utilizados como isca para *Periplaneta americana*s. Vale destacar que todas essas espécies supracitadas fazem parte da mesma família, Euphorbiaceae, revelando sua importância como novas alternativas promissoras não apenas como inseticidas, mas também para outros fins.

Mesmo havendo potentes inseticidas, nos últimos anos o que se têm visto é a capacidade espantosa de resistência e adaptação dos insetos aos inseticidas sintéticos (MAIRESSE, 2005). Na atualidade, aparentemente existe um sucesso no controle biológico, pela utilização de técnicas de melhoramento genético para a resistência a pragas, através da engenharia genética, mas ainda assim, são técnicas caras e pouco exploradas (OLSON et al., 1996).

Não é por acaso que a utilização de inseticidas vem crescendo nas últimas décadas (TSUNECHIRO, FERREIRA, 2000), porém já se conhece os danos causados pela utilização extensiva dos agrotóxicos, como intoxicação e contaminação do meio ambiente, do aplicador e dos alimentos. Este contexto tem contribuído pela busca de novas alternativas, através de bioativos (BESTETE et al., 2011). Torna-se importante destacar que os produtos alternativos, apesar de apresentar menor toxicidade, podem afetar as plantações, por já existir alguns estudos que comprovem a ação na alteração no ciclo germinativo de algumas espécies. Partindo desta prerrogativa, informações sobre este tipo de interação ainda é bastante escasso, fazendo-se necessário estudo mais específicos que contribuam para a seleção de produtos mais adequados para serem aplicados como fitoinseticida (SMANIOTTO et al., 2013). E ainda apresenta vantagens como, alta especificidade em relação à praga alvo, sem causar danos a outros insetos, plantas e animais, sendo mais facilmente degradados que os sintéticos (KOUL; DHAWIWAL, 2001)

Apenas 1% do mercado mundial de inseticidas, é composto por fitoinseticidas. Essa realidade é atribuída a algumas barreiras encontradas. A escassez de recursos vegetais com atividade comprovada, o controle e padronização das formulações, são fatores que dificultam o registro e a comercialização destes produtos. Mesmo assim, é evidente que inseticidas vegetais é uma ferramenta vantajosa, inclusive no que se trata da obtenção de novos compostos bioativos contra novas pragas que possam surgir. Além disso, o interesse crescente por produtos naturais, conscientização de produtores e consumidores inclinando na direção de atitudes ecologicamente correta (ISMAN, 1997; VIEGAS- JUNIOR, 2003; KRINSKI, MASSAROLI, MACHADO, 2014). E ainda apresenta vantagens como, alta especificidade em relação à praga alvo, sem causar danos a outros insetos, plantas e animais, sendo mais facilmente degradados que os sintéticos (KOUL; DHAWIWAL, 2001).

2.4.3.1 O Gorgulho do Milho (*Sitophilus zeamais*), Insetos Praga de Grãos Armazenados

O Brasil é um dos maiores produtores mundiais de frutas (BOTTON et al., 2005a) e de grãos, principalmente de milho o qual é direcionado para alimentação humana e produção de ração animal. Esses produtos podem ser atacados por pragas levando a prejuízos (FONTES, FILHO ALMEIDA, ARTHUR, 2003). Aproximadamente 10% da produção de grãos são descartadas, devido aos danos causados pelo ataque de pragas, em especial pelo gorgulho do milho, o *Sitophilus zeamais* (PAIXÃO et al., 2009). Cerca de 20% da safra de milho, arroz, trigo e feijão, do Brasil entre o ano de 1991- 1992 foi desperdiçada pelo ataque de insetos praga (FONTES, FILHO ALMEIDA, ARTHUR, 2003).

Diante deste cenário, torna-se notória a perda qualitativa e quantitativa desses produtos, que geralmente acontecem no período de armazenamento dos grãos (PAIXÃO et al., 2009) ou ainda durante o período de amadurecimento (pré-colheita) das frutas susceptíveis aos ataques (BONETTI; RIBEIRO; KATSURAYAMA, 2002). Das causas e fatores que contribuem para estas perdas, estão os insetos praga, entre eles: mosca-da-fruta (*Anastrepha fraterculus*) (Figura 13 A), mariposa oriental (*Grapholita molesta*) (Figura 13 B), e o gorgulho (*S.s zeamais*) (Figura 13 C), que são um dos principais agentes causadores de danos em grãos armazenados e frutas, no Brasil, segundo Bonetti et al., (1999) e Botton; LORINI; AFONSO, (2005).



Figura 13: Espécies de insetos pragas que estão associados com os prejuízos e perdas da produção de grãos e frutas no Brasil. (A) *Anastrepha fraterculus* (Mosca das frutas Sul Americana), (B) *Grapholita molesta* (Mariposa oriental), (C) *Sitophilus zeamais* (Gorgulho de milho)

Fonte: [A] <http://quintaisimortais.blogspot.com.br/2013/07/anastrepha-fraterculus-mosca-das-frutas.html>

[B] http://agrolink.com.br/agricultura/problemas/busca/mariposa-oriental_1505.html

[C] <http://www.beefpoint.com.br/cadeia-produtiva/dicas-de-sucesso/pragas-de-armazenamento-de-milho-4575/>

Uma das maiores dificuldades encontradas no combate desses insetos, está envolvido com a forma com que os vegetais são parasitados. Como o gorgulho apresenta um período de ataque justamente próximo ao período de colheita, além, os insetos adultos ficam protegidos dentro dos frutos ou grãos, dificultando o contato com os inseticidas e podendo estes permanecerem depositados nos alimentos (BOTTON et al., 2005b).

O *S. zeamais* (Figura 14), sendo no Brasil, a principal praga para o milho, pode causar danos na reprodução deste grão, redução da biomassa, da qualidade e germinação das sementes (MARSARO JÚNIOR, et al., 2005; PAIXÃO et al., 2009). Foi descrito pela primeira vez em 1885, por Mostschuescky (TAVARES, 2002), hoje bem distribuído em regiões tropicais e temperadas (VILARINHO, 2012). Os insetos adultos (Figura 14 A) são pequenos, medindo em torno de 3 mm, de coloração castanha, possuem manchas avermelhadas nas asas (Figura 14 A-2), cabeça com projeção frontal e rostro curvados (Figura 14 A-1) apresentando peças bucais, as quais são mais curtas e grossas nos indivíduos machos (Figura 14), (VILARINHO, 2012) e ainda alimentam-se dos grãos. As fêmeas ainda utilizam os grãos para oviposição e proteção de seus ovos (Figura 14 B) (ALVES et al., 2008; SANTOS et al., 2010).




Figura 14: Características das fases do *Sitophilus zeamais*. [A]- Inseto adulto com destaque para o rostro (1) e manchas avermelhadas nos élitros (2), [B]- Estágios de desenvolvimento do inseto, (1) Fêmea ovopositando no interior do grão, (2) Larva em desenvolvimento no interior do grão, (3) Pupa, (4) Fase final, adulta, do inseto.

Fonte:

[A] <http://www.azoresbioportal.angra.uac.pt/listagens.php?lang=pt&sstr=8&id=A00470>,
[B] <http://www.agronegocios.eu/noticias/sitophilus-zeamais-e-sitotroga-cerealella-pragas-do-milho/>

As fêmeas da espécie do *S. zeamais*, com o período de pré-oviposição que dura cerca de 6 dias, logo após iniciando o ciclo de oviposição com duração de 104 dias, sendo 282, o número médio de ovos depositados por cada fêmea. Os ovos são depositados no interior dos grãos, através de um orifício aberto pelo aparelho bucal da fêmea. O tempo de incubação varia entre 3 a 6 dias, passando por 4 fases larvais, levando 34 dias até atingirem a fase adulta. Ao deixarem o grão, os novos insetos cruzam e dão início ao novo ciclo (GALLO et al., 2002; ANTUNES, DIONELLO, 2010).

A aplicação de produtos químicos para o combate e controle das pragas, normalmente é alcançado com o uso dos inseticidas do tipo fumigante ou com resíduos protetores, este segundo é o principal método preventivo (VASQUEZ- CASTRO, 2006). Segundo Coitinho et al. (2011), outras práticas também têm sido aplicadas de forma paralela, como a limpeza e secagem dos grãos, aeração e manutenção da temperatura. Porém, todas as alternativas, por mais viáveis que sejam, apresentam alto poder de causar intoxicações, deixar resíduos impregnados nos grãos e indução do aparecimento de espécies resistentes (VASQUEZ- CASTRO, 2006). Porém uma outra alternativa, aparentemente bastante promissora, se faz pela

utilização de espécies vegetais e por isto, o uso de extratos de espécies vegetais, como práticas alternativas podem ser mais sustentáveis (TAVARES et al., 2009; TAVARES et al., 2010).

Sendo assim, as aplicações indiscriminadamente desses inseticidas sintéticos têm desencadeado problemas com a produção de insetos resistentes e contaminação de alimentos com resíduos de agrotóxicos (MARSARO JÚNIOR et al., 2005) e envenenamento dos operadores (VILARINHO, 2016). Desvantagens como essas têm contribuído para impulsionar a busca por alternativas de menor impacto prejudicial para o homem, os grãos e o ambiente. Dentre as alternativas mais atuais são encontrados os inseticidas de origem vegetal (Figura 15). A utilização destas práticas tem como principais vantagens a redução de resíduos impregnados nos alimentos, dos efeitos nocivos a outros organismos não alvo, da intoxicação humana e problemas ambientais. Para tanto, essas pesquisas apresentam expressividade quando objetivam a descoberta de novas moléculas, as quais poderão ser aplicadas para o controle e combate de insetos praga (VILARINHO, 2016).




Figura 15: (A) Exemplar de inseticida de origem vegetal, (B) *Azadirachta indica*, (C) Estrutura química da azadiractina.

Fonte: [A] https://www.google.com.br/search?q=inseticida+de+origem+vegetal&source=lnms&tbm=isch&sa=X&ved=0ahUKEwin_tL2o6jNAhWHjJAKHcnXAFAQ_AUICSgC&biw=1360&bih=643#imgsrc=2Ln6KPqR4DY5NM%3A

[B] <https://www.cpt.com.br/cursos-agricultura/artigos/nim-um-agente-biologico-eficaz-no-controle-natural-de-pragas>

[C] <http://orquideascomocuidar.com/inseticida-natural-para-combater-pragas/>

Vários autores têm demonstrado e constataram muitas espécies vegetais com atividade inseticida. Liu, Goh e Ho (2007), testaram quanto a atividade inseticida de contato, deterrente e de fumigante de 40 espécies de erva medicina de 32 famílias botânicas, frente duas espécies de insetos: *S. zeamais* e *Tribolium castaneum*, dentre as famílias, destaca-se a espécie da família da Euphorbiaceae. Liu e colaboradores relataram que 30 das espécies exibiram atividades inseticidas.

Devappa et al. (2010) sugeriram que inseticidas contendo ésteres de forbol, desempenham atividade inseticida importante e esses produtos são produzidos como metabólitos secundários, pelos vegetais, principalmente por espécies da família Euphorbeaceae, principalmente pelo gênero *Jatropha*. Silva et al., (2012), constataram efeito inseticida sobre *S. zeamais* e *Rhyzopertha dominica*. Em estudos realizados por Silva et al. (2012), apresentaram mortalidade dos insetos para os grupos tratados com extrato aquoso das sementes, comprovando que as ações pesticidas também podem variar de acordo com as partes das ervas.

A utilização de plantas medicinais como *C. urens* e a sua impactante representação encontrada em citações nos estudos etnobotânicos, desperta curiosidade e são alavancas que impulsionam a busca pelo conhecimento sobre esta espécie, a cerca de sua potencial ação biológica e seus mecanismos, apontando o potencial terapêutico e agrícola que não apenas *C. urens*, mas outras espécies possam desempenhar. Assim faz-se importante à realização de novos estudos e pesquisas, afim de ampliar os conhecimentos e tornar esta espécie uma possível alternativa para a prevenção e o tratamento de enfermidade com menor efeito adverso e também seu emprego na agricultura diminuindo as chances de resistência e permanência de resíduos em grãos.

3 OBJETIVOS

3.1 GERAL

Investigar o perfil fitoquímico e avaliar o potencial biológico dos extratos aquoso e orgânico de *Cnidoscolus urens* coletadas em Caruaru/ área de Caatinga- PE.

3.2 ESPECÍFICOS

Realizar triagem Fitoquímica das frações acetato de etila, N- butanol e aquosa de extratos de *Cnidoscolus urens*;

Identificar as principais classes de constituintes químicos presente em extratos orgânicos e aquoso, derivados do metabolismo de *C. urens*, por análise em cromatografia em camada delgada (CCD);

Investigar a capacidade antioxidante dos extratos aquoso e orgânico de *C. urens*;

Determinar o perfil de segurança, através do estudo da toxicidade aguda (*in vivo*) de extratos aquoso e orgânico de *C. urens*;

Avaliar o efeito de citotoxicidade *in vitro* dos extratos aquoso e orgânico de *C. urens* frente à linhagem celular HELA;

Averiguar a atividade inibitória dos extratos aquoso e etanólico de *C. urens* frente a tumor sólido de carcinoma de Ehrlich;

Interpretar o perfil hematológico e bioquímico nos grupos experimentais com tumores sólidos induzidos e tratados com os extratos aquoso e orgânico de *C. urens*;

Estabelecer a capacidade de interferência na normalidade do sistema digestivo de extratos orgânicos de *C. urens*, em modelos animais;

Comprovar a ação antidiarreica de extratos orgânicos de *C. urens* frente a modelo de diarreia induzida por óleo de castor;

Identificar a influência dos extratos orgânicos de *C. urens* sobre a capacidade de interferir no acúmulo de fluido intestinal, além de sua capacidade de inferir sob o peristaltismo em modelos experimentais;

Verificar o efeito dos extratos orgânicos de *C. urens* sobre insetos praga.

Determinar a atividade inseticida de extratos orgânicos de *C. urens* e os índices nutricionais de *S. zeamais*.

Avaliar a toxicidade por ingestão de dieta artificial e da toxicidade por contato de extratos orgânico *C. urens* sobre *S. zeamais*

Avaliar a toxicidade por contato de extratos orgânicos de *C. urens* sobre *S. zeamais*.

REFERENCIAS BIBLIOGRÁFICAS

- ABEL, E.; ANGEL, J.; KIGUCHI, K. E DIGIOVANNI, J. **Multi-stage chemical carcinogenesis in mouse skin: Fundamentals and applications**. Nature Protocol, v. 4, n. 9, p. 1350- 1362, 2009.
- ADDOR, R.W. Insecticides. In: GODFERY, C.R.A. (ed.). **Agrochemicals from natural products**. New York: Marcel Dekker Inc., p. 1-62, 1994.
- AGRA, M. F, FREITAS, P. F., BARBOSA-FILHO, J.M. **Synopsis of the plants known as medicinal and poisonous in Northeast of Brazil**. Brazilian Journal of Pharmacognosy. v. 17, n. 1, p. 114- 140, 2007.
- AGRA, M. F.; BARACHO, G. S.; NURIT, K.; BASÍLIO, I. J. L. D.; COELHO, V. P. M. **Medical and Poisonous Diversity of the Flora “Cariri Paraibano”, Brasil**. Journal of Ethnopharmacology. v. 111, p. 383- 395, 2007b.
- ALBUQUERQUE, A.C. et al. **Patogenicidade de *Metarhizium anisopliae* var. *anisopliae* e *Metarhizium acridum* var. *acridum* sobre *Nasutitermes coxipoensis* (Holmgren) (Isoptera: Termitidae)**. Neotropical Entomology, v. 34, p. 585-592, 2005.
- ALBUQUERQUE, U. P. **Re-examining hypotheses concerning the use and knowledge of medicinal plants: a study in the Caatinga vegetation of NE Brazil**. Journal Ethnobiology and Ethnomedicine, v. 2, n. 3, p. 1- 10, 2006.
- ALBUQUERQUE, U. P., et al. **Medicinal plants of the Caatinga (semi-arid) vegetation of NE Brazil: A quantitative approach**. Journal of Ethnopharmacology. v.114. p.325–354, 2007.
- ALBUQUERQUE, U.P.; ANDRADE, L.H.C. **Uso de recursos vegetais da Caatinga: O caso do Agreste do Estado de Pernambuco (Nordeste do Brasil)**. Interciência, v. 27, p. 336-345, 2002.
- ALMEIDA, C. F. C. B. R., et al. **Life strategy and chemical composition as predictors of the selection of medicinal plants from the Caatinga (Northeast Brazil)**. Journal of Arid Environments. v.62, p. 127–142, 2005.
- ALMEIDA, C. F. C. B. R., et al. **Comparison of knowledge about medicinal plants for three rural communities in the semi-arid region of northeast of Brazil**. Journal of Ethnopharmacology. v. 127, p. 674–684, 2010.
- ALVES, M. V. **Checklist das espécies de Euphorbiaceae Juss. ocorrentes no semi-árido Pernambucano, Brasil**. Acta Botanica Brasilica, v.12, n.3, p. 485-495, 1998.
- ALVES, R. R. N. et al. **Utilização e Comércio de Plantas Medicinais em Campina Grande, PB, Brasil**. Revista Eletrônica de Farmácia. v. 4, n. 2, p. 175- 198, 2007.
- ALVES, W. M.; D’ANTONINO F. L. R.; ALENCAR, E. R.; PAES, J. L. **Influência do inseto-praga *Sitophilus zeamais* (Motschulsky) (Coleoptera - Curculionidae) na taxa**

respiratória e na perda de matéria seca durante o armazenamento de milho. Engenharia na Agricultura, v.16, p.260-269, 2008.

ANTUNES, L. E. G., DIONELLO, R. G. **Bioecologia de *Sitophilus zeamais* Motschulsky 1885 (Coleoptera: Curculionidae).** 2010. Artigo em Hypertexto. Disponível em: <http://www.infobibos.com/Artigos/2010_2/Sitophilus/index.htm>. Acesso em: jun. de 2016.

ARAÚJO, L. D. A., LEAL, A. S., QUIRINO, Z. G. M. **Fenologia e biologia floral da urtiga cansanção (*Cnidoscolus urens* L., Euphorbiaceae).** Revista Brasileira de Biociências. v. 10, n. 2, p. 140-146, 2012.

ARAÚJO, R. M. S, et al. **A new exogen anticoagulant with high selectivity to intrinsic pathway of coagulation.** Thrombosis research, v. 128, p. 395–397, 2011.

AZEVEDO, J. L. **Controle Biológico de Insetos- pragas e seu Melhoramento Genético.** In: Melo, I. S.; AZEVEDO, J. L., eds., Controle Biológico. v.1, Jaguariuna: EMBRAPA, p. 69-96, 1998.

BAMISAYE, F. A., et al. **Phytochemical constituents and antidiarrhoeal effects of the aqueous extract of *Terminalia superba* leaves on Wistar rats.** African Journal of Pharmacy and Pharmacology. Vol. 7(16), pp. 848-851, 2013.

BARROS, R. et al. **Flutuação populacional de insetos predadores associados a pragas do algodoeiro.** Arquivos do Instituto Biológico, v. 73, p. 57-64, 2006.

BARROSO, G.M et al. **Sistemática de Angiospermas do Brasil.** Viçosa: UFV, ed. 2, v. 1, p. 309, 2002.

BATTISTI, C., et al. **Plantas medicinais utilizadas no município de Palmeira das Missões, RS, Brasil.** R Bras Bioci. v. 11, v. 3, p. 338-348, 2013.

BERTI- FILHO, E. et al. **Manual de Pragas em Florestas: Cupins ou Térmitas. Programa Cooperativo de Monitoramento de Insetos em Florestas.** Instituto de Pesquisa e Estudos Florestais- IPEF. 3 ed. p. 56, 1993.

BESERRA, F. P. **Determinação dos Mecanismos de Ação Envolvidos no Efeito Antiulcerogênico, Antidiarreico e Antiinflamatório da “Insulina Vegetal” (*Cissus Sicyoides* Linneu) em Modelos Animais,** 2014. Dissertação (Mestrado), em Ciências Biológicas. Universidade Estadual Paulista “Júlio de Mesquita Filho”. p. 162. Botucatu- SP.

BESTETE, L. R., et al. **Toxicidade de óleo de mamona a *Helicoverpa zea* e a *Trichogramma pretiosum*.** Pesq. agropec. bras., Brasília, v.46, n.8, p.791-797, 2011.

BIESKI, I. G. C. **Plantas Medicinais e Aromáticas no Sistema Único de Saúde da Região Sul de Cuiabá- MT.** Secretaria Municipal de saúde de Cuiabá-MT. Universidade federal de Lavras- Minas Gerais – Brasil. p. 13-18, 2005.

BOGLIOLO, G. B. F. **Patologia Geral.** 2. ed. Rio de Janeiro: Guanabara Koogan. p. 646-647, 1998.

BOGLIOLO, L.; BRASILEIRO FILHO, G. **Bogliolo: Patologia**. 7 ed. Rio de Janeiro. Ed. Guanabara Koogan, p. 1472. 2006

BONETI, J. I. S et al. **Doenças da macieira (*Malus domestica* Bork)**, 1999.

BONETI, J. I. S, RIBEIRO, L. G., KATSURAYAMA, Y. **Manual de identificação de doenças e pragas da macieira**. Florianópolis, Epagri. p. 149, 2002.

BOTTON, M. et al. **O gorgulho do milho *Sitophilus zeamais* (Coleptera: Curculionidae) como praga em frutíferas de clima temperado**. Circular Técnica. EMBRAPA, ISSN 1808-6810. Bento Gonçalves- RS. 2005b.

BOTTON, M. et al. **O gorgulho do milho *Sitophilus zeamais* (Coleptera: Curculionidae) como praga em frutíferas de clima temperado**. Circular Técnica nº 58. Bento Gonçalves: Embrapa, 2005a.

BOTTON, M., LORINI, I., AFONSO, A. P. S. **Ocorrência de *Sitophilus zeamais* Mots. (Coleoptera: Curculionidae) Danificando a Cultura da Videira no Rio Grande do Sul**. Neotropical Entomology. n. 34, v. 2, p. 355-356, 2005.

BRAGA, R. A. **Plantas do Nordeste, especialmente do Ceará. Mossoró**: Col. Mossoerense. Ed. 3; 1976.

BRASIL- OMS. **Organização Mundial de Saúde**. Estrategia de la OMS sobre medicina tradicional 2002-2005. Genebra. p. 67, 2002.

BRASIL. Instituto Nacional do Câncer (INCA). **Estimativa da incidência e mortalidade por câncer no Brasil em 2014**. Rio de Janeiro. 2014. Disponível em:<www.inca.gov.br/estimativa/2014/index.asp?ID=2>

BRASIL. Instituto Oncoguia. **Carcinogênese**. São Paulo- SP. 2014. Disponível em:<<http://www.oncoguia.org.br/conteudo/carcinogenese/6851/844/>>, acessado: 29/06/2016.

BRASIL. Ministério da Saúde (MS). Mensagem aos médicos. **Câncer Fundamentos, Secretária de Assistência Médica-Divisão Nacional de câncer**; Brasília,1971, p. 7-47.

BRASIL. DATASUS. Ministério da Saúde (MS)/ **Sistema de Informações de Mortalidade (SIM)**. Indicadores de Mortalidade, 2012. Disponível em:<<http://tabnet.datasus.gov.br/cgi/tabcgi.exe?idb2012/-c06.def>>. Acessado: 02/04/2016.

BRASIL. Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Departamento de Assistência Farmacêutica. **Política nacional de plantas medicinais e fitoterápicos** / Ministério da Saúde, Secretaria de Ciência, Tecnologia e Insumos Estratégicos, Departamento de Assistência Farmacêutica. – Brasília- DF. Ministério da Saúde, 2006.

BRASIL. Ministério da Saúde. **Fórum de Competitividade da Cadeia Produtiva Farmacêutica**. Acesso aos Medicamentos, Compras Governamentais e Inclusão Social. Brasília- DF. Ministério da Saúde, 2003

BRASIL. Ministério DA saúde. **Política Nacional de Plantas Medicinais e Fitoterápicos**. Brasília: Ministério da Saúde, 2007.

BRASIL. Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Departamento de Assistência Farmacêutica. **A fitoterapia no SUS e o Programa de Pesquisa de Plantas Medicinais da Central de Medicamentos** / Ministério da Saúde, Secretaria de Ciência, Tecnologia e Insumos Estratégicos, Departamento de Assistência Farmacêutica. – Brasília- DF. Ministério da Saúde, 2006b. p.10.

BRASIL. Ministério da Saúde, 2015. **Vinte e uma unidades federativas pactuaram a disponibilização de fitoterápicos com recurso tripartite, conforme a Portaria GM/MS nº 1.555/2013**. Disponível em: <http://portalsaude.saude.gov.br/index.php/o-ministerio/principal/leia-mais-o-ministerio/464-sctie-raiz/daf-raiz/ceaf-sctie/fitoterapicos-cgafb/19473-unidades-federativas-que-pactuaram-a-disponibilizacao-de-fitoterapicos>. Acessado em: 03/08/2017.

BRASIL. Ministério da Saúde, 2014. **Relação Nacional de Plantas Medicinais de Interesse ao SUS**. Disponível em: <http://portalarquivos.saude.gov.br/images/pdf/2014/maio/07/renisus.pdf>. Acessado em: 03/08/2017.

BRASIL. Ministério do Meio Ambiente (MMA). **Caatinga. Esplanada dos Ministérios- Bloco B**. Brasília- DF. 2016. Disponível em: <<http://www.mma.gov.br/biomas/caatinga>>. Acessado em: 19/ 04/ 2016.

BRASIL. Portal de Saúde/ Ministério da Saúde. **Doença Diarreica Aguda, 2014**. Disponível: <<http://portalsaude.saude.gov.br/index.php/o-ministerio/principal/leia-mais-o-ministerio/652-secretaria-svs/vigilancia-de-a-a-z/doenca-diarreica-aguda-dda/12-doenca-diarreica-aguda-dda/11139-informacoes-tecnicas-dda>>. Acessado em: 01/04/16.

BRASILEIRO-FILHO, G. et al. **Distúrbios de crescimento e da diferenciação celular**. In: BRASILEIRO-FILHO, G.. Bogliolo – Patologia. 6ª ed. Belo Horizonte: Ed. Guanabara Koogan, 2000. cap. 8, p. 149-193.

BRUNTON, L.L. **Goodman e Gilman: as bases farmacológicas da terapêutica**. 12ª ed. Rio de Janeiro: McGraw-Hill; 2011.

CALIXTO, J. B. **Biodiversidade como fonte de medicamentos**. Ciência e Cultura, v.55, n. 3, p. 37- 39, 2003.

CANCELLO, E.M.; REIS, Y.T. **Riqueza de cupins (Insecta, Isoptera) em áreas de Mata Atlântica primária e secundária do sudeste da Bahia**. Iheringia: Série Zoologia, v. 97, n. 3, p.229–234, 2007.

CARRARA, E. **Tsi Tewara: um vôo sobre o Cerrado Xavante**. Dissertação de Mestrado, Universidade de São Paulo, Brasil, p. 218, 1996.

CARTAXO, S. L. et al. **Medicinal plants with bioprospecting potential used in semi-arid northeastern Brazil**. Journal of Ethnopharmacology. v. 131, p. 326–342, 2010.

CARVALHO, A. O. R. **O Instituto Nacional de Câncer e sua Memória: Uma Contribuição ao Estudo da Invenção da Cancerologia no Brasil**. Dissertação (Mestrado). Programa de Pós-Graduação em História Política e Bens Culturais – PPHPBC. Fundação Getúlio Vargas. Rio de Janeiro- RJ, 2006.

CARVALHO, J. C. T., et al. **Preliminary studies of analgesic and anti-inflammatory properties of *Caesalpinia ferrea* crude extract**. Journal of ethnopharmacology, v. 53, p. 175–178, 1996.

CASIDA, J. E.; QUISTAD, G. B. **Gold Age of Insecticide Research: Past, Present, or Future**. Ann. Rer. Entomol. v. 43, p. 1-16, 1998.

CERDEIRA FILHO, F. **Prevalência de lesões Bucais em pacientes submetidos à radioterapia associada ou não a quimioterapia para o tratamento do câncer localizado na região de cabeça e pescoço**. Dissertação (mestrado em Periodontia) – Universidade do Grande Rio “Prof. José de Souza Herdy”, Escola de Odontologia, 2008.

CHASSANY, O. et al. **Drug-induced diarrhoea**. Drug Saf. v. 22, p. 53–72, 2000.

CHEN, K. et al. **Termite feeding deterrent from Japanese larch wood**. Bioresource Technology. v. 95, p. 129-134, 2004.

CHEN, Y.T.; et al. **Ghrelin improves LPS-induced gastrointestinal motility disturbances: roles of NO and prostaglandin E2**, Shock. v. 33, p. 205–212, 2010.

CHENG, S. et al. **Anti-termite activities of essential oils from coniferous trees against *Coptotermes formosanus***. Bioresource Technology. v. 98, p. 456-459, 2007.

COITINHO, R.L.B.C. et al. **Toxicidade por fumigação, contato e ingestão de óleos essenciais para *Sitophilus zeamais* Motschulsky, 1885 (Coleoptera: Curculionidae)**. Ciênc. Agrotec. v. 35, p.172-178, 2011.

CONSTANTINO, R. **Abundance and diversity of termites (Insecta: Isoptera) in two sites of primary rain forest in Brazilian Amazonia**. Biotropica, v. 24, p. 420–430, 1992.

CONSTANTINO, R. **OnLine Termites Database**, 2016. Disponível em:<<http://164.41.140.9/catal/>>. Acesso em: 04.jun.2016

CORDEIRO, I., SECCO, R. 2012. **Cnidoscolus in Lista de Espécies da Flora do Brasil**. Jardim Botânico do Rio de Janeiro. Disponível em:<<http://floradobrasil.jbrj.gov.br/2012/FB017491>>. Acessado em: 22 de janeiro de 2012.

CORRÊA, A. D. et al. **Farinha de folhas de mandioca – efeito da secagem das folhas sobre a atividade da linamarase**. Ciência e Agrotecnologia, Lavras, MG, v. 26, n. 2, p. 368-374, 2002.

COSTA, S. O. P. **As bactérias em Biotecnologia**. In: SERAFINI, L. A.; BARROS, N. M.; AZEVEDO, J. L. Coord., Biotecnologia na Agricultura e Agroindústria. Guaíba: Agropecuária. Cap. 1, p. 75- 91, 2001.

COSTA-LEONARDO, A.M. **Cupins-Praga: morfologia, biologia e controle**. Rio Claro: Divisa, p. 128, 2002.

CRUZ, M. J. B. et al. **Use of Medicinal Plants for Families from Jequitinhonha Valley, Minas Gerais, Brazil**. Infarma, Ciências Farmacêuticas. v. 27, ed. 1, p. 38-48, 2015.

Cunha, S L., et al. **Bioatividade do extrato etanólico do caule de *Croton linearifolius* Mull. Arg.(Euphorbiaceae) sobre *Cochliomyia macellaria* (Diptera: Calliphoridae)**. Acta Veterinaria Brasilica, v.4, n.4, p. 252-258, 2010.

DEVAPPA, R.K. et al. **Jatropha Toxicity – a review**. J. Toxicol. Environ. Health B., v.13, p.476-507, 2010.

DINIZ, T. C. **Toxicologia Pré-clínica e Avaliação do Extrato Etanólico Bruto de *Annona vepretorum* Mart. (ANNONACEAE) sobre o Sistema Nervoso Central de Roedores**, 2013. Dissertação (Mestrado), Universidade Federal do Vale do São Francisco. p. 116. Petrolina- PE.)

DONOWITZ, M., et al. **Translational approaches for pharmacotherapy development for acute diarrhea**. Gastroenterol. v.142, n.3, p.1-9, 2012.

DUARTE, M. C. T., et al. **Atividade antimicrobiana de extratos hidroalcolólicos de espécies da coleção de plantas medicinais CPQBA/UNICAMP**. Revista Brasileira de Farmacognosia. v. 14, p. 06- 08, 2004.

DUARTE, N., LAGE, H., FERREIRA, M.J.U. **Three new jatrophone polyesters and anti proliferative constituents from *Euphorbia tuckeyana***. Planta Medica, v. 74, p. 61-68, 2008.

DVORAK, H. F. **Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing**. N. Eng. J. Med., 315, p.1650-1659, 1986.

ELEOTÉRIO, E. S. R. **Levantamento e Identificação de Cupins (Insecta: *Isoptera*) em Área Urbana de Piracicaba, SP**. Dissertação (Mestrado pelo Programa da Escola Superior de Agricultura “Luiz de Queiroz”. Universidade de São Paulo, USP. Piracicaba, SP, p. 101, 2000.

FELIU, D. A. **Análise de Terpenóides de Espécies de *Croton* sect. *Lamprocroton* (Mull. Arg.) *Pax* (Euphorbiaceae)**. Dissertação (Mestrado) - Instituto de Biociências das Universidade de São Paulo. São Paulo, 2011.

FERREIRA, E. V. R. **Composição florística, estrutura da comunidade e síndrome de dispersão de sementes de um remanescente de Caatinga em Poço Verde – Sergipe**. 2011. Dissertação (Mestrado em Ecologia e Conservação) – Universidade Federal de Sergipe, p. 81. Sergipe.

FONSECA, M.C.M. **Epamig pesquisa, produção de Plantas Medicinais para Aplicação no SUS**. Espaço para o produtor, Viçosa, 2012.

FONTE, N. N. **A Complexidade das Plantas Medicinais: Enfoque Farmacêutico.** Colombo. Embrapa: Florestas, p. 24- 46, 2004.

FONTES, L. S.; ALMEIDA FILHO, A. J.; ARTHUR, V. **Danos Causados Por *Sitophilus Oryzae* (Linné, 1763) e *Sitophilus zeamais* Motschulsky, 1855 (Coleoptera: Curculionidae) em Cultivares de Arroz (*Oryza Sativa* L.).** Arq. Inst. Biol., São Paulo, v.70, n.3, p.303-307, 2003.

GALLO, D. et al. **Entomologia agrícola.** Piracicaba: FEALQ. p. 920, 2002.

GALLUN, G. L.; KHUSH, G. S. **Factores Genéticos que Afectan la Expresión y Estabilidad de la Resistencia In. Mejoramiento de Plantas Resistentes a Insectos. México.** Editorial Limusa S. A. p. 83-105, 1984.

GARG, P., KHATRI, P., GANDHI. D. **Plant Tissue Culture of *Jatropha curcas* L.: A REVIEW.** Imperial Journal of Pharmacognosy & Natural Products. v. 1, n. 1, 2011.

GARÓFOLO, A. et al. **Dieta e câncer: um enfoque epidemiológico.** Rev. Nutr., Campinas, v. 17, n. 4, p. 491-505, 2004.

GARÓFOLO, A.; PERTRILLE, A. S. **Omega-3 and 6 fatty acids balance in inflammatory response in patients with cancer and cachexia.** Rev. Nutr., Campinas, v. 19, n. 5, p. 611-621, 2006.

GAZAL, V. **Decayed Wood Affecting the Attraction of the Pest Arboretum *Termite Nasutitermes corniger* (Isoptera :Termitidae) to Resource Foods.** Sociobiology, v.59, p.287–296, 2012.

GOEL, G. et al. **Phorbol esters: Structure, biological activity, and toxicity in animals.** International Journal of Toxicology, v. 26, p. 279-288, 2007.

GOMES, J. P. M. **Pesquisa de Atividade Antitumoral e Mutagênica *in vitro* de Produtos Naturais.** 2008. Tese (Doutorado), pelo Programa de Pós-Graduação em Ciências Farmacêuticas. p. 86, Araraquara-SP.

GOTTLIEB, O. G., BORIN, M. R. M. B. **Químico-Biologia Quantitativa: Um Novo Paradigma?** Química. Nova, v. 35, N. 11, p. 2105-2114, 2012.

GOVAERTS, R.; FRODIN, D.G.; RADCLIFFESMITH, A. **World Checklist and Bibliography of Euphorbiaceae (and Pandaceae).** Royal Botanical Gardens, Kew. v.2, p. 420, 2000.

GREM, J.L. **5-Fluorouracil: forty-plus and still ticking.** A review of its preclinical and clinical development. Investigational New Drugs, v. 18, p. 299–313, 2000.

GRESSLER, V. et al. **Quinolone alkaloids from *Waltheria douradinha*.** Phytochemistry, v. 69, p. 994-999, 2008.

GRZESIUK, V. L.; CATELAN, T. S.; GEBARA, K. S. **Evaluation of Insecticidal Potential of Plant Specie *Croton floribundus* (EUPHORBIACEAE) Front of Periplaneta americana (BLATTIDAE).** Interbio. v.7, n.1, 2013.

GULLO, V. P. et al. **Drug discovery from natural products.** J. Ind. Microbiol. Biotechnol., v.33, p.523- 531, 2006.

GUYTON, ARTHUR C.; HALL, JOHN E. **Tratado de fisiologia médica.** ed. 11. Rio de Janeiro: Elsevier, 2006.

HALBERSTEIN, R. A. **Medicinal Plants: Historical and Cross-Cultural Usage Patterns.** Ann Epidemiol, v. 15, p. 686–699, 2005.

HEYWOOD, V.M. et al. **Flowering Plant Families of the World.** Firefly Books. p. 424, 2007

HIGASHIE, M., ABE, T. **Global diversifications of térmites driven by evolution of symbiosis and sociality.** (ed. Higashie). Biodiversity – an Ecological Perspective. Springer-Verlag, p. 83- 112, 1997.

HOJO, M. et al. **Identification of soldier caste-specific protein in the frontal gland of nasute termite *Nasutitermes takasagoensis* (Isoptera: Termitidae).** Insect Biochem Mol Biol. v.35, p. 347–354, 2005.

ISMAN, M.B. **Neem and other botanical insecticides: barriers to commercialization.** Phytoparasitica, Berlin, v. 25, n. 4, p. 339-344, 1997.

INSTITUTO ETHOS, 2016. **Programa incentiva o cultivo de plantas medicinais.** Disponível em: <https://www3.ethos.org.br/cedoc/programa-incentiva-o-cultivo-de-plantas-medicinais/#.WYMqZ4jyvcc>. Acessado: 03/08/2017.

JUNIOR, C. V. **Terpenos com Atividade Inseticida: uma Alternativa para o Controle Químico de Insetos.** Química Nova, v. 26, n. 3, p. 390-400, 2003.

KIEM, P.V. et al. **New Triterpenoid Saponins from *Glochidion eriocarpum* and Their Cytotoxic Activity.** Chemical and Pharmaceutical Bulletin, v. 57, p. 102-105, 2009.

KNAAK, N. et al. **Atividade Inseticida de Extratos de Plantas Medicinais sobre *Spodoptera frugiperda* (J.E. Smith) (Lepidoptera: Noctuidae).** Sociedade Entomológica do Brasil. BioAssay, v.7, n.1, 2012.

KOEPPEN, B. M.; STANTON, B. A. **Berne & Levy – Fisiologia.** 6. ed. Rio de Janeiro: Elsevier. 26-30:491 – 543, 2009.

KÖHLER, I.; et al. **In vitro antiplasmodial investigation of medicinal plants from El Salvador.** Zeitschrift für Naturforschung C., v. 57c, p. 277–281, 2002.

KOUL, O.; DHAWIWAL, G. S. **Phytochem. Biopesticides.** Harwood Academis Publisheres. 2001.

KRINSKI, D., MASSAROLI, A., MACHADO, M. **Potencial Inseticida de Plantas da Família *Annonaceae***. V Congresso Internacional & Encontro Brasileiro sobre *Annonaceae*: do gene à exportação. Botucatu-SP. v. 36, edição especial, e., p. 225-242, 2014.

LA CRUZ, M. N. S., et al. **Terpenos em Cupins do Gênero *Nasutitermes* (Isoptera, Termitidae, Nasutitermitinae)**. Química Nova, v. 37, n. 1, p. 95-103, 2014.

LEITE, M.I.S. et al. **Ação residual de inseticidas para larvas e adultos do predador *Cycloneda sanguinea* (Linnaeu, 1763) (Coleoptera: Coccinellidae)**. Arquivos do Instituto Biológico, v. 74, p. 251-258, 2007.

LIMA, A. P. **Avaliação da Atividade Antitumoral e Citotóxica da Planta *Siolmatra brasiliensis***. Revista Eletrônica de Farmácia. v. 3, n. 2, p. 10-12, 2006.

LIU, D. et al. **Thermostable cellulase production of *Aspergillus fumigatus* Z5 under solid-state fermentation and its application in degradation of agricultural wastes**. International. Biodeterioration Biodegradation, v. 65, n. 5, p. 717-725, 2011.

LIU, Y. et al. **Antimalarial flavonol glycosides from *Euphorbia hirta***. Pharmaceutical Biology, v. 45, p. 278-281, 2007.

LIU, Z. L; GOH, S. H.; HO, S. H. **Screening of Chinese Medicinal Herbs for Bioactivity Against *Sitophilus zeamais* Motschulsky and *Tribolium castaneum* (Herbst)**. Journal of Stored Products Research, v. 43, p. 290-296, 2007.

LONGLEY, D.B.; HARKIN, D.P.; JOHNSTON, P.G. **5-Fluorouracil: Mechanisms of Action and Clinical Strategies**. Nature Reviews Cancer, v. 3, p. 330-33, 2003.

LUCENA, M. F. A., ALVES, M. **Notas taxonômicas para *Euphorbiaceae* s.l. do Nordeste do Brasil**. Hoehnea, v. 71, n. 1, p. 71-85, 2010.

LUCENA, M. F. A.; AMORIM, B. S.; ALVES, M. **Sinopse das espécies de *Euphorbiaceae* s. l. do Parque Nacional Serra de Itabaiana, Sergipe, Brasil**. Revista Caatinga, Mossoró. v.22, n.4, p. 214-224, 2009.

LUCENA, R.F.P. et al. **Uso de recursos vegetais da Caatinga em uma comunidade rural no Curimataú Paraibano (nordeste do Brasil)**. Polibotânica, v. 34, p. 237-258, 2012.

MACENA, L. M., et al. **Plantas medicinais utilizadas por gestantes atendidas na unidade de saúde da família (USF) do Bairro Cohab Tarumã no Município de Tangará da Serra, Mato Grosso**. Revista de Biologia e Farmácia - Biofar, v. 7, n. 1, p.143-155, 2012.

MAIRESSE, L. A. S. **Avaliação da Bioatividade de Extratos de Espécies Vegetais, Enquanto Excipientes de Aleloquímicos**, 2005. Tese (Doutorado). Programa de Pós-Graduação em Agronomia. Universidade Federal de Santa Maria (UFSM). p. 326. Santa Maria, RS.

MALHEIROS, S. G. M. **Estudo Farmacobotânico de Seis Espécies de Uso Medicinal no Nordeste Brasileiro**. Dissertação (Mestrado). Universidade Federal da Paraíba. João Pessoa, PB, 2012.

MARCOS, L.A.; DUPONT, H.L. **Advances in defining etiology and new therapeutic approaches in acute diarrhea**. J Infect. v.55, p.385-393, 2007.

MARQUES, J.B. **Comércio e conservação de três espécies vegetais da Caatinga ameaçadas de extinção e de uso medicinal em duas áreas do Cariri Oriental Paraibano**. 2008. 105 f. Dissertação (Mestrado em Desenvolvimento e Meio Ambiente) – Universidade Federal da Paraíba, João Pessoa, 2008.

MARREIROS, N. A. et al. **Conhecimento Botânico Tradicional sobre Plantas Medicinais no Semiárido da Paraíba (Nordeste, Brasil)**. Revista Ouricuri, Paulo Afonso, Bahia, v.5, n.1, p.110-144, 2015.

MARSARO JÚNIOR, A. L. et al. **Evaluation of Resistance of Corn Hybrids Against the Attack of *Sitophilus zeamais* mostchulsky (Coleoptera: Curculionidae) in Stored Kernels**. Semina: Ciências Agrárias, Londrina, v. 26, n. 2, p 173- 178, 2005.

MARTINS, M. C. B. **Aplicações biotecnológicas de Compostos obtidos dos Línques**. Tese (Doutorado em Bioquímica e Fisiologia), Universidade Federal de Pernambuco, Recife, 2013.

MARTIUS, K. P. von. **A viagem de Von Martius: tabulae physiognice**. Rio de Janeiro. v. 1, p. 1840. 1996.

MAZOYER, M.; ROUDART, L. **História das agriculturas no mundo: do neolítico a crise contemporânea**. São Paulo: Editora UNESP; Brasília, DF: NEAD, 2010.

MELO, A. L.; SALES, M. F. **O gênero *Cnidoscolus* Pohl (Crotonoideae-Euphorbiaceae) no Estado de Pernambuco, Brasil**. Acta bot. Bras, v. 22,n. 3, p. 806-827,. 2008.

MIURA, T.; ROISIN, Y.; MATSUMOTO, T. **Molecular phylogeny and biogeography of the nasute termite genus *Nasutitermes* (Isoptera: Termitidae) in the Pacific tropics**. Molecular Phylogenetics and Evolution, v. 17, p. 1-10, 2000.

MOURA, M. D. et al. **Matural Products Inhibitors of Models of mammary**. Neoplasia. Revista Brasileira de Farmacognosia, v. 5, p.124- 145, 2001.

NAPOLEÃO, T. H. **Atividade Inseticida E Mecanismos de Ação de Lectinas de *Myracrodruon urundeuva* Contra *Nasutitermes corniger*, *Aedes aegypti* e *Sitophilus zeamais***, 2012. Tese (Doutorado pelo Programa de Pós-Graduação de Bioquímica e Fisiologia). Universidade Federal de Pernambuco- UFPE, p.142, Recife- PE.

OLIVEIRA, D. G. **The family Euphorbiaceae Juss. in a fragment of Caatinga in Sergipe**. Scientia Plena, v. 9, n. 4, 2013.

OLIVEIRA, S. G. D. et al. **An ethnomedicinal survey on phytotherapy with professionals and patients from Basic Care Units in the Brazilian Unified Health System**. Journal of Ethnopharmacology, v.140, p. 428– 437, 2012.

OLSON, D. L. et al. **Comparative Evaluation of Population Effect and Economic Potential of Biological Supression Tactics Versus Chemical Control for squash Bug (Heteroptera: Coreidae) Managment on Pumpkins.** J. Econ. Entomol, v. 89, n. 3, p 361-639, 1996.

ORTMAN, E. E.; PETERS, D. C. **Introducción In. Mejoramento de Plantas Resistentes a Insectos.** México, D. F.: Editorial Limusa S. A. p. 21- 32, 1984.

PAIXÃO, M. F. et al. **Alternative control of corn weevil, *Sitophilus zeamais*, in storage using byproducts of oil shale processing in Paraná, Brazil.** Revista Brasileira de Agroecologia. n. 4, v. 3, p. 67-75, 2009.

PASCOAL, C. K. P. et al. **Relatos de Mulheres Submetidas à Biópsia do Linfonodo Sentinela quanto às Orientações Recebidas para Prevenção de Linfedema: Um Estudo Qualitativo.** Revista Brasileira de Cancerologia, v. 56, p. 219-226, 2010.

PEDROSA, K.M. et al. **Uso e disponibilidade local de *Sideroxylon obtusifolium* (ROEM. & SCHULT.) T.D. PENN. (quixabeira) em três regiões da depressão sertaneja da Paraíba, nordeste do Brasil.** Revista de Biologia e Farmácia – Biofar, volume especial, p. 158-183, 2012.

PEI-WEN, et al. **Apigenin induced apopyosis through p53-dependent patway in human cervical carcinoma cells.** Life Sci., v.76, p.1367-1389, 2005.

PEIXOTO SOBRINHO, T. J. S. **Estudo Químico e Biológico de Espécies do Gênero *Cnidoscolus* Presente no Ecossistema Caatinga com Potencial Atividade Terapêutica.** 2011. Tese (Doutorado) pelo Programa de Pós-Graduação em Ciências Farmacêuticas. Universidade Federal de Pernambuco. Recife-PE.

PEIXOTO SOBRINHO, T. J. S. et al. **Phenolic content and antioxidant capacity of four *Cnidoscolus* species (Euphorbiaceae) used as ethnopharmacologicals in Caatinga, Brazil.** African Journal of Pharmacy and Pharmacology, v. 5, n. 20, p. 2310-2316, 2011.

PEIXOTO SOBRINHO, T. J. S. et al. **Phytochemical Screening and Antibacterial Activity of four *Cnidoscolus* Species (Euphorbiaceae) Against Standard Strains and Clinical Isolates.** Journal of Medicinal Plants Research, v. 6, n. 21, p. 3742-3748, 2012.

PEIXOTO, T. J. S. S. **Estudo Químico e Biológico de Espécies do Gênero *Cnidoscolus* Presente no Ecossistema Caatinga com Potencial Atividade Terapêutica,** 2011. Tese (Doutorado), pelo programa de Pós- Graduação em Ciências Farmacêutica, Universidade Federal de Pernambuco, p. 113. Recife- PE.

PEREIRA, I. T. et al. **Antiulcer Effect of bark extract of *Tabebuia avellanedae*: Activation of cell proliferation in gastric mucosa during the healing process.** Phytotherapy Research. v. 27, n. 7, p. 1067- 1073. Jul. 2012.

PINHEIRO, E. A. R. et al. **Effective root depth of the Caatinga biome.** Journal of Arid Environments, v.89, p. 1- 4, 2013.

PINHO, A.; PICHONELLI, M. **Governo lista plantas que poderão virar fitoterápicos.** São 71 espécies, que servirão de base para o desenvolvimento de remédios. Folha de São Paulo, 2009.

PINTO, A. C.; et al. **Produtos Naturais:** Atualidades, Desafios e Perspectivas. Química Nova, v. 25, p. 45-61, 2002.

PINTO, E.P.P.; AMOROZO, M.C.M.; FURLAN, A. **Conhecimento popular sobre plantas medicinais em comunidades rurais de mata atlântica – Itacaré, BA, Brasil.** Acta Botanica Brasilica, v. 20, n. 4, p. 751-762, 2006.

RADCLIFFE- SMITH, A. **Genera Euphorbiacearum.** Royal Botanic Gardens, Kiew, p.464, 2001.

RAINER, J. et al. **Glucocorticoid-regulated microRNAs and mirtrons in acute lymphoblastic leukemia.** Leukemia, v. 23, n. 4, p. 746-52, 2009.

RANG, H.P., et al. **Fármacos ansiolíticos e hipnóticos.** In: Farmacologia. Rio de Janeiro: Elsevier. p.531-39, 2011.

REZENDE H. A., COCCO M. I. M. **A utilização de fitoterapia no cotidiano de uma população rural.** Revista Esc Enferm.USP, v. 36, p. 282-288, 2002.

RIBEIRO, A. Q., LEITE, J. P. V., DANTAS-BARROS, A. M. **Profile of the utilization of phytotherapie medicines in communitary pharmacies of Belo Horizonte, under the influence of the national legislation.** Brazilian Journal of Pharmacognosy, v. 15, p. 65–70, 2005.

ROQUE, A. A., ROCHA, R. M., LOIOLA, M. I. B. **Uso e diversidade de plantas medicinais da Caatinga na comunidade rural de Laginhas, município de Caicó, Rio Grande do Norte (nordeste do Brasil).** Revista Brasileira de Plantas Medicinais, v. 12, n. 1, p. 31-42, 2010.

ROQUE, A.A.; LOIOLA, M.I.B. **Potencial de uso dos recursos vegetais em uma comunidade rural no semiárido potiguar.** Revista Caatinga, v. 26, n. 4, p. 88-98, 2013.

ROSSI, D. et al. **Evaluation of the mutagenic, antimutagenic and antiproliferative potential of *Croton lechleri* (Muell. Arg.) latex.** Phytomedcentral, v. 10, p. 139-144, 2003.

SALAZAR, E. C. **Inseticidas e Acaricidas.** Pelotas: Universidade Federal de Pelotas, p. 646, 1997.

SANTOS, F. J. B. et al. **Genotoxic and mutagenic properties of *Bauhinia platyptala* extract.** Traditional Brazilian medicinal plant. v. 144, p. 474- 482, 2012.

SANTOS, J.P.; ARAÚJO, E.L.; ALBUQUERQUE, U.P. **Richness and distribution of useful woody plants in the semi-arid region of northeastern Brazil.** Journal of Arid Environments, v. 72, n. 5, p. 652-663, 2008.

SANTOS, T. C.; JUNIOR, J. E. N.; PRATA, A. P. N. **Frutos da Caatinga de Sergipe utilizados na alimentação humana**. Scientia Plena, v. 8, n. 4, 2012.

SANTOS, S. B.; MARTINS, M. A.; D'ANTONINO FARONI, L. R.; RODRIGUES JUNIOR, V.; DHINGRA, O. D. **Quality of maize grains treated with allyl isothiocyanate stored in hermetic bags**. Journal of Stored Products Research, v.46, p.111-117, 2010.

SÁTIRO, L. N., ROQUE, N. **A Família Euphorbiaceae nas Caatingas Arenosas do Médio Rio São Francisco, BA, Brasil**. Acta Botanica Brasilica, v. 22, n. 1, p. 99-118, 2008.

SATISH, E. B; RANJANA S. K. **Antidiarrheal activity of ethanolic extract of *Manihot esculenta* Crantz leaves in Wistar rats**. Journal of Ayurveda and Integrative Medicine. v. 6, n. 1, p. 35–40, 2015.

SCHEFFRAHN, R.H. et al. **Nasutitermes costalis (Isoptera: Termitidae) in Florida: first record of a non-endemic establishment by a higher termite**. Florida Entomologist, v. 85, p. 273-275, 2002.

SECCO, R. S. et al. **An Overview of Recent Taxonomic Studies on Euphorbiaceae s. I. in Brazil**. Rodriguésia. v. 63, n. 1, p. 227- 242, 2012.

SECCO, R.S. **Flora da Reserva Ducke, AM, Brasil: Euphorbiaceae-Parte-I** Rodriguésia, Revista do Jardim Botânico do RJ. v.56, n. 86, p.143-168, 2005.

SEVERIANO, M. V. N. et al. **Levantamento das Plantas Medicinais Cultivadas no Centro de Estudo e Pesquisa Malaquias da Silva Amorim**. Revista de Biologia e Farmácia. v. 4, n. 1, p. 93- 101, 2010.

SILVA S. I. **Euphorbiaceae da Caatinga: distribuição de espécies e potencial oleaginoso**. Tese (Doutorado) São Paulo: Universidade de São Paulo; 1998.

SILVA, G. N., et al. **Bioactivity of *Jatropha curcas* L. to insect pests of stored products**. J. of Stored Products R. v. 48, p. 111-113, 2012.

SILVERTHORN, D. U. **Fisiologia humana: uma abordagem integrada**. 5. ed. Porto Alegre: Artmed, 2010.

SIMÕES, C.M.O. et al. **Farmacognosia – da Planta ao Medicamento**. Porto Alegre / Florianópolis: Editora da UFRGS/ Editora da URSC, 2004.

SMANIOTTO, L. F., et al. **Selectivity of alternative products to *Telenomus podisi* Ashmead (Hymenoptera: Scelionidae)**. Semina: Ciências Agrárias, Londrina, v. 34, n. 6, p. 3295-3306, 2013.

SNYDER, T.D.; MERSON, M.H. **The Magnitude of the Global Problem of Acute Diarrhoeal Disease: A Review of the Active Surveillance Data**. Bulletin World Health Organization. V. 60,n. 4, p. 605- 613, 1982.

SOUZA, V. C.; LORENZI, H. **Botânica Sistemática: guia ilustrado para identificação das famílias de Fanerógamas nativas e exóticas no Brasil, baseado em AGP II**. Nova Odessa, SP: Instituto Plantarum, ed. 2, p. 704, 2008.

TACK, J. **Gastric motor disorders**. Gastroenterol. v. 21, p. 633-644, 2007.

TAN, A.C. et al. **Towards the discovery of novel phytochemicals for disease prevention from native Australian plants: an ethnobotanical approach**. Asia Pacific Journal of Clinical Nutrition. v. 19, p. 330–334, 2010.

TAVARES, M. A. G. C. **Bioatividade da erva-de-santa-maria, *Chenopodium ambrosioides* L. (Chenopodiaceae), em relação a *Sitophilus zeamais* Mots., 1855 (Col. Curculionidae)**. Piracicaba. Dissertação (Mestrado), ESALQ. p. 59, 2002.

TAVARES, W. S. et al. **Deleterious activity of natural products on postures of *Spodoptera frugiperda* (Lepidoptera: Noctuidae) and *Diatraea saccharalis* (Lepidoptera: Pyralidae)**. Zeitschrift für Naturforschung C, v. 65, 2010.

TAVARES, W. S. et al. **Potential use of Asteraceae extracts to control *Spodoptera frugiperda* (Lepidoptera: Noctuidae) and selectivity to their parasitoids *Trichogramma pretiosum* (Hymenoptera: Trichogrammatidae) and *Telenomus remus* (Hymenoptera: Scelionidae)**. Industrial Crops and Products, v.30, p.384-388, 2009.

TEICH, NM; FRANKS, LM. **Introdução a biologia celular e molecular do câncer**. Ed. Roca, São Paulo, 1ª ed, 1990.

THIELMAN, N. M.; GUERRANT, R.L. **Acute infectious diarrhoea**. New Engl J Med, v. 350, p. 38-47, 2004.

THORNE, B. L. **Termite terminology**. Sociobiology, v. 28, p. 253-263. 1996.

TRENTIN, D. S. et al. **Potential of medicinal plants from the Brazilian semi-arid region (Caatinga) against *Staphylococcus epidermidis* planktonic and biofilm lifestyles**. Journal of Ethnopharmacology, v. 137, p. 327–335, 2011.

TREVISAN, M. T. S.; MACEDO, F. V. V. **Seleção de plantas com atividade anticolinesterásica para tratamento da doença de Alzheimer**. Química Nova, v. 26, n. 3, p. 301–304, 2003.

TRINDADE, M. J. S.; LAMEIRA, O. A. **Species from the Euphorbiaceae family used for medicinal purposes in Brazil**. Rer. Cubana de Plantas Medic. v. 19, n. 4, p. 292-309, 2014.

TSUNECHIRO, A., FERREIRA, C. R. R. P. T. **Defensivos: Mercado em Alta**. Cultivar. Pelotas, RS. n. 22, p. 22- 24, 2000.

United Nations Children’s Fund (UNICEF)/ World Health Organization (WHO), 2009. **All rights reserved. Diarrhoea: Why children are still dying and what can be done**. Disponível em:<http://www.unicef.org/media/files/Final_Diarrhoea_Report_October_2009_final.pdf>. Acessado em: 01/04/2016.

VANNUCCI, F.A.; GUEDES, R.M.C. **Fisiopatologia das diarreias dos suínos**. Ciência Rural.v.39, p.233-42, 2009.

VASCONCELLOS, A. et al. **Cupins de duas florestas de restinga do nordeste brasileiro**. Iheringia - Série Zoologia, v. 95, n. 2, p. 127-131, 2005.

VASQUEZ-CASTRO, J. A. V. **Resíduos de fenitrothion e esfenvalerato em grãos de milho e trigo, em alguns de seus subprodutos processados e sua ação residual sobre *Sitophilus oryzae* (L.,1793) *Sitophilus zeamais* Motsch., 1855 (Coleoptera: Curculionidae) e *Rhyzopertha dominica* (Fabr., 1792) (Coleoptera: Bostrichidae)**. Tese (Doutorado) Escola Superior de Agricultura Luiz de Queiroz, Piracicaba, SP. p. 213, 2006.

VIEGAS JR, C.; BOLZANI, V. DA S.; BARREIRO, E. J. **Os produtos naturais e a química medicinal moderna**. Quím. Nova, v. 29, n. 2, p. 326-337, 2006.

VIEGAS-JUNIOR, C. **Terpenos com atividade inseticida: uma alternativa para o controle químico de insetos**. Química Nova, São Paulo, v. 26, n.3, p.390-400, 2003.

VILARINHO, M. K. C. **Chemical Pesticides and Vegetal Extracts on *Sitophilus zeamais* Control in Stored Corn Grains**. Biosci. J., Uberlândia, v. 32, n. 2, p. 288-297, 2016.

VILARINHO, M. K. C. **Inseticidas Químicos e Extratos Vegetais Aquosos no Controle de *Sitophilus zeamais* em Grãos de Milho sob Condições de Armazenamento**. Dissertação (Mestrado) pelo Programa de Pós-Graduação em Engenharia Agrícola Campus Universitário de Rondonópolis. Universidade Federal de Mato Grosso- UFMG. p. 84, 2012.

WANG, H.H. et al. **A blind, randomized comparison of racecadotril and loperamide for stopping acute diarrhea in adults**. World J Gastroenterol. v.11, n.10, p.1540-1543, 2005.

WEBSTER, G.L. **Systematics of the Euphorbiaceae**. Annals of the Missouri Botanical Garden, v.81, n. 1, p.1-144, 1994.

WMINE, J. T., DAMME, P. V. **Why do Euphorbiaceae tick as medicinal plants? A review of Euphorbiaceae family and its medicinal features**. Journal of Medicinal Plants Research, v. 5, n. 5, p. 652-662, 2011.

WGO: World Gastroenterology Organisation Global Guideline. **World Gastroenterology Organisation Global Guideline**, 2012. Disponível em: <http://www.worldgastroenterology.org/UserFiles/file/guidelines/acute-diarrhea-portuguese-2012.pdf>. Acessado: 06/10/2016.

XAVIER, M.V.A., et al. **Toxicidade e repelência de extratos de plantas da Caatinga sobre *Tetranychus bastosi* Tutler, Baker & Sales (Acari: Tetranychidae) em pinhão-mansão**. Rev. Bras. Pl. Med., Campinas, v.17, n.4, p.790-797, 2015.

YANG, X.W. et al. **Bioactive Phenols from the leaves of *Baccaurea ramiflora***. Planta Medica, v. 73, p. 1415-1417, 2007.

ZANETTI, R. et al. **Manejo integrado de cupins**. Lavras: UFLA, 2002.

CAPÍTULO II

Manuscrito 1: *In vitro* and *in vivo* antineoplastic activity of *Cnidoscolus urens* (L). Arthur extracts.



Souza, P.G.V.D.^a; Araújo, T.F.S.^b; Campos, J.K.L.^b; Martins, M.C.B.^a; Lima, V.L.M.^b;
Santos, N.P.S.^{c,d}; Silva, N.H.^{a*}

Manuscrito a ser submetido ao periódico *Journal of Ethnopharmacology* no formato *Original Research Article* (FI: 3.055; QUALIS CB II: B1).

***In vitro and in vivo antineoplastic activity of Cnidoscolus urens* (L). Arthur extracts.**

Souza, P.G.V.D.^a; Araújo, T.F.S.^b; Campos, J.K.L.^b; Martins, M.C.B.^a; Lima, V.L.M.^b; Santos, N.P.S.^{c,d}; Silva, N.H.^{a*}

^a Laboratório de Produtos Naturais. Departamento de Bioquímica, Centro de Biociências, Universidade Federal de Pernambuco, Brazil.

^b Laboratório de Metabolismo de Lipídios e Lipoproteínas. Departamento de Bioquímica, Centro de Ciências Biológicas, Universidade Federal de Pernambuco, Brazil.

^c Laboratório de Biotecnologia de Fármacos, Centro Acadêmico de Vitória, Universidade Federal de Pernambuco, Brazil.

^d Laboratório de Imunopatologia Keizo-Asami (LIKA), Universidade Federal de Pernambuco, Brazil.

*Corresponding author

Laboratório de Produtos Naturais, Departamento de Bioquímica, Centro de Biociências, Universidade Federal de Pernambuco. Avenida Professor Moraes Rego, s/n, Cidade Universitária, CEP 50670-420, Recife/ Pernambuco, Brasil. (55) 81 21268541, (55) 81 21268540 (219), e-mail: nicacio_hsilva@hotmail.com

ABSTRACT

Ethnopharmacological relevance: Brazil comprises 20% of biodiversity in the world and one the six major biomes, the Caatinga, is a highly threatened biome, covering an area of 60% in Northeast region, totally restricted this country. *Cnidoscolus urens* (Euphorbiaceae) is a plant commonly known as “urtiga” by rural community of Northeast of Brazil. This species has been used for rubber production, are widely used, empirically, alternatively paw treating diseases by many popular.

Aim of the study: Evaluate the antitumor activity *in vivo* and *in vitro* of aqueous and ethanol extracts of *C. urens*.

Materials and Methods: Aqueous and ethanolic extracts were obtained from total parts of *C. urens*. Ehrlich carcinoma (EC) solid tumor which induced in mice and then treated with aqueous or ethanolic extracts at 200 mg / kg. Tumor weight, biochemical and hematological parameters of the animals were analyzed. Toxicity of the extracts was tested antineoplastic *in vitro* test HELA cells and antioxidant activity was accessed by 1,1- diphenylpicrylhydrazyl (DPPH) method at different concentrations 50, 100, 200 e 500 µg/mL of extracts. Phytochemical screening of *C. urens* was realized by Thin Layer Chromatography (TLC).

Results: Flavonoids, terpenoids, coumarins, tannins and reducing sugars were found in aqueous, ethyl acetate and n-butanolic extracts of *C. urens*. Aqueous and ethanolic extracts at 200 mg / kg were effective in inhibiting the tumor growth 84.4% and 79.2%, respectively and no adverse side effects due to the treatment were observed in biochemical urea, creatinine, total cholesterol, HDL-cholesterol, glucose and triglycerides and hematological red and white blood cells and hemoglobin parameters. *C. urens* extracts did not show any *in vitro* toxicity effect against HELA, however showed great antioxidant potential > 50% at 50, 100, 200 and 500 µg/mL.

Conclusions: Aqueous and ethanolic extracts of *C. urens* have a notorious antitumoral effect and could explain the basis for traditional use to treatment of cancer by rural community of Northeast of Brazil.

Keywords: *Cnidoscolus urens* (Euphorbiaceae), antitumoral activity, EC solid tumor, antioxidant, HELA cells, toxicity.

1 INTRODUCTION

Cancer is a particular group of diseases, characterized by uncontrolled cellular growth, tissue invasion and metastases (**Dashora et al., 2011; Instituto Oncoguia, 2015; SBCO, 2015**). This is one leading causes of death in world (**Ferlay et al., 2015**) and accounted for 7.9 million deaths in 2007, with 38% in developed countries and 62% in developing countries. Projections to 2030 show that almost 21.4 million of new cancer cases and more 13.2 million deaths will occur worldwide (**GLOBOCAN, 2008**). According to INCA, it is esteemed 600.000 new cancer cases only in Brazil, a country in Development (**INCA, 2016**).

Chemotherapy is an effective treatment against various types of cancer singly or in combination with surgery and radiotherapy. However, chemotherapeutic effects of most the drugs showed a limited efficacies due to the development of many side effects, nausea causing, pain, neurotoxicity, nephrotoxicity and Other So many effects (**Asirvatham et al., 2012; Ostadhadi et al., 2015**). This have been stimulated to evaluate new products against cancer (**Syamala et al., 2015**) capable to cause less serious side effects (**Aranjani et al., 2013**). The plant kingdom is a potential source of bioactive compounds of varying composition (tannins, coumarins, phenols, flavonoids, catechins, anthocyanins and proanthocyanins) (**Jeevananthan et al., 2011; Ashraf et al., 2015**) with antitumor activities and various plants which traditionally have been used in the treatment of infectious diseases and in particular cancer (**Noolu et al., 2013; Servin Wesley et al., 2013; Ramasamy et al., 2013 and Ashraf et al., 2015**).

Brazil comprises 20% of biodiversity in the world and the six major biomes (Amazon, Atlantic Forest, Pantanal, Cerrado, Caatinga and Pampa) comprise the highest levels of

diversity in the on world (**Pilatti et al., 2011; Rada, 2015**). The Caatinga vegetation is a highly threatened biome, covering an area of 60% in Northeastern region of Brazil. This ecosystem is dominated by one of the few types of vegetation whose distribution is totally restricted to the country (**Silva et al., 2012**).

Euphorbiaceae is a family of plants which has high medicinal use, as well as the genus *Cnidoscolus*, popularly known as “urtiga” or “favela”, and highly cited due its properties (**Crepaldi et al., 2016**). This genus has 50 to 75 representatives, whose characteristic is the presence of stinging trichomes that when stimulated by contact with skin, can cause severe and localized pain (**Sátiro and Roque, 2008; Melo and Sales, 2008**). In the Caatinga biome the genus is represented by various species, among them *Cnidoscolus urens* (L). Arthur (**Sobrinho et al., 2012**). Popularly this species have been used orally for the treatment of hemorrhage, inflammation, antiseptic, for treat kidney infections and antitumoral in the Brazilian region Northeastern (**Sobrinho et al., 2012; Albuquerque and Andrade, 2002; Sobrinho et al., 2011, Menezes et al., 2014**).

In this way we can suggest that this species can present effective therapeutic properties, based on its popular use and the presence of metabolites such as flavonoids and terpenoids, which are cited with properties in studies demonstrating its antiinflammatory, analgesic and antitumor action.

This study was carried out to evaluate the antitumoral activity of the ethanolic and aqueous extracts of total plant of *Cnidoscolus urens* against *in vivo* Ehrlich tumor solid model and *in vitro* toxicity of HELA cells and determine the antioxidant activity of these extracts.

2 MATERIALS AND METHODS

2.1 Chemicals

1,1-diphenylpicrylhydrazyl (DPPH), Neutral Red, 3-[4,5-Dimethylthiazol-2-yl]-2,5-Diphenyltetrazolium Bromide (MTT), 5-Fluorouracil (5-FU) and standard for Thin Layer chromatography (TLC) was purchased from Sigma-Aldrich Chemical Company, St. Louis, MO. Solvents for this work were purchased from Merck, Darmstadt, Germany. All the chemicals were of analytical grade.

2.2 Collect of Botanical Material

C. urens were collected in the county Agrestina, Pernambuco, Northeasth Brazil in Caatinga area (Lat 8 ° 23'04.8 "S; Long 35 ° 58'49.7". W), from June 2011. A sample of collected material is archived as voucher specimen number 84.190, at the herbarium of *Instituto Agronômico de Pernambuco (IPA)*.

The total plant (root, stems, leaf, seeds and flowers) materials were dried at room temperature, followed by milling of the dry plant material, was carried out in a Willey type mill, guaranteeing the standardization of the vegetal fragments. The crushed amperial was used for the preparation of the extracts.

2.3 Preparation of Extracts

2.3.1 Preparation of Extract for Phytochemistry

Screenig Extract: 50 g of dried plant material were homogenized for 20 minutes in a mechanical stirrer with 100 mL of methanol in ebullition and filtered with Whatman filter paper (No. 1). The extract was concentrated to dryness, by rotary evaporator pressure Buchler Instruments, Fort Lee, NJ, USA, and resuspended in water (100 mL). The aqueous extracts (Aq) obtained was subjected to partition into separatory funnel with an equal volume of ethyl acetate (EA). Obtaining 2 phases, where the EA phase was separated. This process was repeated twice in order to obtain 2 fractions: Aq and AE. The EA fraction was reserved and Aq was used to obtain N-butanolic fraction that was performed in the same manner of EA fraction. At the end was obtained three fractions: Aq, EA and N-bu (**Wagner; Bladt, 1996**).

2.3.2 Preparation of Extracts for Biological Activities

Aqueous Extract: Dried plant material 100 g were homogenized for 1 hour in a mechanical stirrer with 200 mL of water, kept under refrigeration (4 – 10°C) during 24 hours and filtered with Whatman filter paper (No. 1). This process was repeated twice more. The extract was lyophilized (Liofilizador L101, LIOTOP[®], São Paulo, Brasil).

Ethanolic Extract: 100 g of dried plant material were homogenized for 1 hour in a mechanical stirrer with 200 mL of absolut ethanol, kept under refrigeration (4 – 10°C) and filtered with Whatman filter paper (No. 1). The extract was concentrated to dryness, by rotary evaporator pressure Buchler Instruments, Fort Lee, NJ, USA.

The extracts EA, N-bu and Aq were selected according to **Wagner; Bladt (1996)**, for a better elucidation of the chemical constituents of the extracts, while the extracts aq and EtOH were chosen for the toxicity, antioxidant and antitumor experiments in vivo and in vitro, based on ethnomedical (ethnopolopulational) information available in ethnobotanical studies.

2.4 Phytochemical Screening of *Cnidoscolus. urens*

Thin layer chromatography (TLC) assays were performed for qualitative detection of the substances contained in *C. urens*. Samples of Aq., EA and N-bu extracts were applied to specific Merck silica gel F₂₅₄₊₃₆₆ chromatoplates developed in ascending unidimensional, according **Wagner; Bladt (1996)**. Spots were revealed by spraying and revealing specific followed by visualization under UV light of wavelength of shorter (256 nm) and long (366 nm). In order to identify the main chemical groups of secondary metabolites. The results were compared to the standards specific for each metabolite analysis.

2.5 Animals

The study was carried out with adult male albino Swiss mice (30 ± 5g), obtained from Biotherium of Laboratory of Immunopathology Keizo-Asami (LIKA), UFPE, Brazil. There were housed at a temperature of 22 ± 2°C with a schedule of 12 h light and 12 h dark cycle. Mice were allowed to feed on chow (Labina®, Purina, Brazil) and water *ad libitum*. All experiments reported herein are in accordance with the Animal Care and Use Committee at the Federal University of Pernambuco n° 23076.041082/2011-25 and Guidelines for Care and Use of Laboratory Animals.

2.6 Acute Toxicity in Mice

Acute Toxicity study performed as per Organization for Economic Co- operation and Development (OECD Guidelines) (**OECD, 2004**). Swiss Albino mice of either sex were used. The animals were fasted for 4 h, allowed free access water. Dose maximum of the extracts of *C.s urens* were from 2000 mg/kg, solubilized in saline solution, through the intraperitoneal route of administration. The mice were observed continuously for behavioral changes for the first 4 h and then observed for mortality if any 24 h after the extract administration.

The dose used for other tests was determined from the maximum dose (2000 mg / kg) for the acute toxicity test and the dose applied, corresponding to 10% of the maximum dose.

2.7 Antitumoral Activity of Extracts of *Cnidoscolus urens* in Mice

Ehrlich carcinoma (EC) solid tumor cells were supplied by the Department of Antibiotics, Federal University of Pernambuco (UFPE), Brazil. The cells were maintained *in vivo* in mice by intraperitoneal transplantation. EC cells aspirated from the peritoneal cavity of mice were washed with saline and injected subcutaneously to develop EC solid tumor. For the experimental tumor induction mice were injected with EC (5.0×10^7), subcutaneously in the left footpad to obtain the EC solid tumor (**Stock; Clack; Philip, 1955**).

The mice (n=36) were divided into 6 groups (n=6, for group) as follows:

Group (I) – Control mice without induction of tumor, receiving saline solution 0.9%, named normal control (NC);

Group (II) – Control mice with induction of tumor, treated with saline solution 0.9%, named saline treated (Saline);

Group (III) – Control mice with induction of tumor, treated with 5-FU (20mg/kg- according to the manufacturer), named 5- FU treated;

Group (IV) – Group of mice with induction of tumor, treated with aqueous extract 200mg/kg, named aqueous fresh treated (Aq200);

Group (V) – Group of mice with induction of tumor, treated with ethanolic extract 200mg/kg, named aqueous dried treated (EtOH200).

All the groups were treated for seven days, beginning after the tumor inoculation. On the 8th day, after fasting overnight, all mice were anaesthetized with urethane 1.25g/kg and blood samples were withdrawn by retro-orbital venipuncture technique. After, all mice were euthanized by cervical dislocation and the tumor, liver, kidney and spleen were collected and weighed.

The blood was stored in two separate tubes: (1) containing the anticoagulant ethylenediamine tetraacetic acid (EDTA) and other (2) without anticoagulant, called dry tube (VACUETTETM, Greiner, Kremsmunster, Austria). The dry tube was immediately centrifuged 2500 rpm / 15 min to obtain serum. Serum was utilized for determination of levels of glucose, total cholesterol, HDL-cholesterol, triglycerides, urea, creatinine, total protein, albumin and globulin by chemical automatic analyzer (COBAS[®] 6000, Roche Diagnostics, England). The tube containing EDTA was used to determine the hemathological parameters: total white blood cell (WBC), red blood cell (RBD) and hemoglobin (Hb) were determined by standard method using haemocytometer (SYSMEX XT-4000iTM, Sysmex Corporation, Curitiba, Brazil).

2.8 Antiproliferative Activity of Extracts of *Cnidoscolus urens* in HELA Cells

Antiproliferative activity of extracts of *C. urens* was assessed by cell culture method used to epithelial cell carcinoma of human cervix (HELA). HELA is a line of human cell oldest and most used in scientific research since 1951 (**Masters, 2002**). The cells were obtained from the Cell Bank of the Rio de Janeiro, Brazil. The HELA cells were maintained in 90% Dulbeccos's Modified Eagle (DMEM) supplemented with 2mM L-glutamine, peniciline 100 IU/mL, streptomycin 25mg/mL and 10% heat-inactivated fetal bovine serum.

The cell viability was assessed by Trypan Blue staining with assistance of an inverted microscope. The cell suspension 105 cells/mL was plated in 96-well flat bottom plates 220 µL/well. Cells were allowed to adhere to the wells overnight, and then the extracts of *C. urens* were added to triplicate wells 22µL/well. These plates were incubated at 37 °C, 5% CO₂ for 72 hours, then assayed from growth inhibition using a colorimetric method of MTT, according to protocol of National Cancer Institute, such method, allows to measure the ability to metabolize tetrazolium, by viable cells. A second colorimetric method used to measure cell viability was neutral red, capable of measuring the retention of the dye by the lysosomes of viable cells. and also by the neutral red method. The percentage of cell viability was calculated as:

% Cell viability = $\text{ABS mean extract wells} \times 100 / \text{ABS mean control well}$ and

% Cell inhibition = $100 - \text{ABS mean extract wells} / \text{ABS mean control well} \times 100$.

2.9 In vitro Antioxidant Activity of Extracts of *Cnidoscolus urens*

The method was carried out as described by **Brand- Williams et al. (1995)**. Various concentrations 50, 100, 200 and 500 µg/mL of the ethanolic and aqueous extracts of total plant

of *C. urens* were used. The DPPH solution 150 μ M was prepared with methanol solvent. The assay mixture had a total volume of 1 mL (500 μ L of the extract + 500 μ L of DPPH solution). α -tocopherol (50, 100, 200, 500 μ g/mL). was used as the positive control. After 30 min it's incubation at 25 °C, the absorbance was measured at 490 nm (EL_X 800uv Universal Microplate Reader, BIO-TEK INSTRUMENTS, INC., VINOOSKI, VT). The radical scavenging activity was calculated from the equation:

$$\% \text{ Scavenging} = [(A_{\text{control}} - A_{\text{sample}}) / A_{\text{control}}] \times 100$$

2.10 Statistical Analysis

Data were expressed as mean $\pm$ standard deviation (SD). Statistical significance was determined by one-way ANOVA followed by Turkey's tests. $P < 0.05$ implied significance. All analyses were carried out using software PRISMA (GraphPad Software, Inc., San Diego, CA, version 5.01).

3 RESULTS

3.2 Phytochemical Screening

Phytochemicals assays were used to determine the presence of the main secondary metabolites present in the Aq, EA and N-bu extracts *C. urens*. Through the tests can reveal the significant presence of chemical groups such as flavonoids and terpenoids in EA extract and reduction of sugar in extract Aq. At lower concentrations, we can also detect a presence of tannins and coumarins without N-bu extract, in addition to traces of proanthocyanidins in EA. In the meantime, alkaloids and saponins can not be detected in the samples used for the

phytochemical experiment. In previous studies carried out in 2007 by Yuan et al., Also indicated the presence of flavonoids, terpenoids and coumarins in methanolic extract of *C. texanus*. More recently Peixoto Sobrinho, et al. (2012), identified the presence of anthocyanin, coumarins, flavonoids, tannins and terpenoids in methanolic extracts of aerial parts and root of *C. urens*, corroborating our results. In disagreement, the author referend above detected the presence of saponins in methanolic extract of the *C. urens* root, such a metabolite can not be detected in our studies. As early as 2016, Gomez et al., identified a presence of eight different flavonoids, nine phenolic acids, as well as saponins and alcalde in aqueous extract of *C. chayamansa* leaves. As well as Pérez-González et al., 2017, determine a presence of phenolic compounds and flavonoids in methanolic extract of *C. chayamansa* leaf.

3.2 Acute Toxicity

Intraperitoneal administration of a maximum dose 2000 mg/kg of the *C. urens* did not result in any mortality or observable behavioral changes such as writhing, gasping, palpitation, pilo-erection, hyperventilation and decreased respiratory rate, in the treated mice. Additional studies about chronic toxicity are necessary, which are needed for the best solution on the effects that may or may not be induced by treatment with extracts of *C. urens*.

3.3 Antiproliferative Effect of *Cnidoscolus urens* Extracts

As shown in **(Figure 1)** the Aq and EtOH extracts of *C. urens* exhibited no satisfactory growth and inhibitory activity against a HELA cells. However, ethanolic (100µg/ mL) extract showed greater inhibition of cell growth by the MTT method, with a percentage of approximately 40% **(Figure 1- A)**. The aqueous (100µg/ mL) extract was more effective during

antiproliferative activity with neutral red method, demonstrated a percentage of inhibition of approximately 25% (**Figure 1- B**). In the meantime, if we compare the MTT and NR methodology, the ethanolic extract shows to have developed a simple improvement of the antiproliferative activity. (**Figure 1- A, B**).

3.4 Antitumor Activity of *Cnidoscolus urens* Extracts

After induction of EC solid tumor, the footpad thickness curve presented a significantly behavior from the fourth day post inoculation (**Figure 2- A**). The saline treated group (negative control) showed significant differences in tumor growth between 6th and 8th days. There was a significant reduction of tumor growth in mice treated with 5-FU, Aq200 and EtOH200 at 6th and 8th day, different from control group that increased the tumor weight.

The EC solid tumor weight in the saline treated group was $2.31 \pm 0.35\text{g}$ (**Figure 2- B**). The treatment with Aq200 and EtOH200 showed a significant antitumor activity which was further evidence by percentage reduction (84.4% and 79.2%, respectively). Administration of 5-FU, a commercial drug for treatment of cancer, also lowered tumor weight in 65.4%. However, treatment with Aq200 was significantly ($P < 0.05$) greater than the treatment with 5-FU.

The antitumor nature of Aq200 and EtOH200 was accompanied by the significant reduction in organ weights of animals treated with the extracts ($P < 0.05$ compared to EC solid tumor bearing mice). It was also supported by the significant reduction in liver EtOH200 and kidneys Aq200 and EtOH200 in the extracts treatment when compared to the EC solid tumor treated with saline, named Saline Group (**Table 1**).

Urea, creatinine, total cholesterol, HDL-cholesterol and triglycerides were significantly decreased in animals treated with Aq200 as compared to the saline treated group (**Table 1**). The glucose levels alteration were significantly in all groups with EC solid tumor, and treatment with Aq200 was able to reverse this condition. The 5-FU is a potent agent against tumor (**Figure 2- B**), however, biochemical parameters such as urea, creatinine, total cholesterol, HDL-cholesterol and triglycerides were higher in this group as adverse effects. These parameters were significantly ($P < 0.05$) lower in the groups treated with Aq200 when compared with the group treated with 5-FU. The treatment with EtOH200 showed a significant reduction in the creatinine, total cholesterol and triglycerides levels when compared with the 5-FU group.

The time of tumor development 7 days, which already allows us to see some changes in white blood cells in the treated groups 5-FU and Aq200 (**Table 2**). Also, the treatment with 5-FU promoted significant ($P < 0.05$) decreasing in white blood cells number when compared to the saline treated group. The Aq200 and EtOH200 showed significantly increased in the WBC parameter when compared to the 5-FU treated group.

3.5 Antioxidant Activity of *Cnidoscolus urens* Extracts

The antioxidant method performed by DPPH can be achieved by the elimination of its radicals, being determined by the absorbance. The antioxidant capacity of extracts of *C. urens* and of α -tocopherol can be evidenced in **Figure 3**, showing a decrease ($p < 0.05$) in the concentration of DPPH radicals, this is due to the ability of extracts and α -tocopherol to eliminate reactive species. The radical scavenger activity of the standard and extracts followed the order α -tocopherol > aq > EtOH, with a percentage of 85, 65 and 52% in the concentration of 500 $\mu\text{g} / \text{mL}$. These results indicated that the extract Aq of *C. urens* has a better effect by eliminating the free radicals than the extracted EtOH of *C. urens*, independent of concentration

4 DISCUSSION

Bioactive products of plants have served as a good source of antitumor treatment. Recently, several studies have been conducted and a large number of plants possessing anticancer properties have been documented (**Aranjani et al., 2013; Noolu et al., 2013; Servin Wesley et al., 2013; Ramasamy et al., 2013; Thummar et al., 2015 and Aliya, et al., 2016**). The *Cnidoscolus* genus was traditionally used for the treatment of many diseases (**Bijekar, Gayatri, 2014**), especially against cancer in Northeast Brazilian population (**Jiménez-Arellanes et al, 2014**). Administration of the Aq200 and EtOH200 extracts of *C. urens* for 7 days showed an expressive and significant antitumoral activity. Similar results were found by **Ribeiro et al., (2012)**, when inducing solid tumor of Ehrlich in mice and performing the treatment with aqueous and ethanolic extract of leaf of *Arrabidaea chica*. Thus, it can show the smaller development of the tumor mass when compared to the control. The antitumor activity was demonstrated for the methanolic extract of *Euphorbia dendroides* (Euphorbiaceae) when used for the treatment of mice also with Ehrlich solid tumor. Fayad et al. (2017) highlighted reduction of tumor volume and weight in addition to Increase in the mean survival time of the animals treated with such extracts.

The treatment with Aq200 extract of *C. urens* was a significantly better in decreasing the tumor growth in comparison with treatment of 5-FU, and significantly improve hemoglobin, RBC and WBC. Indicating that extract from *C. urens* has antitumor activity and protective action to hematopoietic system. Similar results were found by Pillai et al. (2012), when used ethanolic extract of *C. chayamansa* sheet for the treatment of Dalton's ascitic Lymphoma. In most cases chemotherapy is accompanied by adverse effects as myelosuppression and anemia.

This framework is already well known tumor patients and can be associated with iron deficiency or hemolytic conditions.

Recent studies with other species of the Euphorbiaceae family also collaborate with our findings, indicating a potent anti-tumor action of these species. Acetone extract of aerial parts of *Phyllanthus niruri* (Euphorbiaceae) showed the presence of flavonoids which was used to demonstrate and prove its antitumor activity (**Padmapriya; Poonguzhali, 2015**). The results found by our phytochemical tests also revealed the significant presence of flavonoids in *C. urens* extract. The presence of this compound in the extracts can be directly related to its potent anti-tumor action, as suggested by scientific studies (**Babu et al., 2013; Yu-Ke et al., 2014; Zhong et al., 2015**).

Under normal conditions, the synthesis of new fatty acid molecules is inhibited by the presence of fatty acids derived from food. This condition altered appears in patients with tumors installed. There is a probability that the altered cells lose their sensitivity, fail to notice an increase in the concentration of fatty acids, and continue to synthesize. Researchers propose that enzymes involved in the synthesis of fatty acids (ATP citrate lyase (ACLY), acetyl-CoA carboxylase α (corn meal), fatty acid synthase (FASN), and long chain acyl-CoA fatty synthetases 1, 3 and 5 (ACSL1, ACSL3, ACSL5)) are increased (**Wu et al., 2014**), being able to influence the lipid profile.

Elevated triglycerides levels were observed in EC solid tumor group in comparison to the normal control group (**Laza-Jacoby et al., 1984**). This finding may be related to changes in lipid metabolism that occurs during cancer development, where a defect in clearance, due to the decrease in the activity of adipose tissue LPL, may be responsible for the early development

of hypertriglyceridemia during tumor growth (**Laza-Jacoby et al., 1984; Wu et al., 2014**). The treatment with Aq200 and EtOH200 extracts of *C. urens* showed reduction of serum triglycerides and total cholesterol. The previous biochemical studies supported properties of bioactive plant compounds that can contribute to the lipid profile ameliorating (**Kumar et al., 2011; Ramachandran et al., 2012**).

Elevated urea and creatinine levels are well reported as one of the most sensitive markers of kidney damage (**Omara et al., 2012**). In the serum of EC solid tumor animals urea showed elevated, indicating kidney damage in these groups. After 8 days of treatment of aqueous extract of *C. urens*, the levels of urea significantly decreased and this result clearly indicates that Aq200 possess effectiveness to improve kidney damage in EC solid tumor animals. Species such as *Jatropha gossypifolia* (Euphorbiaceae) were tested in order to assess the toxicological ability of ethanol extract of the leaves. The animals treated with doses of 1-5 g / kg were analyzed for their biochemical profile after 14 days (**Silva et al., 2014**). The same study showed the ability to reduce the concentration of urea. By contrast observed an increase in creatinine concentration. Data partially corroborate our.

Recent surveys depict glucose metabolism related to the development of tumor cells. Tumor cells are involved in changes in glycolytic and mitochondrial metabolism, providing enough energy for the multiplication of altered cells, to the synthesis of ATP and NADPH, as well as amino acids, lipids and nucleotides. One of the consequences of the change of glucose metabolism, is the decreased level of glucose significantly. This change may be triggered by a disruption in signaling pathways and activation of oncogenes, allowing the production of glucose via the intermediates (**Weinberg; Chandel, 2015**). Decrease in glucose level is a characteristic feature of all types of tumor (**Reinhold et al., 1991**). This may be attributed to

the multiplication of cells requiring more glucose to produce energy in cancer cells (**Bartrons; Caro, 2007; Weinberg; Chandel, 2015**).

Treatment with Aq200 *C. urens* extract increased glucose levels with treatment after 8 days, corroborating with decreasing in a multiplication of EC solid tumor cells in vivo model. **Shetti; Kaliwal** (2015) was able to prove that different species of Euphorbiaceae can also show an improvement in glycemic profile of animals with diabetes induced by alloxan. After treatment with a single dose of 400mg / kg ethanol extract of *Phyllanthus amarus*, the animals demonstrated a low level of blood glucose and hypoglycemic activity of *P. amarus* extract was maintained until the ending of the experiment. The results of Shetti and Kaliwal help prove the hyperglycemic capacity Aq200 and EtOH200.

Gomez et al (2016), used the *C. chayamansa* extract 2% and were able to prove that at the end of the experiments the animals treated with the extract it sufficient to cause an improvement in glucose levels, suggesting the presence of phenolic compounds from the extract could improve insulin secretion, cellular regeneration and inhibition of digestion and absorption of glucose.

Tumor development time for 8 days was able to induce changes in the hematological profile of the groups, improving the immune response of animals that were treated with extract of *C. urens*, with an expressive increase in the number of white blood cells (WBC). Also, the treatment with 5-FU, promoted significant ($P < 0.05$) decreased in white blood cells number. The myelosuppression and anemia are the great problems caused by tumors and the anemia encountered in EC solid tumor animals is mainly due to reduction in red blood cells (RBC) or hemoglobin (Hb) percentage and this may occur either due to iron deficiency or due to

hemolytic or myelopathic conditions (**Sreelatha et al., 2011**). Similar results were showed in animals with EC solid tumor in the present study. The treatment with Aq200 extract promoted a reverse condition for these hematological parameters, suggesting that the aqueous extract of *C. urens* may possess protective action on the hematopoietic system.

Preliminary studies with leaf extract *C. aconitifolius* administered (400, 600 and 800 mg/kg) in groups of diabetic rats showed a great improvement in hemoglobin concentration. This improvement is related to the presence of phenolic compounds identified by prior phytochemical analysis. These phytochemicals findings of the study **Obichi, et al.** (2015), as our results are similar and suggest that these species possess potential anti-inflammatory and antioxidant and strong indication for the treatment of cancer. **Pillai et al** (2012) Also found similar results by treating mice with induced tumors with ethanol extract of *C. chayamansa*.

Aqueous and ethanolic extracts of *C. urens* exercised the antioxidant potential and previous studies showed that the antitumor activity of plant extracts may be attributed to the antioxidant principles present in the extract (**Sreelatha et al., 2011**). These findings in the present study are consistent with the earlier reports, which support the antioxidant activity of of methanolic extract of root and leaves *C. urens* (**Sobrinho et al., 2011**). The antioxidant activity is not just a feature of the species *C. urens*, other species of *Cnidoscolus* also showed antioxidant activity, with the antioxidant activity of *C. aconitifolius* demonstrated by **Obichi, et al., 2015**.

Cytotoxic activity of the extracts was determined according to NCI scale. Extracts are considered without cytotoxic activity when inhibition percentage range was 1-20%, with little activity when such percentage was between 20 and 50%, moderate activity when the inhibition

was 50 to 70% and high activity when the inhibition range was 70 to 100%. Thus, aqueous and ethanolic extracts had their cytotoxicity evaluated by two different methodologies, MTT (access cell with active mitochondrial metabolism) which evaluates the succinate dehydrogenase enzyme ability to reduce MTT to formazan in the mitochondria cell and Neutral Red (soluble in water that accumulates in the lysosomes of viable cells), which assesses the damage caused in the cell membrane. Both extracts showed little cytotoxic activity at the highest concentration (100 ug) by MTT and neutral red dye, similar to that observed by **Sobrinho et al. (2011)**.

The preliminary phytochemical screening of *C.urens* indicated the presence of various compounds. A number of studies reports indicate terpenoids, and phenolic compounds such as tannins, coumarins and flavonoids have a chemo preventive role in cancer through their effects on signal transduction in tumor cell proliferation and many of such compounds are known to possess potent antitumor activity (**Weber et al., 1996; Blois, 2002**). The biochemical studies supported its antioxidant properties and preliminary phytochemical screening showed compounds that can contribute to the *in vivo* antitumor activity of *C. urens* extracts (**Obichi, et al., 2015**).

5 CONCLUSION

The aqueous and ethanolic extracts of *C.urens* were effective in inhibiting the growth of Ehrlich solid tumor models and no adverse side effects due to treatment were observed. However, the cytotoxicity of *C. urens* extracts in HELA cells showed no *in vitro* antiproliferative activity. The biochemical studies supported its antioxidant properties and preliminary phytochemical screening showed the presence of flavonoids, terpenoids, coumarins

and reducing sugar that can contribute to the *in vivo* antitumor activity of *C. urens* extracts. *C. urens* merites further investigation in a tumor model to elucidate its mechanism of action and isolation of its active constituents may prove rewarding in cancer treatment.

The data our pre-clinical suggest that *C. urens* extract is a systematically and nontoxic available angiogenesis inhibitor and should be further evaluated as a potent chemotherapeutic agent. Although *C. urens* be defended as an effective treatment against cancer and widely used for this purpose by the people claiming that in some cases cure the disease, and our preliminary studies have shown promising results, more detailed scientific studies to evaluate its effectiveness and mechanism of action are missing.

CONFLICT OF INTERESTS

All authors declare that they have no competing interests in the present work.

ACKNOWLEDGMENTS

This work was supported by *Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)*, *Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)* and *Fundação de Amparo à Ciência do Estado de Pernambuco (FACEPE)*.

REFERENCES

- Albuquerque, U. P., Andrade, L. H. C., 2002. **Uso de recursos vegetais da Caatinga: O caso do Agreste do estado de Pernambuco (Nordeste do Brasil)**. Revista de Ciências e Tecnologia da América, 27(7), 336- 346.
- Aliya, S., et al., 2016. **Plants as Potential Resources of Anticancer Drugs**. *Current Trends in Biotechnology & Pharmacy*, 10(1).
- Aranjani, J. M. et al., 2013. **Preliminary evaluation of *in vivo* cytotoxicity and *in vivo* antitumor activity of *Xanthium strumarium* in transplantable tumors in mice**. The American Journal of Chinese Medicine 41(1), 145-162.
- Ashraf et al., 2015. **Antioxidant, Antimicrobial, Antitumor, and Cytotoxic Activities of an Important Medicinal Plant (*Euphorbia royleana*) from Pakistan**. Journal of Food and Drug Analysis, 23, 109- 115.
- Asirvatham, R. et al., 2012. **Anticancer activity of *Jasminun angustifolium* Linn against Ehrlich ascites carcionoma cells bearing mice**. Journal of Experimental and Integrative Medicine 2, 271-275.
- Babu, B. V., et al., 2013. **Experimental and theoretical advances in functional understanding of flavonoids as anti-tumor agents**. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 13(2), 307-332.
- Bijekar, S; Gayatri, M.C., 2014. **Ethanomedicinal Properties of *Euphorbiaceae*-Family- A Comprehensive Review**. International Journal of Phytomedicine, 6, 144- 156.
- Bartrons, R., Caro, J., 2007. **Hypoxia, glucose metabolism and the Warburg's effect**. Journal of Bioenergetics and Biomembranes 39(3), 223-229.
- Blois. M.S., 2002. **Antioxidant determination by the use of a stable free radical**. Nature 26, 1199-1200.

Brand-Williams, W. et al., 1995. **Use of free radical method to evaluate antioxidant activity.** Lebensmittel – Wissenschaft und -Technologie, 22, 25-30.

Crepaldi, C. G. et al., 2016. **Richness and ethnobotany of the family Euphorbiaceae in a tropical semiarid landscape of Northeastern Brazil.** South African Journal of Botany, 102, 157- 165.

Dashora, N. et al., 2011. **Antitumor activity of *Dendrophthoe falcata* against Ehrlich ascites carcinoma in Swiss albino mice.** Pharmacoeutical Crops 2, 1-7.

Fayad, W. et al. **A systematic multicellular spheroids screening approach lead to the identification of antineoplastic activity in three different plant extracts from the Egyptian flora.** Journal of Applied Pharmaceutical Science, v. 7, n. 6, p. 013- 022, 2017.

Ferlay, J., et al., 2015. **Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012.** International Journal of Cancer, 136 (5), E359-E386.

Gomez, M. R. et al. **Phytochemical Profile, Antioxidant Properties and Hypoglycemic Effect of Chaya (*Cnidoscolus Chayamansa*) in STZ-Induced Diabetic Rats: STZ-Induced Diabetic Rats.** Journal of Food Biochemistry, 2016

GLOBOCAN- **International Agency for Research on Cancer**, 2008 online
<http://globocan.iarc.fr> accessed on Jan 08'2013.

INCA, 2016. **ESTIMATIVA/ 2016: Incidência de Câncer no Brasil.** Instituto Nacional de Câncer José Alencar Gomes da Silva – Rio de Janeiro: INCA. online:
<<http://www.inca.gov.br/estimativa/2016/estimativa-2016-v11.pdf>>. Accessed on Jul 10'2016.

INSTITUTO ONCOGUIA, 2015. On line: <http://www.oncoguia.org.br/conteudo/-cancer/12/1/?utm_source=google&utm_medium=cpc&utm_term=conteudo_cancer&utm_campaign=conteudo_cancer&gclid=CjwKEAjw_LG8BRDb1JTxm8uP_UwSJADu_8pW1Ayy>

Gzb13WV_HBZtTQnUmxG3muIYsKjElVnnFZkXoCPMnw_wcB> accessed on Jul 18’2016.

Jeevanantham, P., et al., 2011. **Anticancer activity of methanolic extract of aerial parts of *Momordica cymbalaria* Hook F. against Ehrlich ascites carcinoma in mice.** Journal of Pharmaceutical Sciences and Research 3, 1408-1411.

Jiménez-Arellanes et al., 2014. **Biological potential of medicinal species of *Cnidoscolus* genus.** Rev Mex Cienc Farm, 45 (4).

Kumar, S. et al., 2011. **Antidiabetic, hypolipidemic and histopathological analysis of *Dillenia indica* (L.) leaves extract on alloxan induced diabetic rats.** Asian Pacific Journal of Tropical Medicine, 347-352.

Laza-Jacoby, S. et al., 1984. **Sequential Changes in the Activities of Lipoprotein Lipase and Lipogenic Enzymes during Tumor Growth in Rats.** Cancer Research, 44, 5062-5067.

Masters, J. R., 2002. **TIMELINE: HeLa cells 50 years on: the good, the bad and the ugly.** Nature Reviews Cancer, 2 (4), 315–319.

Melo, A. L., Sales, M. F., 2008. **O gênero *Cnidoscolus* Pohl (Crotonoideae-Euphorbiaceae) no Estado de Pernambuco, Brasil.** Acta Botanica Brasilica, 22(3), 806-827.

Menezes, Y. A. S. et al., 2014. **Protein-Rich Fraction of *Cnidoscolus urens* (L.) Arthur Leaves: Enzymatic Characterization and Procoagulant and Fibrinolytic Activities.** Molecules, 19 (3), 3552-2569; doi:10.3390.

Noolu, B. et al., 2013. ***Murraya koenigii* leaf extract inhibits proteasome activity and induces cell death in breast cancer cells.** BMC Complementary and Alternative Medicine 13(7), 3-17.

Obichi, E. A. et al., 2015. **Effect of *Cnidoscolus aconitifolius* (Family Euphorbiaceae) Aqueous Leaf Extract on Some Antioxidant Enzymes and Haematological Parameters of High Fat Diet and Streptozotocin Induced Diabetic Wistar Albino Rats.** J. Appl. Sci. Environ, 19 (1) 201-209.

OECD 432, **Organization for Economic Co-operation and Development.** Guideline for Testing of Chemicals 432: In vitro e 3T3 NRU phototoxicity test, abr. 2004.

Omara, E.A.et al., 2012. **Therapeutic effect of *Acacia nilotica* pods extract on streptozotocin induced diabetic nephropathy in rat.** Phytomedicine 19, 1059-1067.

Ostadhadi, S. et al., 2015. **Therapeutic Potential of Cannabinoids in Counteracting Chemotherapy- induced Adverse Effects: Na Exploratory Review.** Phytotherapy Research, 29, 332-338.

Padmapriya, N.; Poonguzhali, T. V. **Evaluation of Anticancer Activity of Flavonoid Isolated From the Acetone Extract of the Aerial Parts of *Phyllanthus Niruri* Against Human Lung Cancer Cell Line (A549).** International Journal of Pharma and Bio Sciences. v. 6, n. 3, p. 296 – 304, 2015.

Peixoto Sobrinho, T. J. D. S., Saraiva, A. M., Almeida, D. M., Tavares, E. A., Pisciotano, M. N. C., & de Amorim, E. L. C. **Phytochemical screening and antibacterial activity of four *Cnidoscolus* species (Euphorbiaceae) against standard strains and clinical isolates.** *Journal of Medicinal Plants Research*, v.6, n.21, p. 3742 - 3748, 2012.

Pérez-González, M. Z., et al. **Antiprotozoal, antimycobacterial, and anti-inflammatory evaluation of *Cnidoscolus chayamansa* (Mc Vaugh) extract and the isolated compounds.** *Biomedicine & Pharmacotherapy*, v.89, p. 89- 97, 2017.

Pillai, K. et al., 2012. **Antitumor Activity of Ethanolic Extract of *Cnidoscolus Chayamansa* Mcvaugh Against Dalton’s Ascitic Lymphoma In Mice.** Int J Pharm Pharm Sci., 4 (4), 647-652.

Pilatti, F.K. et al., 2011. ***In vitro* and cryogenic preservation of plant biodiversity in Brazil.** In vitro Cellular & Development Biology: Journal of the Tissue Culture Association 47, 82-98.

Rada, N. E., 2015. **Assessing Brazil's Cerrado Agricultural Miracle: an Uptade.** Revista de Economia e Agronegócio, 11 (1), 1-38.

Ramachandran, S. et al., 2012. **Investigation of hypoglycemic, hypolipidemic and antioxidant activities of aqueous extract of *Terminalia paniculata* bark in diabetic rats.** Asian Pacific Journal of Tropical Biomedicine, 262-268.

Ramasamy, S. et al., 2013. **Effect of extracts from *Phyllanthus watsonii* airy shaw on cell apoptosis in cultured human breast cancer MCF-7 cells.** Experimental and Toxicology Pathology 65, 341-349.

Reinhold, H.S. et al., 1991. **Dose-effect relationships for glucose-induced tumor acidification and erythrocyte flux.** European Journal of Cancer 27(9), 1151-1154.

Ribeiro, A. F. C. et al., 2012. **Effect of *Arrabidaea chica* extracts on the Ehrlich solid tumor development.** Brazilian Journal of Pharmacognosy, 22(2), 364-373.

Sátiro, L. N., Roque, N., 2008. **A família Euphorbiaceae nas Caatingas arenosas do médio rio São Francisco, BA, Brasil.** Acta Botanica Brasilica, 22(1), 99-118.

Servin Wesley, P. et al., 2013. ***In vitro* phytochemical screening, free radical scavenging activity and anticancer activity of *Abutilon hirtum* (Lam.) Sweet (Malvaceae).** International Journal of PharmTech Research 5(1), 155-161.

Silva, J. F. et al., 2014. ***Jatropha gossypifolia* L. (Euphorbiaceae): A Review of Traditional Uses, Phytochemistry, Pharmacology, and Toxicology of This Medicinal Plant.** Evidence-Based Complementary and Alternative Medicine, 2014, 32.

Silva, M. I. G. et al., 2012. **Bioactivity and potential therapeutic benefits of some medicinal plants from the Caatinga (semi-arid) vegetation of Northeast Brazil: a review of the literature.** Brazilian Journal of Pharmacognosy, 22(1), 193-207.

Shetti, A. and Kaliwal, B. B., 2015. **Hypoglycemic Activity of Ethanolic Leaf Extract of *Phyllanthus Amarus* In Alloxan Induced Diabetic Mice.** European Journal of Experimental Biology, 5(1), 26-29.

Sobrinho, T. J. S. P. et al., 2011. **Phenolic content and antioxidant capacity of four *Cnidoscolus* species (Euphorbiaceae) used as ethnopharmacologicals in Caatinga, Brazil.** African Journal of Pharmacy and Pharmacology, 5(20), 2310-2316.

Sobrinho, T. J. S. P. et al., 2012. **Antiproliferative activity of species of the genus *Cnidoscolus* against HT-29, Hep-2 and NCI-H292 cells.** Molecular & Clinical Pharmacology, 3(2), 55-61.

SBCO- **Sociedade Brasileira de Cirurgia Oncológica**, 2015. On line:
< <http://www.sbco.org.br/comunidade/o-que-e-cancer/> > accessed on Jul 15'2016.

Sreelatha, S., et al., 2011. **Evaluation of anticancer activity of ethanol extract of *Sesbania grandiflora* (Agati Sesban) against Ehrlich ascites carcinoma in Swiss albino mice.** Journal of Ethnopharmacology 134, 984-987.

Stock, C. C.; Clarck, D. A.; Philipis, F. S., 1955. **Sarcoma 180- Inibition of Screening date.** Cancer Research, 2, 2- 3.

Syamala, G. et al., 2015. **Antitumor Potential of Standardized Extract From *Aegle Marmelos* Root on Dalton's Lymphoma Induced Mice Model.** IJPSR, 6(5), 2066-2071.

Thummar et al., 2015. **Evaluation of in vivo Antitumor Activity of Cleistanthin B in Swiss Albino Mice.** Journal of Traditional and Complementary Medicine. Doi: 10.1016/j.jtame.2015.08.004.

Wagner, H.; Bladt, S., 1996. **Plant drug analysis. A thin layer chromatography atlas.** 2 ed. Berlin. Springer Verlag, 384.

Weber, G. et al., 1996. **Increased signal transduction activity and down regulation in human cancer cells.** Anti-cancer Research 16, 3271-3282.

Weinberg, S. E. and Chandel, N. S., 2015. **Targeting mitochondria metabolism for cancer therapy.** Nat Chem Biol., 11 (1), 9-15.

Wu, X. et al., 2014. **Lipid Metabolism in Prostate Cancer.** Am J Clin Exp Urol., 2(2), 111-120.

Yuan, W., Li, S., Ownby, S., Zhang, Z., Wang, P., Zhang, W., Beasley, R. S.
Flavonoids, coumarins and triterpenes from the aerial parts of *Cnidoscolus texanus*.
Planta Medical, v. 73, p. 1304 – 1308, 2007.

Yu- Ke, J. et al., 2014. **Evaluation of a citrus flavonoid as a chemopreventive agent against breast câncer. In: Proceedings of the 105th Annual Meeting of the American.**
Association for Cancer Research. San Diego, CA. Philadelphia (PA): AACR; Cancer, 74 (19).
doi:10.1158/1538-7445.AM2014-2151.

Zhong, M. et al. 2015. **Protective Effects of Total Flavonoids in *Polygonum perfoliatum* L. on the Acute Liver Injury of Mice Induced by CCl₄ and Its Action Mechanism.** Medicinal Plant, 6 (3-4), 12-13, 17.




Figure1. Antiproliferative activity of extracts of *Cnidoscolus urens* in HELA cells by MTT method (A) and Neutral Red method (B). * $P < 0.05$ for all analysis as compared with Aq group.




Figure 2. Effect of *C. urens* extracts on footpad thickness (A) and EC solid tumor weight (B). Data are reported as the mean $\pm$ S.D. Statistical differences from the controls were determined by ANOVA followed Tukey's Test. * $P < 0.05$ for all groups as compared saline treated group (negative control); † $P < 0.05$ for all groups as compared with 5-FU treated group.




Figure 3. Radical scavenging activity of *Cnidoscolus urens* extracts by DPPH method. * $P < 0.05$ for all analysis as compared with α -tocopherol; * $P < 0.05$ for all analysis as compared with Aq group.

Table 1. Biological parameters in mice bearing EC solid tumor treated with *Cnidoscolus urens* extracts.

Biological Parameters	Groups				
	Normal Control	Saline	5-FU	Aq200	EtOH200
Liver (g)	1.84 ± 0.15	2.16 ± 0.10	2.27 ± 0.10 [†]	1.97 ± 0.43	1.71 ± 0.29 ^{*,†}
Spleen (g)	0.17 ± 0.02	0.18 ± 0.02	0.23 ± 0.03	0.23 ± 0.05	0.20 ± 0.07
Kidneys (g)	0.56 ± 0.04	0.51 ± 0.02	0.42 ± 0.03 ^{‡,*}	0.42 ± 0.07 ^{‡,*}	0.38 ± 0.06 ^{‡,*}
Total Proteins (g/ dL)	5.24 ± 0.39	4.25 ± 0.17	4.42 ± 0.15	4.45 ± 0.46	3.53 ± 1.26 [‡]
Albumin (g/ dL)	3.52 ± 0.19	2.37 ± 0.23 [‡]	2.45 ± 0.16 [‡]	1.97 ± 0.21 [‡]	2.13 ± 0.80 [‡]
Globulin (g/ dL)	1.72 ± 0.50	1.88 ± 0.11	1.97 ± 0.05 [‡]	2.48 ± 0.42	1.40 ± 0.46
Urea (mg/ dL)	27.67 ± 3.78	46.55 ± 5.68 [‡]	48.67 ± 5.07 [‡]	27.1 ± 7.80 ^{*,†}	38.1 ± 11.90
Creatinine (mg/ dL)	0.21 ± 0.01	0.5 ± 0.06 [‡]	0.65 ± 0.09 ^{‡,*}	0.22 ± 0.04 ^{*,†}	0.25 ± 0.14 ^{*,†}
Glucose (mg/ dL)	116.1 ± 10.40	81.3 ± 2.04 [‡]	79.5 ± 2.80 [‡]	127.9 ± 47.40 ^{‡,†}	115.9 ± 17.20
TC (mg/ dL)	120.6 ± 9.10	116.1 ± 10.40	138.1 ± 11.30 [*]	77.6 ± 8.10 ^{‡,*}	88.3 ± 17.00 ^{‡,*}
HDL-c (mg/ dL)	69.1 ± 5.20	63.3 ± 3.10	72.1 ± 8.20	41.1 ± 4.10 ^{‡,*}	58.3 ± 18.90
Triglycerides (mg/ dL)	118.7 ± 5.90	292.5 ± 29.20	209.4 ± 25.30 ^{‡,*}	167.8 ± 35.70 ^{‡,*}	173.6 ± 31.20 ^{‡,*}

Data represent the mean ± S.D. (n=6). Statistical differences from the controls were determined by ANOVA followed Tukey's Test. [‡]*P*<0.05 for groups as compared with normal control group; ^{*}*P*<0.05 for groups as compared with saline treated group (saline group); [†]*P*<0.05 for groups as compared with 5-FU (positive control). TC – total cholesterol; HDL-c – high density lipoprotein cholesterol.

Table 2. Hematologic parameters in mice bearing EC solid tumor treated with *Cnidoscolus urens* extracts.

Hematologic Parameters	Groups				
	Normal Control	Saline	5-FU	Aq200	EtOH200
Total RBC	98.0 ± 26.90	71.2 ± 28.60 [‡]	88.4 ± 25.60	93.5 ± 0.40*	84.1 ± 0.70
Total WBC	1.31 ± 0.05	1.25 ± 0.09	0.35 ± 0.06 ^{‡,*}	2.74 ± 0.50 ^{‡,*}	1.51 ± 0.26 [†]
Hb (%)	15.0 ± 0.30	12.8 ± 0.40 [‡]	13.9 ± 0.40	14.8 ± 0.40* [‡]	13.4 ± 1.30 ^{‡,*}
PLT	1.31 ± 0.08	1.67 ± 0.12 ^{‡,*}	1.13 ± 0.11	1.48 ± 0.35 [†]	1.00 ± 0.02 [‡]

Data represent the mean ± S.D. (n=6). Statistical differences from the controls were determined by ANOVA followed Tukey's Test. [‡]*P*<0.05 for groups as compared with normal control group; **P*<0.05 for groups as compared with saline treated group (saline group); [†]*P*<0.05 for groups as compared with 5-FU (positive control). RBC – red blood cells (x10⁵ cells/mL); WBC – white blood cells (x10⁴ cells/mL); Hb – hemoglobin; PLT – platelets (x10⁶).

CAPÍTULO III

Manuscrito 2: Effects of methanolic extract of aerial parts of *Cnidoscolus urens* (Euphorbeaceae) on the spontaneous contractile activity and induced castor oil in an animal model.



Souza, P. G. V. D.^a; Campos, J. K. L.^b; Lima, V. L. M.^b; Silva, N. H.^{a*}.

Manuscrito a ser submetido ao periódico *Journal of Ethnopharmacology* no formato *Original Research Article* (FI: 3.055; QUALIS CB II: B1).

Effects of methanolic extract of aerial parts of *Cnidoscolus urens* (Euphorbeaceae) on the spontaneous contractile activity and induced castor oil in an animal model.

Souza, P. G. V. D.^a; Campos, J. K. L.^b; Lima, V. L. M.^b; Silva, N. H.^{a*}.

^aLaboratório de Produtos Naturais. Departamento de Bioquímica, Centro de Biociências, Universidade Federal de Pernambuco, Brasil. ^a

^bLaboratório de Metabolismo de Lipídeos e Lipoproteína. Departamento de Bioquímica, Centro de Biociências, Universidade Federal de Pernambuco, Brasil. ^b

*Corresponding author

Laboratório de Produtos Naturais. Departamento de Bioquímica, Centro de Biociências, Universidade Federal de Pernambuco. Avenida Professor Moraes Rego, s/n, B. Cidade Universitária, CEP 50670-420, Recife- Pernambuco, Brasil. 55 81 21268541, 55 81 21268540 (219), e-mail: nicacio_hsilva@hotmail.com

ABSTRACT

Ethnopharmacological relevance: *Cnidoscolus urens* (Euphorbiaceae) popularly called "nettle" and well known for causing irritating reactions when in contact with the skin. Area native species of Caatinga, always present in situations in ethnopharmacological surveys. Parts of this plant, root and stem are widely used as herbal medicines. *C. urens* popular believe that can be used for the treatment of cancer, inflammation, pain, kidney problems and diarrhea. But there is limit scientific study on its activity and mechanism against almost any of these diseases which are used as therapeutic, nor for the treatment of gastrointestinal disorders.

Aim of the study: To evaluate the anti-diarrheal activity and acute toxicity *in vivo* of the methanol extract of aerial parts of *C. urens*.

Materials and Methods: The methanolic extract of aerial parts of *C. urens* (MeOH) was tested at two different doses (200 and 400 mg / kg, p.o. in mice), against experimental models which evaluated the effect in normal stools and diarrhea models using the test Castor- oil induced diarrhea, enteropooling and Charcoal meal. The evaluated criteria were whether the administration MeOH (200 and 400 mg / kg) induce a change as the consistency and total number of stools in diarrhea model induced by castor oil; production and fluid accumulation was achieved by enteropooling model and intestinal transit as to the methodology of choice was the Charcoal meal test. The acute toxicity was evaluated following the guidelines of the OECD.

Results: The MeOHC extract *C. urens* was unable to cause toxic effects at the highest dose tested, which was 2000 mg / kg. For the antidiarrheal activity, the doses of 200 and 400 mg / kg MeOHC. *urens* showed a significant decrease in diarrhea, inhibiting in 68 and 87% respectively, the number of bowel movements. The MeOHC. *urens* (200 and 400 mg / kg) was also able to decrease to 3.4 and 3.0 respectively, wet number stools on castor oil induced diarrhea, compared to the control, which was 11.2, improving the consistency of the faeces over

of time. In an enteropooling assay of the two doses were capable of inhibiting fluid accumulation induced by oil, given value of 23.4, at a dose of 200mg / kg and 20.8, at a dose of 400mg / kg. Finally the Charcoal meal test demonstrated efficacy as the action of the intestinal transit. In this test it was obtained a reduction in motility percentage equal to 36.3 for the dose of 200 mg / kg and 25.5 to 400mg / kg, a significant reduction when compared to the negative control that reduced to a percentage of 79.3.

Conclusions: These results indicated MeOH extract an anti-diarrheal action, working on improving the consistency of stool, decreased intestinal motility and the accumulation of intestinal fluid.

Keywords: *Cnidoscolus urens* (Euphorbiaceae), Diarrhea, Castor oil, Motility and Charcoal.

1 Introduction

Gastrointestinal infections present as fear symptoms, diarrhea, which may be, caused by a wide array of pathogens. Among the main pathogens, we mention can bacteria, viruses and protozoa. In the meantime a single pathogen, it becomes primarily responsible for about 40% of hospital admissions for diarrhea due to the rotavirus. However, we can, not help but draw attention to other important actors, such as bacteria, including: *E. coli*, *V. cholerae*, *Shigella* and *Salmonella*. (WHO, 2009; Palla; Gilani, 2015)

Gastrointestinal disorders are usually, accompanied by muscular contractions that cause abdominal pain, constipation, intestinal colic, diarrhea or occlusions leading to an inflammation of the mucosa, this symptomatology is caused by the alteration in the movement of the smooth muscle of the small intestine, which can increase or decrease the speed of the Muscle contractility (Salaga et al., 2015). Intestinal transit, gastrointestinal tract length, muscle tone and myoelectric and contractile activity are a set of actions that contribute to gastrointestinal system (SGI). (Joseph et al., 2015).

According to the World Health Organization (2013), diarrheal disease is a leading cause of child mortality and morbidity worldwide. Developing countries are the most affected by these types of diseases, in these children under three years of age, have on average three episodes of diarrhea / year. The Acute Diarreal Diseases (DDA) is the second leading cause of death in children under five years. It is estimated, about 760 000 children under five will death/ year due to diarrheal disease origin, which is the main cause of malnutrition in children under five years of age, and 1.7 billion cases of diarrhea each year. Diarrhea is a major cause of malnutrition in children under five years of age.

Important cause of mortality and morbidity in Brazil and in developing countries, the DDA has a high prevalence (Ministério da Saúde Brasília/DF, 2004). According Eduardo et al., em 2005, the Brazil, in spite of limitations to how many records DDA cases reached more than 600,000 hospitalizations due to intestinal infections and about almost 8000 deaths. In 2011, there were 49,175 deaths from infectious and parasitic diseases (Ministério da Saúde, 2012a), and these numbers became more significant when analyzing the number of deaths due to ADD in children under 5 years of age, reaching a total of 756 per year In Brazil (Ministério da Saúde, 2012b).

Many countries live a socioeconomic condition of transition, like Brazil. And for this reason their populations coexist with important social problems that end up in severely affect public health. These problems such as lack of sanitation and environmental pollution, contribute to intestinal infections. This type of infection is, considered relevant because it can cause damage to the physical and intellectual development, in particular, children under 5 years (Santos et al., 2014). Other important factors that may be associated diarrheal diseases are reduced productivity at work, morbidity, increased use of medical and hospital resources, and unnecessary expenses (Palla; Gilani, 2015).

To support our research, the Caatinga, exclusively Brazilian biome, presents about 900 plant species (Zanirato, 2010; Pinheiro et al., 2013). They have aroused great interest among researchers from around the world, for its high therapeutic power and their ability to expand the arsenal of bioactive molecules (Cartaxo et al., 2010). The scientific community has shown that many species of plants are, enjoyed by the population as a therapeutic product and the Euphorbiaceae family it stands out for the wide use. Among those belonging to his family, give

emphasis on the gender *Cnidoscolus* (Gomes et al., 2014; Peixoto Sobrinho et al., 2012). In the Caatinga biome, the *Cnidoscolus* genre is represented by four, *C. infestus*, *C. pubescens*, *C. quescifolius* and *C. urens*, species that are used as therapeutic componentes, such as anti-inflammatory, appendicitis, rheumatism, kidney infections among other utilities (Peixoto Sobrinho et al, 2012; Agra et al., 2008; Coelho et al., 2012; Gomes et al., 2014).

The species *C. urens* gained great prominence in the popular medicinal, for always appear in quotes with therapeutic activities in ethnobotanical studies. To find out its biological activity, methanolic extract of parts of *C. urens* sand was, used to demonstrate its antidiarrheal effect in experimental models in mice.

2 MATERIALS AND METHODS

2.1 Chemicals

Castor oil (SD Fine Chem. Ltd.), loperamide [2 mg] were from square pharmaceuticals limited and Vincristine Sulphate (VINCRIST ®) from Techno Drugs Ltd, atropine sulphate were purchased from Sigma Aldrich Chemie GmbH (Taufkirchen, Germany), activated charcoal (Vetec), methyl alcohol (99.8% - Vetec).

2.2 Collect of Botanical Material

C. urens, commonly known as nettle, were collected in Agrestina, located 136 km from the capital Recife, state of Pernambuco, Brazil Northeasth, in Caatinga area (Lat 8 ° 23 '04.08", Long 35 ° 58' 49.7" w) from January 2014. The collected sample was, filed with the voucher specimen number 84.190, in the herbarium of the Agronomic Institute of Pernambuco (IPA).

Aerial parts (leaves, flowers and fruits) were, dried at room temperature ($27 \pm 28^\circ \text{C}$) and used to extract preparations.

2.3 Preparation of Extract

Methanol extract: 100 g aerial parts of *C. urens* collected and adequately dried, it was placed in a percolator and added to 1 liter of methanol, left overnight and then filtered with Whatman filter paper (no. 1), this procedure, was repeated until exhaustion. The extract was concentrated to dryness by rotary evaporator pressure Buchler Instruments, Fort Lee, NJ, USA.

2.4 Animals

Swiss male albino mice, weighing 30 to 35 g were, used for all experiments. All animals were, originally obtained from the vivarium Keizo Asami Immunology Laboratory (LIKA), UFPE, Brazil. The animals were, housed in polypropylene cages ($47 \times 34 \times 18 \text{ cm}^3$), with sawdust at a temperature of $22 \pm 2^\circ \text{C}$, with a schedule of 12 h light and 12 h dark cycle. Mice were, allowed to feed on Labina® chow, Purina, Brazil and water *ad libitum*. All tests described herein are in accordance with the Animal Care and Use Committee at the Federal University of Pernambuco (No. 23076.041082 / 2011-25) and Guidelines for Care and Use of Laboratory Animals of Laboratory

2.4.1 Study Design

The study was, designed to evaluate the methanol extract of *C. urens* (MeOH) in different concentrations and different models of diarrhea induction. The activities I and II (Normal defaecation and Castor- oil induced diarrhea, respectively) and III and IV (Enteropooling and Charcoal meal, respectively) followed the same design distribution groups.

The mice (n = 24) Were divided in to 4 groups (n = 6, for group) as follows:

2.4.1.1 Drawing for the activities I and II:

Group (I) - Negative control, inducing diarrhea from castor oil and treated with saline solution only.

Group (II) - Control loperamide (10mg / kg), inducing diarrhea from castor oil and treatment with standard drugs.

Group (III) - Group test, inducing diarrhea from castor oil and treated with MeOH [200mg / kg].

Group (IV) - Group test, inducing diarrhea from castor oil and treated with MeOH [400 mg / kg].

2.4.1.2 Drawing for the activities III and IV:

Group (I) - Negative control, inducing diarrhea from castor oil and treated only with saline.

Group (II) - Control atropine sulfate (0, 25mg/kg), inducing diarrhea from castor oil and treated with standard drugs.

Group (III) - Group test, inducing diarrhea from castor oil and treated MeOH [200mg / kg].

Group (IV) - Group test, inducing diarrhea from castor oil and treated MeOH [400mg / kg].

2.5 Toxicity Study

Before starting any type of test, the extract was, tested for its acute oral toxicity. For the determination of acute toxicity, we follow the guidelines of the Organization for Economic Cooperation and Development (OECD, 2004). Swiss Albino mice, females and males, were, used to evaluate the toxicity of the methanolic extract of *C. urens*. The animals were fasted for 6 h, received free water. After the fasting period, the animals were, treated with a maximum dose of 2.000 mg / kg MeOH and diluted in saline solution. Administration of the extract was, done orally. The treated animals remained under observation for 4 h to detect any changes in their behavior such as: Piloerection, train survey, agitation, respiratory and cardiac frequency and then were evaluated for mortality, if there was mortality up to 24 h after administration of the extract of *C. urens*.

From the acute toxicity test, we can determine the dose of choice used for the treatment of the experimental tests, which corresponded to 10% of the maximum dose of the toxicity test, which is equal to 200 mg / kg. An additional dose, which corresponds to twice the dose of choice, being 400 mg / kg was, also used in order to evaluate if there would be improvement as the dose was increased.

2.6 Evaluation of the effect of the extract MeOH on normal defaecation (I)

The effect of the extract on the production of the normal number of stools was, assessed as described by Melo et al., 1988. Adult rats were fasted for 18 h with free access to water and

divided into four groups (n = 6) and treated according to the design described in item 2.4.1.1.

The animals were, individually placed in plastic cages coated with filter paper.

The 4 groups were, treated orally, with saline, loperamide and MeOH (200 and 400 mg / kg). The total number of feces of each group was, counted every hour for 4 hours. The percentage reduction in the number of feces of the treated groups was, compared with the control group.

2.7 Evaluation of the Castor- oil induced diarrhea in mice (II)

Adult mice were, divided into 4 groups randomly fasted for 18 h with free access to water. The groups were, divided and treated in accordance with item 2.4.1.1. After 30 minutes of treatment was, administered to all animals 0.1 mL of castor oil orally. The animals were, placed in polyethylene cages lined with filter paper and evaluated for 4h for the production of diarrheal stools. The total count of diarrheal stools of treated groups was, compared to the control group, which was, considered 100% of diarrheal stools production. Thus, the results were expressed as % reduction of the production of diarrhea stools (Awouters et al., 1978). Percent reduction was, calculated by using equation as follows:

$$\% \text{ reduction: } [(\text{Mean castor oil diarrhea score (control)} - \text{mean score of treatment group}) / \text{Mean castor oil diarrhea score (control)}] \times 100$$

2.8 Castor oil induced enteropooling assay in mice (III)

As part of the studies that evaluated the antidiarrheal activity of MeOH extract, the accumulation of intraluminal fluid was determined by the method of Robert et al., 1976; Capasso et al., 2002; Gilani et al., 2005. The animals fasted for 24 h were divided into 4 groups (n = 6) and treated (saline, loperamide and MeOH 200 and 400 mg / kg), as described in activity III of the study desing (topic 2.4.1.2). After 30 minutes of treatment, all animals received 10 ml / kg of castor oil orally. A further 30 minutes after administration of the oil, the animals were, sacrificed by servic displacement and the small intestine was, removed. The small intestine was filled heavy (W1), then emptied and weighed again (W2) and the length, determined (L). The weight difference divided by the length demonstrates the enteropooling in mg / cm when applied the following formula:

$$\text{Enteropooling: } (W1-W2)/L$$

2.9 Charcoal meal in mice (IV)

To determine the transit of the small intestine, a solution of charcoal suspended in carboxymethylcellulose (CMC), orally administered in mice was, used as previously described by IZZO et al. (1992). The animals were fasted for 18 h with free access to water and divided into 4 groups. The four groups were, treated according to item 2.4.1. 2, being administered as saline treatment, atropine sulfate and MeOH (200 and 400 mg / kg). After 30 minutes of pretreatment, all animals received castor oil (0.2 mL). After a further 30 minutes, after administration of the oil, a suspension of CMC coal (0.5%) was, given in all animals orally. After 30 minutes of administration of the charcoal suspension, the animals were, sacrificed. The

abdomen of each animal was, opened, removing the small intestine from the pylorus to the cecum. The small intestine was, carefully stretched under a tape measure to obtain, in centimeters, the total length of the small intestine and the distance traveled by the charcoal. Intestinal transit was expressed as a percentage of the total intestinal length and the values applied in the following formula: Intestinal transit (%) = $(DC / LSI) \times 100$, where DC is the distance reached by charcoal and LSI refers to the length Total of the small intestine.

2.10 Statistical evaluation

The results were submitted to analysis of variance (ANOVA) followed by Tukey's multiple comparison test, with $p < 0.05$ considered to denote a statistically significance .all data were expressed as mean values $\pm$ standard deviation (SD).

3 RESULTS

3.1 Toxicity activity

The MeOH extract was, used to test its possible toxicity at a dose of 2000 mg / Kg in albino camundogos, by oral route, which has shown to be devoid of any toxic effect. Thus, for the antidiarrheal effect studies, doses of 200 and 400 mg / kg of MeOH extract were used.

3.2 Evaluation of the effect of MeOH extract on normal defaecation

Oral administration of MeOH 200 and 400 mg / kg showed that there was an inhibition percentage of the number of evacuations of 68 and 87% respectively, during the 4 h evaluation. In the same way the group that was treated with loperamide showed a percentage of 74% inhibition compared to the negative control.

3.3 Effect of the MeOH extract on the diarrhea induced by castor oil in mice

C. urens extract was, used to test its ability to inhibit the diarrhea caused by castor oil after 4 hours. The negative control group, the castor oil administration promoted early on, an increase in the total number of bowel movements and loose stools. The treatment prior to administration oil with MeOH (200 and 400 mg / kg) and loperamide, caused a reduction in the total number of stools, and the final number of diarrheal stools, plus an increase in the first time defecation. It can be observed an improvement in the consistency of fecal material causing a change from solid to aqueous state. These results can be found in Table 1.

3.4 Castor oil Induced enteropooling Assay in Mice

The castor oil administration a dose of 0.2 mL induces an increase in the production and intestinal fluid accumulation in mice, as can be seen by the control group, Figure 1. Treatment with MeOH at doses of 200 and 400mg/kg, was shown to be significantly effective ($p < 0.0001$) inhibition of fluid accumulation induced by the oil, given a value of $(23.4 \pm 1.9$

and 20.8 ± 3.2), respectively, when comparison is made with the control negative that was equal to (30.2 ± 3.9) .

3.5 Evaluation of the small intestinal transit model charcoal meal in mice

The effect of MeOH on intestinal motility induced a change in the rhythm of intestinal transit in mice. In the table 2, we can see that, the negative control group showed a distance traveled by coal in % 79.3 ± 4.7 . The groups treated with loperamide and MeOH (200 and 400 mg / kg) showed an average 19.7 ± 2.3 , 36.3 ± 4.5 and 25.5 ± 4.7 respectively. The groups treated with MeOH and atropine sulfate, produced a significant reduction of motility precentual when measuring the distance traveled by the charcoal in the intestine compared to the negative control. When comparing the average dose was, taken between 200 and 400 mg / kg treated groups MeOH can, not be observed significant effects.

4 DISCUSSION

It affects children more frequently, so diarrhea is a national health and common problem among people with low hygiene standards. The number of causes of morbidity and mortality and diarrhea in all age groups, is higher in developing countries. It is, estimated that 4 million cases of diarrhea occur each year (Sachdeva et al., 2012). Therapies currently used as rehydration has, been indicated with good prognosis in cases of diarrhea Acute. Between both chronic cases are more, serious problems, and can progress to death of the patient.

The disturbing and shocking situation of diarrhea causes, contributes to the search for new drugs, and the plants are targeted at the moment. Despite the wide availability of simple and inexpensive for diarrhea treatments, poor communities and popular still use and rely on herbal remedies, herbal, being extremely contribution the herbal treatments and research the background of its pharmacological action (Heinrich et al., 2005; Smith et al., 2016).

The use of castor oil diarrhea inducer is common and has been reported (Bamisaye et al., 2013). The obtained, oil is accomplished by extraction *Ricinus communis* seeds (Guo et al., 2014). An active metabolite, castor oil constituent is ricinoleic acid. In the intestinal mucosa, ricinoleic acid has an irritant causing inflammation and changes in the permeability of membranes of water and electrolyte (Guo et al., 2014; Bamisaye et al., 2013). Quickly becomes fluid and the aqueous contents of the intestinal lumen, resulting in a hypersecretory response (Guo et al., 2014). These events contribute to the release of substances such as prostaglandin, nitric oxide, platelet-activating factor and cAMP. Luderer et al (1980) found experimentally that mice had a high serum concentration of prostaglandins, after oral administration of castor oil. These substances induce an increase in the motility and secretion of the intestinal fluid, in addition to reducing the reabsorption of sodium and potassium ions. (Guo et al., 2014; Bamisaye et al., 2013). Thus, the induction of diarrhea model castor oil is the motility and secretory diarrhea (Guo et al., 2014).

Some synthetic drugs which act by inhibiting prostaglandin synthesis, are recommended to retard diarrhea induced by castor oil (Bamisaye et al., 2013). A drug sample holding action antagonist to the castor oil is loperamide, used against diarrheal disturbances (Magaji et al.,

2007). It reduces fecal volume, intestinal fluid and the unnecessary excretion of electrolytes (Sarin et al., 2013).

The drug causes almost immediate inhibition peristalsis, by decreasing the circular and longitudinal muscle action in the intestine, besides having antisecretory activity by acting on opipaceos receptors. Atropine is an alkaloid extracted, mainly from the plant *Atropa belladonna*, consists of a powerful muscarinic blocker with action in the central and peripheral nervous system. Being commercially available as atropine sulfate, it is a drug that works by blocking the action of acetylcholine on receptors present on smooth muscles and is therefore an antispasmodic agent (Sarin et al., 2013).

In this way, we can prove that the methanol extract of *C. urens* in the two tested doses, may be, indicated as having antidiarrheal activity since caused decreased frequency of stooling and fecal parameters such as, number of stools, physical condition (dry, or wet pasty), intestinal transit and production of fluid.

Shalaby et al. (2015) demonstrated antidiarrheal activity for the aqueous and ethanolic extracts of *Euphorbia helioscopia* (250 mg / kg and 500 mg / kg, respectively) belonging to the Euphorbiaceae family. Its finding was, based on tests of diarrhea induced by castor oil and charcoal meal, observing a significant decrease in the number of feces and reducing intestinal transit. Antidiarrheal activity induced by oil, was also, achieved when ethanol extract of *Cronton grewioides* (Euphorbiaceae) induced a significant reduction in frequency of stool and the number of liquid stools. The same extract was, tested for its action on the intestinal transit and intestinal fluid accumulation (Silva et al., 2016).

Other authors also reported several other species of Euphorbiaceae with antidiarrheal activity. As is the case of methanol extract of the bark of the stem of *Jatropha curcas* (100 and 300 mg / kg) that has been, shown effective in the treatment of diarrhea (Sacheva et al., 2012). To test for efficacy of another species activity, aqueous extract of the stem bark of *Sapium ellipticum* was used and during the tests, it was observed that animals treated had reduced start time of the first stool, decreased frequency of defecation and intestinal transit, suggesting strong antidiarrheal action (Wansi et al., 2014).

Preparation of aqueous and methanolic extract of *Sebastiania chamaelea* leaves, administered at a dose of 100 and 200 mg / kg were, used to establish the antidiarrheal activity of this species. A significant antidiarrheal activity has, been demonstrated up to 90% for this kind of treatment. Yasodamma et al (2013) suggest that activity may be related to the present tannins and cinnamic acid in the extracts causing astringently and anti-inflammatory action resulting in an effective antidiarrheal action.

Authors suggest that the antidiarrheal activity of Euphorbiaceae family species can this related to the anti-inflammatory capacity and the anti-inflammatory activity, which has also, been proven for other species of this family, such as *Cnidoscolus quercifolius* (Gomes et al., 2014). Ethanolic extracts of bark and leaves of *C. quercifolius* (100, 200 and 400 mg / kg, ip) was used to test the antinociceptive activity, and the end of the experiments was supported popular use of this plant for the treatment of inflammatory pain. Magaji et al. (2007) also portrays the anti-inflammatory activity of extracts from leaves, bark and root *Securinega virosa*

(Euphorbiaceae) exhibited anti-inflammatory action in paw edema induced by carrageenan and writhing induced by acetic acid.

The biosynthesis of prostaglandins has been involved in inflammatory processes. Many plants are, related to inhibitory effect of these substances production, especially those that produce flavonoids as its secondary metabolite. It has been, well described in the literature that flavonoids may alter biosynthesis of cyclooxygenase and lipoxygenase inhibiting inflammation (Magaji et al., 2007).

The activity demonstrated by our studies with methanolic extract of aerial parts of *C. urens*, can probably be, attributed by the presence of flavonoids and tannins with or without combination with other constituents. The presence of such secondary metabolites in extracts of *C. urens* has, already been proven in studies by Peixoto Sobrinho et al. (2012). In the diarrhea induced model castor oil, we had a decrease in the number of wet stool next to loperamide group. We have also achieved a significant decrease as the decrease the accumulation of fluids and intestinal transit. This scenery can corroborate with the results of other surveys conducted with other species of the Euphorbiaceae family, as demonstrated above. We therefore suggest that the results demonstrated that methanol extract of *C. urens* can inhibit the motility and hypersecretion induced by castor oil.

5 Conclusion

This study thus demonstrates that methanol extract of aerial parts of *C. urens* has significant antidiarrheal activity. This activity is, correlated with its inhibitory effect of

propulsion and intestinal secretion. This study also claims that the dynamic mechanism involved in these findings may be the main inhibitory activity of inducing substances inflammation and hypersecretory activity. Thus, the indication of this herbal medicine for the treatment of diarrhea is justified by the pharmacological properties described herein. Studies about extract mechanism of action should be performed, especially by hardly exist descriptions with antidiarrheal activities for this species.

Conflict of Interests

The authors have not declared an conflict of interest.

Acknowledgments

This work was supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).

REFERENCIAS

- Agra, M. F. et al., 2008. **Medical and Poisonous Diversity of the Flora “Cariri Paraibano”, Brasil.** Journal of Ethnopharmacology, 111: 383- 395.
- Awouters, F. et al., 1978. **Delay of castor oil diarrhoea in rats: a new way to evaluate inhibitors of prostaglandin biosynthesis.** Journal of Pharmacy and Pharmacology, 30: 41–45.
- Bamisaye, F. A. et al., 2013. **Effects of Aqueous Extract of *Phyllanthus muellerianus* Leaves on Castor Oil-induced Diarrhoeal Rats.** J Pharmacol Biomed Anal, 1:2.
- Capasso, R. et al., 2002. **Effect of piperine, the active ingredient of black pepper on intestinal secretion in mice.** Life Sci., 71: 2311–2317.
- Cartaxo, S.L. et al., 2010. **Medicinal plants with bioprospecting potential used in semi-arid northeastern Brazil.** Journal of Ethnopharmacology, 131: 326–342.
- Coelho, M.S. et al., 2012. **Herbivory among habitats on the Neotropical tree *Cnidoscolus quercifolius* Pohl. in a seasonally deciduous forest.** Brazilian Journal Biology, 72: 453-7.
- Eduardo, M.B.P. et al., 2005. **Principais Doenças Emergentes e Reemergentes – Atualização e Perspectivas.** Centro de Vigilância Epidemiológica. Disponível em:<http://ses.sp.bvs.br/lis/resource/28627#.Vp5RyiorLIU>. Acessado em: 19/01/2016.
- Gilani, A.H. et al., 2005. **Presence of antispasmodic, antidiarrheal, antisecretory, Ca²⁺ antagonist and acetylcholinesterase inhibitory steroidal alkaloids in *Sarcococa saligna*.** Planta Med, 71 (2): 1–6.
- Gomes, L. M. A. et al., 2014. **Antinociceptive activity of the ethanolic extract from barks and leaves of *Cnidoscolus quercifolius* (Euphorbiaceae) in mice.** Journal of Young Pharmacists, 6 (2).
- Guo, H. et al., 2014. **Anti-diarrhoeal activity of methanol extract of *Santalum album* L. in mice and gastrointestinal effect on the contraction of isolated jejunum in rats.** Journal of Ethnopharmacology, 154:704–710.
- Heinrich, M., et al., 2005. **Spasmolytic and antidiarrhoeal properties of the Yucatec Mayan medicinal plant *Casimiroa tetrameria*.** Journal of Pharmacy and Pharmacology, 57; 1081–1085.

Izzo, R. S. et al. **Interleukin-8 and Neutrophil Markers in Colonic Mucosa from Patients with Ulcerative Colitis**. American Journal of Gastroenterology, v. 87, n. 10, p1447-1452, 1992.

Joseph, N. et al., 2015. **Effects of the aqueous extract of *Pittosporum mannii* Hook. f. (Pittosporaceae) stem barks on spontaneous and spasmogen-induced contractile activity of isolated rat duodenum**. Journal of Ethnopharmacology, 172: 1-9.

Luderer, J.R. et al., 1980. **Advances in Prostaglandin and Thromboxane Research**. Raven Press, 1633-1638.

Magaji, M. G. et al., 2007. **Preliminary antidiarrhoeal activity of methanolic extracts of *Securinega virosa* (Euphorbiaceae)**. African Journal of Biotechnology, 6(24):2752-2757.

Melo, M.F.F. et al., 1988. **Antidiarrhoeal activity of bisnordi hydrotoxiferine isolated from the root bark of *Strychnos trinerbis* (Vell.) Mart. (Loganiaceae)**. Journal of Pharmacy and Pharmacology, 40: 79–82.

Ministério da Saúde Brasília/ DF, 2004. **Doenças Diarréicas Agudas: Guia de Bolso**. Ed. 3, 1. Disponível em:<http://www.saude.pr.gov.br/modules/conteudo/conteudo.php?conteudo=376>. Acessado em: 19/01/2016.

Ministério da Saúde, 2012a. **Mortalidade Proporcional por Grupos de Causas**. Disponível em:<http://tabnet.datasus.gov.br/cgi/tabcgi.exe?idb2012/c04.def>. Acessado em 15/12/2015.

Ministério da Saúde, 2012b. **Proporção de Óbitos por Doença Diarreica Aguda em Menores de 5 Anos de Idade**. Disponível em:<http://tabnet.datasus.gov.br/cgi/tabcgi.exe?idb2012/c06.def>. Acessado em 15/12/2015.

Palla, A.H., Gilani, A.H., 2015. **Dual effectiveness of Flaxseed in constipation and diarrhea: Possible mechanism**. Journal of Ethnopharmacology, 169: 60–66.

Peixoto Sobrinho, T. J. S. et al., 2012. **Phytochemical Screening and Antibacterial Activity of Four *Cnidoscolus* species (Euphorbiaceae) Against Standard Strains and Clinical Isolates**. J. Med. Plants Res., 6 (21): 3742- 3748.

Pinheiro, E. A. R. et al., 2013. **Effective root depth of the Caatinga biome**. Journal of Arid Environments, 89: 1- 4.

Organisation for Economic Co-operation and Development (OECD), 2004. **Guideline for the Testing of Chemicals: (Part 202)**.

Robert, A. et al., **Enteropooling assay: atest ford diarrhoea produced by prostaglandins**. Prostaglandins, 111: 809–814, 1976.

Sachdeva, k. et al., 2012. **Pharmacological evaluation of *Jatropha curcas* L. extract for Anti-diarrhoeal Activity**. Research in Pharmacy, 2 (2), 01-07.

Sařaga, M. et al., 2015. **Calea zacatechichi dichloromethane extract exhibits antidiarrheal and antinociceptive effects in mouse models mimicking irritable bowel syndrome**. Naunyn-Schmiedeberg's Arch Pharmacology. DOI 10.1007/s00210-015-1142-1.

Santos, C.B. et al., 2014. **Diarrhea incidence and intestinal infections among rotavirus vaccinated infants from a poor area in Brazil: a spatial analysis**. Biomed Central, 14: 399.

Sarin, R. V. et al., 2013. **Anti-diarrhoeal activity of aqueous extract of *Ocimum kilimandscharicum***. Journal of Ethnopharmacology, 148: 223–228.

Shalaby, M. A. et al., 2015. **Phytochemical Screening, Acute Toxicity and Antidiarrheal Activity of *Euphorbia Helioscopia* Plant**. World Journal of Pharmacy and Pharmaceutical Sciences, 5 (2): 1519- 1532.

Silva, A. D. S. et al., 2016. ***Croton grewoides* Baill. (*Euphorbiaceae*) shows antidiarrheal activity in mice**. Phcog Res [serial online], 8: 202-205. Available from: <http://www.phcoqres.com/tex.asp?2016/8/3/202/181465>.

Wansi, S. L. et al., 2014. **Antidiarrheal Activity of Aqueous Extract of the Stem Bark of *Sapium Ellipticum* (*Euphorbiaceae*)**. Tropical Journal of Pharmaceutical Research, 13 (6): 929-935.

World Health Organization, 2009. **Diarrhoeal: Why Children are Still Dying and What Can be Done**.

World Health Organization, 2013. **Diarrhoeal Disease**. Disponível em: <http://www.who.int/mediacentre/factsheets/fs330/en/>. Acessado em 05/01/2016.

Yasodamma, N. et al., 2013. **Antidiarrhoeal Activity of *Sebastiania chamaelea* Muell. Arg**. International Journal of Pharmacy and Pharmaceutical Sciences, 5 (2): 169- 171.

Zanirato, S.H.O., 2010. **Patrimônio Natural do Brasil**. Patrimônio e Cultura Material, 40: 127- 145.

Table 1. Effect of the MeOH (200 and 400 mg/kg) extract of *C. urens* on castor oil induced diarrhea.

Treatment	Dose (mg/Kg)	Total n ^a of stools	N° of dry stools	N° of pasty stools	N° of wet stools
Control	-	11.2 ± 2.7	0.5 ± 0.8	0 ± 0	10.7 ± 2.1
Loperamide	2	5.8 ± 3.3	1.5 ± 1.6	0.8 ± 1.6	3.5 ± 0.8
MeOH	200	7 ± 0.9*	2.3 ± 0.5	1.3 ± 1.0	3.4 ± 1.4*
MeOH	400	7.2 ± 1*	2.6 ± 0.5	1.6 ± 1.4	3 ± 1.5*

*Data are presented as mean ± SD. P values are significantly diferente from control using Tukey post hoc test (n=6). P< 0.0001.




Fig 1: Effect of the MeOH (200 and 400 mg/kg) extract of *C. urens* on enteropooling induced by castor oil in mice. $P < 0.001$ vs. Control.

Table 2. Effect of the MeOH (200 and 400 mg/kg) extract of *C. urens* on small intestinal transit in mice.

Parameters/ dose	Control	Atropine sulphate	MeOH 200 mg/Kg	MeOH 400 mg/Kg
LSI (cm)	50.3 ± 2.3	50.8 ± 1.9	57.7 ± 2.7	57.5 ± 4.3
DC (cm)	39.8 ± 2.3	10 ± 1.1	21.2 ± 6.8	14.5 ± 7.5
Intestinal transit (%)	79.3 ± 4.7	19.7 ± 2.3	36.3 ± 10.6*	25.5 ± 15.8*

*Data are presented as mean ± SD. P values are significantly diferente from control using Tukey pos hoc tes (n= 6). P< 0.001.

CAPÍTULO IV

Manuscrito 3: Potential effect of extracts of *Cnidoscolus urens* on *Sitophilus zeamais*, an insect Prague Biology.



Pâmella G. V. D. de Souza^a, Cibele M. A. Silva^a, Paula F. Mercês^a, Bernardo R. Belmonte^b,
Mônica C. B. Martins^a, Thiago H. Napoleão^b, Nicácio H. Silva^{a*}.

Manuscrito a ser submetido ao periódico Pesticide Biochemistry & Physiology no formato Original Research Article (FI: 2. 388; QUALIS CBII).

Potential effect of extracts of *Cnidoscolus urens* on *Sitophilus zeamais*, an insect Prague.

Pâmella G. V. D. de Souza^a; Cibele M. A. Silva^a, Paula F. Mercês^a, Bernardo R. Melmonte^b,
Mônica C. B. Martins^a, Thiago H. Napoleão^b, Nicácio H. Silva^{a*}.

Laboratório de Produtos Naturais. Departamento de Bioquímica, Centro de Biociências,
Universidade Federal de Pernambuco, Brasil. ^a

Laboratório de Bioquímica de Proteínas. Departamento de Bioquímica, Centro de
Biociências, Universidade Federal de Pernambuco, Brasil. ^b

*Corresponding author

Laboratório de Produtos Naturais. Departamento de Bioquímica, Centro de Biociências,
Universidade Federal de Pernambuco. Avenida Professor Moraes Rego, s/n, B. Cidade
Universitária, CEP 50670-420, Recife- Pernambuco, Brasil. 55 81 21268541, 55 81 21268540
(219), e-mail: nicacio_hsilva@hotmail.com

ABSTRACT

Products obtained from botanical material (extracts, oils and purified compounds) were suggested as an excellent alternative for the control of stored grain pests. The deterioration of these grains by pest insects leads to unpredictable economic losses. Species such as *Sitophilus zeamais* are responsible for crop damage of many foods, grains, rice and wheat. Conventional insecticides present high environmental and human toxicity, as well as causing many cases of resistance. Plants are currently target in the alternative search for new products with insecticidal action. In this study, we demonstrated the effect of crude methanolic extract (MeOHC.*urens*) and fractionated (ether, chloroform, acetone and methanol (MeOHFrac.)). The choice of the use of the types of extracts was based on the extracts that presented the best results. From the aerial parts (leaves, flowers and seeds) of *C. urens*, extracts MeOHC. *urens* and MeOHFrac available from ingestion, which adult insects of *S. zeamais*, divided into 5 groups, were exposed to a diet containing MeOHC. *urens* (0.18, 0.25, 0.5 mg / g) and MeOHFrac (0.25, 0.5 mg / g) showed an induction of 27 to 90% and 33 to 91% in ingestion mortality, respectively. For the same extracts at concentrations of 50 and 100 µg / mL and presented 45 to 75% and 77 to 87% of mortality respectively. The LC50 was also determined, both by ingestion for MeOHC.*urens* and MeOHFrac (LC50 = 0.24 and LC50 = 0.11, respectively), and by contact for the same extracts (LC50 = 0.012 and LC50 = 0.026), respectively. These methodologies also allowed us to evaluate that the extracts induced significant changes in the nutritional indices, leading to a decrease of the biomass, being perceived by the negative values of the relative biomass gain and conversion of ingested foods, in addition to inducing food rejection, inducing a strong deterrence to the food source available during the test. In conclusion, the extract of aerial parts of *C. urens* potential for the control of *S. zeamais*. The deleterious effects of extracts may be associated with the presence of flavonoid and terpenes.

Keywords: *Cnidoscolus urens*; Insecticidal activity; *Sitophilus zeamais*

1 Introduction

The first reported insecticide resistance occurred about a century ago. Soon after, other sporadic cases of insecticide inactivity were reported. In the mid 1940, new management methods were implemented, such as synthetic organic pesticides, for example organophosphates and phosphine, which were then used in biological control. Synthetic compounds were efficient in their insecticidal activity, resulting in large-scale application ^[6].

Consequently the great use of pesticides, resistance cases have rapidly increased again, along with the number of resistant species and new compounds. Over the decades, herbicides and fungicides have also shown reduced efficiency, but resistance to insecticides has increased ^[6]. Attempts to control insect pest attacks, by synthetic compounds, are volatile, toxic to the environment and to the human, contribute to insect resistance and target non-target insects. Cleaning, drying, aeration and temperature control of stored grains are also alternatives to combat, however they still do not seem to be enough ^[4,7].

Populations of agricultural and urban insect pests have demonstrated an evolution in their physiological and behavioral mechanism, becoming increasingly resistant. In view of this condition, the importance of more accurate information before the choice to replace the new control method to be used in plantations, storage places and urban centers ^[8,9,10,11] is important. Many insect species are being reported and causing post-harvest losses ^[12, 13].

The three major grain pests belong to the same genus, *Sitophilus* ^[14]. *S. zeamais*, from brown to reddish color, is described among the three ^[2,15]. It presents preference for cereals such as wheat, rice and corn, which are the most cultivated, consumed and well distributed in the world ^[16, 17]. Adult individuals and larvae feed on intact grains and cause damage such as weight loss and economic value ^[16,18]. Tefera et al. ^[19], found that the damage begins at harvesting, with about 10% of perches and continues to spread during storage, reaching up to 50% ^[4]. *S. zeamais* presents a moderate level of resistance to some synthetic insecticides ^[2]. Meanwhile the increase in the levels of inactivity are expected due to excessive application, in addition to environmental damages ^[8].

Proved by several studies ^[1,8,11], the resistance to existing pesticides is very important and in view of the great losses caused, the development of new control strategies, with greater specificity for the target species, low toxicity to the environment Environment and the farmer, in addition to minimizing waste, are increasingly sought after ^[12,20]. A new way out can be found in our biodiversity.

Pest control is a worldwide practice ^[1]. Public Health and Agroindustry organs have been faced with major concerns regarding care and protection with food grown and stored ^[2,3]. Among the foods most attacked by pests are wheat, rice, barley ^[4], corn and even industrialized foods such the pasta ^[2]. According to Lira et al. ^[4], the damages caused by insect pests are devastating, leading to economic and environmental damages. These damages account for about 30% - 60% of total production ^[5], contributing to the loss of billions of dollars ^[2]. However, the pest perch occurs from agricultural products and non-renewable source products ^[2].

Biodiversity and its chemical compounds have been explored for their biological performance. Extracts and purified plant compounds are the main focus of these studies. These products are being reported with high insecticidal potential for many different species of these organisms including species that have created resistance to existing insecticides ^[21,22].

Some plant species have already been indicated with insecticidal properties, *Jatropha curcas*, *Ricinus communis* ^[1], *Tithymaloides pedilanthus*, *Phyllanthus amarus*, *Euphobia hirta* and *Euphorbia tirucalli* ^[23]. These species, which are part of the Euphorbiaceae family, have been tested against insects such as *Anopheles stephensi*, *Aedes aegypti* L. and *Culex quinquefasciatus* ^[1,23], however, the number of studies proving their insecticidal activity on Euphorbiaceae species is still few when tested against *S. zeamais*. This evidence is even smaller, when we speak of some species of the family Euphobiaceae, as is the case *Cnidoscolus urens*.

C. urens is a weed species, which has a wide distribution throughout the Brazilian territory, mainly in the Caatinga area ^[24,25]. Popularly, this species is used for the treatment of hemorrhage, cancer and inflammation ^[26,27,28]. Among the rare studies, antibacterial actions ^[29] and fibrinolytic could be attributed to the use of derivatives of this species ^[26].

In this study, we report for the first time, the biocidal properties of different extracts of aerial parts of *C. urens*, evaluating its insecticidal action with *S. zeamais*. In addition to suggesting a new low cost and sustainable botanical insecticide ^[30].

2 Materials and Methods

2.1 Plant material

The collection of *C. urens* samples was carried out in the city of Agrestina, located approximately 136 km from the capital of the state of Pernambuco, in northeastern Brazil (Lat 8 ° 23'04 .08 ", Long 35 ° 58'49 .7" W). The sample period was collected in January 2014. A small part of the collected botanical material, containing root, leaves, flowers and fruit, was prepared for identification and sent to the Herbarium of the Instituto Agronômico de Pernambuco (IPA). The species collected and used for biological testing was deposited and identified by the number 84.190. The aerial parts (leaves, flowers and seeds) of *C. urens* were, dried at room temperature (27 to 28 ° C) and used to prepare extracts.

2.2 Preparation of Methanolic Extract

Methanolic extract: Initially, the collected botanical material was sanitized and separated 100 g of aerial parts of *C. urens*. Then, the material already selected was adjusted for drying in the oven at room temperature (27 to 28 ° C) and controlled in a drying oven for botanical material. After drying, the plant material was triturated and placed in a erlenmeyer, 100mL of methanol was added and left overnight, then filtered with Whatman paper (No. 1). This process was repeated several times until complete exhaustion. The methanolic extract of *C. urens* (MeOHC.urens) was concentrated by rotary evaporator pressure Buchler Instruments, Fort Lee, NJ, USA, resulting in the corresponding crude organic extract (Figure 1) ^[31].

2.2.1 Fractionation of the methanolic extract

Aerial parts (100 g) of *C. urens* dried and crushed were used to obtain fractionated extracts. Initially 100 mL of ether was added to the plant material and kept under stirring for 1h, then left under refrigeration for 24h. After 24 h the solvent was filtered and the same volume of ether added again. This procedure was repeated 3 times with each solvent (ether, chloroform, acetone and methanol) using the same plant material (Figure 1). This method of extraction allowed the probable separation of the major secondary metabolites resulting in a total of 4 different types of extracts.




Figure 1: Diagram of production of raw extracts and partitioning of *C. urens*.

2.3 Ethical considerations

All experimental procedure used for the construction of this study were submitted for evaluation and approval by the Animal Experiment Ethics Committee of the Universidade Federal de Pernambuco, from the Center for Biological Sciences (CEEa-UFPE). Under protocol approval 23076.012693/2016-71.

2.4 Insects

Adult insects of *S. zeamais*, taxonomically identified by specialists from the Department of Biology of the Federal University of Pernambuco (UFPE), were obtained from colonies kept in the Department of Mycology of UFPE, located in the city of Recife, Brazil. The insects were kept in breeding grounds at the Natural Products Laboratory, Department of Biochemistry, also from the same university. The creation of the insects was granted permission, N°. 36301-2, from the Chico Mendes Institute for Biodiversity Conservation (ICMBio) of the Ministry of Environment.

The insects purchased were placed in a glass container (1L), sealed with nonwoven (TNT) fabric, allowing the aeration at a relative humidity of 70%, in addition to photoperiod of 12: 12 light: dark and temperature 28 ± 2 ° C. The individuals of *S. zeamais* were submitted to a diet of corn grains, selected under conditions of health, sanitary and absence of contamination. The insects used for the tests were approximately 30-50 days old.

2.5 Bioanalysis of toxicity by ingestion of extracts of *C. urens*

The toxicity level of the different types of extracts of *C. urens* was determined following the methodology of Xie ^[32], with adaptations described by Napoleão ^[2], that was used to determine the insecticidal activity of *C. urens* extracts. For each test, a suspension of 2 mg of properly-prepared wheat flour (Dona Benta, Bunge Alimentos S.A., Benevides, PA, Brazil) was used, homogenized with a solution of 5 mL of the 5 extracts (MeOHC. *urens*, ether, chloroform, acetone and MeOHFrac), in the concentrations 0.18, 0.25, 0.5 mg / g with sterile distilled water. Five aliquots (200 µL) of the obtained solutions were distributed in Petri dishes (90 mm x 100 mm, of known weight) with the help of micropipette coupled to a disposable and cut tip (2mm internal diameter). Subsequently, placed in a greenhouse overnight, at 37 ° C to dry. Thereafter, each plate was reweighed and the weight of the dough was determined by the difference of the empty plate between the plate and the flour disc. Twenty individuals of *S. zeamais* (n= 20), of known weight, were placed on each plate. Finally, each test was performed in quadruplicate and the tested concentrations of samples on disc at the following final concentrations [0.18, 0.25, 0.5 mg/g] (mg of each extract/g of wheat flour). For comparison, another group of the same *S. zeamais* number was maintained in petri dish containing only the flour solution diluted in sterile water.

All groups were maintained at 28± 2 ° C in the dark for 15 days. At the end of this period, can determine the mortality rate and weights of flour discs.

2.6 Determination of feeding-deterrence index and nutrition

The determination of feeding-deterrence (FDI) was achieved by applying the following formula: $FDI (\%) = 100 \times (A-B) / (A)$. Where A is the feed mass ingested by the control test insects and B is equal to the feed mass ingested by the groups of insects exposed to the different extracts ^[33]. The difference between the weight of the plate containing the flour discs (0 days) and the empty plate (15 days), was used to determine the FDI. In agreement with the IDE, the samples were classified: Strong feeding deterrence ($FDI \geq 70\%$), moderate feeding deterrence ($70\% > FDI \geq 50\%$), weak feeding deterrence ($50\% > FDI \geq 20\%$) or feeding deterrence ($FDI < 20\%$) ^[34]. The data found by the assay described in the above table can be used to determine the relative consumption rate (RCR) by the formula: $RCR = C / (D \times \text{Days})$, where C, the ingested feed mass (mg) and D corresponding to the initial biomass of the insects (mg). The ratio of the biomass gain rate (RBGR) = $E / (D \times \text{Days})$, where E is equal to the biomass obtained (mg). Regarding the efficacy of food intake concersion (ECIF) = $E / (C \times 100)$.

The concentrations applied in this study and varied from 0.18 to 0.5 mg /g were determined according to the LC_{50} values were cauculated using StatPlus. These concentrations were, applied to the tests for the determination of ingestion toxicity against *S. zeamais*, being able to vary between the types of extracts.

2.7 Evaluation of contact toxicity of *C. urens* extracts

To determine the toxicity potential of *C. urens* extracts on populations of *S. zeamis*, the assay was performed according to Liu and Ho ^[35]. The extracts MeOHC. *urens* and MeOHFrac

(50 and 100 $\mu\text{g} / \text{mL}$) were solubilized in distilled water. From the aliquot removal solutions (0.5mL), was applied with a micropipette, on the dorsal surface of the insects thorax. For this test, 5 groups (n= 20) each were created and each experiment was repeated in quadruplicate. The group classified as control only distilled water. The other groups make up the tested groups. Mortality of insects was observed daily until end-point, when the number of dead insects did not increase over time.

The ability to induce toxicity of extracts from aerial parts of *C. urens* was evaluated by 5 different extracts: crude methanol (MeOHC.urens), and the fractions: ether, chloroform, acetone and methanol (MeOHFrac) as described in item 2.2. 1. Initially pilot tests were performed, which helped to select the extract with better efficiency with the tested insects. From the pilot test, two extracts, MeOHC.urens and MeOHFrac, which showed a significant insecticidal effect when compared to the control were selected, the other extracts practically did not exert effective mortality. Regarding to the choice of concentrations to be tested, they were determined according to the lethal dose (LC_{50}).

2.8 Statistical analysis

GraphPad Prism version 5.1 for Windows (GraphPad Software, San Diego, California, USA) was used to express a mean of replicates $\pm$ SD. Significant differences between the test treatment groups were developed by the Tukey's test for multiple comparisons (significance $p < 0.05$) using PRISMA software (GraphPad Software, Inc., San Diego, CA, version 5.01). For determination of lethal concentration to kill 50% of insects (LC_{50}) Probit was used with a 95% confidence interval with StatPlus $\text{\textcircled{R}}$ 2008 computer software (AnalystSoft, Canada) ^[36].

3 Results

3.1 Determination of mortality by ingestion of *S. zeamais* from extracts of *C. urens*

Thus, it was possible to identify that MeOHC.*urens* extracts at all concentrations (0.18, 0.25; 0.5 mg/ g) and MeOHFrac (0.25; 0.5 mg/ g) had a significant effect ($p < 0.05$) on the percentage of ingestion mortality when compared to the control (Figure 2), during the ingestion toxicity bioassay. As for the percentage of mortality, MeOHC.*urens* induced a percentage of 27, 73 and 90% death at concentrations (0.18; 0.25; 0.5 mg / g), whereas MeOHFrac induced 33 and 92% mortality at concentrations (0.25; 0.5mg / g).




Figure 2: Percentage of mortality by ingestion of *S. zeamais* exposed to different concentrations of MeOHC.*ures* and MeOHFrac of *C. urens*. * $P < 0.05$ for all groups compared to control.

3.2 Determination of the effects of extracts of *Cnidoscolus urens* on nutritional indexes

The nutritional results obtained through the ingestion methodology, including the application of both extracts of *C. urens* in the diet available for *S. zeamais*, interfered in the nutritional development of the insects distributed in the test groups, significantly affecting nutritional indices (Figure 3). The relative mean biomass gain (Figure 3A) and the average feed conversion efficiency (Figure 3B) were remarkably affected, approaching zero or becoming negative, according to the increase in the concentration of the extracts tested. These findings reveal that insects were unable to ingest and / or digest the available food and still used their nutritional reserves to generate energy. The biomass gain is relevant when we compare the lowest and highest concentration of MeOHC.*urens*.

Meanwhile, with respect to feed intake conversion efficiency (ECI), only MeOHFrac (0.25 mg / g) was not significant when compared to the control. In addition, the relative consumption rate (RCR) was also affected, observing a significant and significant reduction in insect food consumption (Figure 3C) in all groups that received both extracts and in all concentrations when compared to the group control ($p < 0.05$).




Figure 3: Evaluation of the anti-feeding action of *S. zeamais* grown in artificial diets (0.18 - 0.5 mg / g of wheat flour). (A) Rate relative to biomass gain (RBGR) indicates a biomass (mg) gained every day per mg of initial body weight. (B) The percentage of conversion of ingested food (ECI%) indicates the amount of food consumed and converted to insect mass. (C) A relative consumption rate (RCR) indicates an amount of food consumed by *S. zeamais* (mg) per mg of body weight per day. Each column corresponds to the mean $\pm$ SD of five replicates. The different letters are indicative of the significant differences ($p < 0.05$) between the treatments by the Tukey's test.

3.3 Feeding-deterrent index (FDI)

As regards the feeding-deterrent effect, representing the capacity of repulsion to the food, it was observed that the MeOHC.*urens* and MeOHFrac (0.5mg / g) had an FDI of 72 and 78% respectively, having a strong action effect, according to the Classification of Liu ^[34]. As the concentration is decreased observed a weak action, corresponding to 21 and 38% (Table 1).

As the concentration increases MeOHC.*urens* (0.18- 0.5 mg / g) showed a strong effect on the percentage of FDI increasing from 21 to 72% (Table 1). Similar behavior can be identified in the groups receiving food impregnated with MeOHFrac. A 38% feeding-deterrent percentage was found for the concentration of 0.25mg / g, becoming strong, 78%, when there was an increase in concentration (0.5mg / g). For this, the MeOHFrac shows a slightly better effect, but with no significant difference between the two extracts.

Table 1: Effect the feed-deterrence index of extracts of *C. urens* against *S. zeamais*.

Group	Concentration (mg/g)	% FDI (Mean±SD)	Classificação (Segundo Liu et al. ^[43])
MeOHC. <i>urens</i>	0.18	21 ± 0.003	FDI- Fraca
	0.25	78 ± 0.002	FDI- Forte
	0.5	72 ± 0.004	FDI- Forte
MeOHFrac	0.25	38 ± 0.008	FDI- Fraca
	0.5	78 ± 0.002	FDI- Forte

The data here are expressed, represented by mean ± SD.

3.4 Ingestion toxicity assessment of extracts of *C. urens*

MeOHC.*urens* has promoted mortality of 50% of the insect population with an LC₅₀ of 0.236 ± 0.01 mg / g, while MeOHFrac presented an LC₅₀ of 0.114 ± 0.03 mg / g (Table 2).

Table 2: Determination of the lethal dose (LC₅₀) of extracts of *C. urens*, capable of inducing mortality in 50% of the population of *S. zeamais* by ingestion.

Group	LC ₅₀ (mg)	95% Confidence limits	
		LCL	ULC
MeOHC. <i>urens</i>	0.236 ± 0.01	0.209	0.263
MeOHFrac	0.112 ± 0.03	0.061	0.167

LC₅₀ values were caculated using StatPlus. The 95% confidence limits between the paragraphs were based on five replicates (P<0.05). LCL: Lower confidence limit. UCL: Upper confidence limit.

3.5 Determination of mortality of *S. zeamais* by contact of *C. urens* extracts

The toxic potential of MeOHC.*urens* and MeOHFrac was significantly (p <0.05). Meanwhile of all concentrations and types of extracts tested, only MeOHC.*urens* (50µg / insect) did not present a significant percentage (45%) when compared to the control (38%). MeOHC.*urens* (100µg / insect) presented an average of 75% (Figure 4), being significantly different from the control.

Better results were observed when the insects were submitted to MeOHFrac contact (50; 100µg / insect) with averages of 77 and 78% (Figure 4) of mortality, respectively, and were therefore significant when compared to the control.




Figure 4: Percentage of mortality by contact of *S. zeamais* exposed to different concentrations of extracts of MeOHC.urens and MeOHFrac of *C. urens*. * $P < 0.05$ for all groups compared to control.

3.6 Assessment of contact toxicity of extracts *Cnidoscolus urens*

The contact toxicity of MeOHC.urens induced a mortality of 50% of the *S. zeamais* population with an LC_{50} of $0.012 \pm 0.05 \mu\text{g} / \text{insect}$. MeOHFrac, however, showed an LC_{50} of $0.026 \pm 0.001 \mu\text{g} / \text{insect}$ (Table 3).

Table 3: Determination of the lethal dose (LC_{50}) of extracts of *C. urens*, capable of inducing mortality in 50% of the population of *S. zeamais* by contact.

Group	LC_{50} ($\mu\text{g} / \text{inseto}$)	95% Confidence limits	
		LCL	UCL
MeOHC. urens	0.012 ± 0.05	0.109	-0.086
MeOHFrac	0.026 ± 0.01	0.009	0.042

LC_{50} values were calculated using StatPlus. The 95% confidence limits between the paragraphs were based on five replicates ($P < 0.05$). LCL: Lower confidence limit. UCL: Upper confidence limit.

4 Discussion

With a territorial extension and extensive biodiversity, the Caatinga is a biome still little explored, but it has a huge potential to be an inexhaustible source of bioactive. Currently, many studies, based on the use of extracts, oils and even purified compounds, suggest that plant products from this biome present bioinsecticidal action ^[30,37]. However, there are few studies that portray the potential of the Caatinga plants as protectors of stored grains, their potential to influence nutritional indices and deterrent capacity, and that few existing studies only determine the potential of mortality ^[38, 39].

The use of plant extract to control insect-pest infestation is an old practice ^[40]. Published studies show a growing interest in the alternative search for the use of synthetic products ^[41]. In the present study, the insecticidal activity at different concentrations and different types of extracts of *C. urens* were tested in order to investigate their ability to act on contact and ingestion toxicity, as well as to analyze their potential to infer the nutrient indices of *S. zeamias*.

As described in the methodology of ether, chloroform and acetone extracts from aerial parts of *C. urens* that showed no insecticidal action at any concentration tested, nor did they interfere with nutritional indices. Different results were obtained on the action of MeOHC. *urens* extracts and MeOHFrac, which showed influence on biomass gain, consumption rate, feed conversion efficiency and even on mortality. This difference can be related to the different compounds extracted by using solvents with polarity difference, indicating that bioactive with insecticide action, were extracted by using methanol or if they remained in the last fraction,

these different extract may still contain the same compounds, but may differ in relation to their concentration ^[42].

Meanwhile, the extracts MeOHC. *urens* and MeOHFrac demonstrated a great insecticidal effect when compared to the control. Numa et al.; Candido et al.; LEE et al. ^[43,44,45] in their research have indicated the insecticidal potential of some species of the Euphobiaceae family, including *Sebastiana corniculata* and *Cnidoscolus acontifolius* and *Cnidoscolus phyllacanthus*, which are of the same genus of *C. urens*, for different species of insects, *Tetranychus urticae*, *Aedes aegypti* and *Nilaparvata lugens*, *Sogatella furcifera*, *Laodelphax striatellus*. However, this study seems to be a pioneer in presenting the bioside effect of *C. urens*. Both extracts exerted effects on the nutritional parameters in *S. zeamais* population. In addition to proving to be a potent deterrent agent. According to the data found in this study we can suggest that the insecticidal action may be related to an effect linked to the pre-ingestion of the flour treated with the extracts. Sievers, in 1949 ^[46], had already reported some plants in tropical areas with action to combat insects.

Combating *S. zeamais*, one of the insects with destructive capacity, by consuming the stored grains at high speed ^[4,14,47,48], may have as an alternative the use of MeOHC. *urens* and MeOHFrac. For demonstrating anti-nutritional effects, its anti-nutritional effects affected the assimilation of food as a result of rejection of available food. Similar results to those found in these studies were reported by Taghizadeh, the use of aqueous and hydroalcoholic extracts from aerial parts of *Alhagi maurorum*, to demonstrate their anti-nutritional potential against *Tribolium castaneum*. Applying the same methodology (the flour disk bioassay) that we used

the author found a significant decrease in RGR, RCR and ECI, in addition to the increase in FDI, results were improved as concentrations were increased, as were our ^[49].

In previous studies, a Phytochemical analysis of extract *Cnidoscolus sp* was performed. Among the analyzed species was *C. urens*. In extracts of aerial parts identified a low presence of anthraquinones and xanthine derivatives, in moderate concentration which were triterpenes and steroids, but among the groups of major compounds: anthocyanins, flavonoids, tannins, mono and diterpenes ^[29]. Upasani et al. reported the isolation of flavonoids from aqueous leaf extract of *Ricinus communis* L. (Euphorbeaceae) and it exerted insecticidal action against *Callosbruchus chinensis* ^[50]. These results help us to suggest that extracts of *C. urens*, due to their expressive flavonoid content, their insecticidal activity may be related to the great presence of these compounds. Another recent study shows the repelling action of hydroethanolic extracts of leaves of *R. communis*, which has been tested and proven its repellent action against *Scyphophorus acupunctatus*, also known as weevil ^[51].

Some species of the Euphorbiaceae family, are already used in the fields with the objective of inhibiting the infestations by pests. On these aspects, it was demonstrated that a mixture of the *R. communis* plant with the beans repelled the weevil ^[52]. Another study evaluated the potential of inducing mortality of larvae and adults of *Tribolium castaneum* from *R. communis* seed extracts, concluding that mortality increases as a consequence of concentration and time of exposure ^[53]. Mortality of eggs and larvae of *S. zeamais* was attributed to potent action of *C. quercifolius* extracts ^[38].

An important aspect for the effectiveness of the insecticidal action of any plant material is its lower lethal dose ^[54]. In this same concept, we can prove that through the numbers obtained by this study, extracts of *C. urens*, are excellent when the subject is mortality, because the MeOHC. *urens* and MeOHFrac. They showed high mortality with low concentrations, 75% and 87% of contact mortality, and 90% and 91% mortality from ingestion. Promising results were shown for *Jatropha curcas*, where the petroleum ether extract acted as an antifeedent agent, with an LC₅₀ of 6.82 µl / g for a species of *Sitophilus* sp ^[55]. A 100% mortality was reached by root methanol extract and 70% for the ethereal extract of the *J. curcas* leaf, according to Verma et al. ^[56]. Silva et al. also showed the bioactivity of powders and aqueous extract of seeds and pericarp of *J. curcas*. The mortality of *S. zeamais* in this study was attributed the presence of toxic compounds such as esters ^[57], which are commonly found in species of the family Euphorbiaceae ^[58].

Many studies have shown that many extracts and plant oils may have a representative percentage of mortality against insects ^[59,60,61], especially against *S. zeamais* ^[2,4,38,57,62]. Some of the tested plants were part of more than ten different families, among them Anonaceae and Euphorbiaceae, which the species *Anona muricata* and *J. curcas* had a percentage of mortality of 100%, while the other species evaluated had a mortality less than 50%. The results could still be different if we compare with different extracts obtained from different parts of the same plant and if the concentrations are increased ^[63]. These data corroborate with those found in the present study, where we observed an increase in mortality when the concentration was increased. However, we found no significant difference between MeOHC.*urens* and MeOHFrac when applied by contact, the significant difference was evidenced when the same extracts were ingested at a concentration of 0.25 mg / g. The presence of diterpenes has been described for

the oil of *J. curcas* ^[64], and the insecticidal property of the products extracted from botanical material can also be bound by the presence of diterpenes ^[65].

5 Conclusion

The use as insecticidal agents and application of botanical materials in rural areas, aiming at the protection of stored grains which is a traditional method in these areas. Many farmers use bioavailable resources, especially in areas where commercial resources are difficult to access, such as in the Caatinga area. These farmers have low incomes and need to surrender their production soon after harvest to avoid possible infestations by pest insects.

In conclusion we can suggest that the extracts of aerial parts of *C. urens* have the potential to be used in the control of *S. zeamais* because it has been toxic to adult insects when exposed through contact or through ingestion, besides having exerted anti-nutritional effect. MeOHC.*urens* and MeOHFrac may be an alternative, without the need to isolate secondary metabolites, but the insecticidal effect may possibly be associated with the presence of flavonoid and terpene fractions, which have been described for this action. Further research should be conducted to increase the efficiency of these extracts.

The results reported here are initial findings and for use of *C. urens* extracts in agriculture as an insecticide, further studies including testing with other insect species are needed.

Acknowledgments

This work was supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).

References

- [1] N. Chauhan, P. Kumar, S. Mishra, S. Verma, A. Malik, S. Sharma. Insecticidal activity of *Jatropha curcas* extracts against housefly, *Musca domestica*. *Environ Sci Pollut Res.* 22 (2015)14793–14800.
- [2] T. H. Napoleão, B. R. Belmonte, E. V. Pontual, L. P. Albuquerque, R. A. Sá, L. M. Paiva, L. C. B. B. Coelho, P. M. G. Paiva. Deleterius effects of *Myracrodruon urundeuva* leaf extract and lectin on the maize weevil, *Sitophilus zeamais* (Coleoptera, Curculionidae). *Journal of Products Research.* 54 (2013) 26-33.
- [3] UNEP/FAO (2000) Global IPM facility expert group on termite biology and management. Finding alternatives to persistente organic pollutants (POPs) for termite management.<http://www.unep.org/chemicalsandwaste/Portals/9/Pesticides/Alternatives-termite-fulldocument.pdf>. (acessado em 05.01.2017).
- [4] C. S. Lira, E. V. Pontual, L. P. Albuquerque, L. M. Paiva, P. M. G. Paiva, J. V. Oliveira, T. H. Napoleão, D. M. A. F. Navarro. Evaluation of the toxicity of essential oil from *Alpinia purpurata* inflorescences to *Sitophilus zeamais* (maize weevil). *Crop Protection* 71 (2015) 95-100.
- [5] E. F. Mutsamba, I. Nyagumbo, P. Mafongoya. Termite prevalence and crop lodging under conservation agriculture in sub-humid Zimbabwe. *Crop Protection* 82 (2016) 60- 64.
- [6] T. C. Faísca, R. Nauen. IRAC: Mode on action classification and insecticide resistance management. *Pesticide Biochemistry and Physiology.* 121 (2015) 122- 128.
- [7] M. O. Carvalho, I. Pires, A. Barbosa, G. Barros, J. Riudavets, A.C. Garcia, C. Brites, S. Navarro. The use of modified atmospheres to control *Sitophilus zeamais* and *Sitophilus oryzae* on stored rice in Portugal. *J. Stored Prod. Res.* 50 (2012) 49-56.
- [8] L.S. Braga, A.S. Corrêa, E.J.G. Pereira, R.N.C. Guedes. Face or flee Fenitrothion resistance and behavioral response in populations of the maize weevil, *Sitophilus zeamais*. *J. Stored Prod. Res.* 47 (2011) 161–167.
- [9] M.A.G. Pimentel, L.R.A. Faroni, A.S. Corrêa, R.N.C. Guedes. Phosphine-induced walking response of the lesser grain borer (*Rhyzopertha dominica*). *Pest Manag. Sci.* 68 (2012) 1368–1373.
- [10] K. Haddi, L.P. Mendonça, M.F. Santos, R.N.C. Guedes, E.E. Oliveira. Metabolic and behavioral mechanisms of indoxacarb resistance in the maize weevil *Sitophilus zeamais*, *J. Econ. Entomol.* 108 (2015) 362–369.
- [11] Y. D. C. G. Correa, L. R.A. Faroni, K. Haddi, E. E. Oliveira, E. J. G. Pereira. Locomotory and physiological responses induced by clove and cinnamon essential oils in the maize weevil *Sitophilus zeamais*. *Pesticide Biochemistry and Physiology* 125 (2015) 31–37.
- [12] E. H. G. Diouf¹, M. Diop¹, A. Sène¹, A. Samb. Phytochemical screening and insecticidal activity of three extracts of *Tapinanthus bangwensis* (Engl. & Krause) on *Sitophilus zeamais* (Maize Weevil). *Agricultural Science.* 3 (2016) 1-10.
- [13] T. C. Sparks, G. B. Watson, M. R. Loso, C. Geng, J. M. Babcock, J. D. Thomas. Sulfoxaflor and the sulfoximine insecticides: Chemistry, mode of action and basis for efficacy on resistant insects. *Pesticide Biochemistry and Physiology.* 107 (2013) DOI: 10.1016/j.pestbp.2013.05.014.
- [14] C. Norambuena, G. Silva, A. Urbina, I. Figueroa, J. C. R. Maciel. Insecticidal activity of *Laureliopsis philippiana* (Looser) Schodde (Atherospermataceae) essential oil against *Sitophilus* spp. (Coleoptera Curculionidae). *ChileanJar.* 76 (2016) 330- 336. doi:10.4067/S0718-58392016000300010.

- [15] A.S. Corrêa, L. Orlando de Oliveira, L.S. Braga, R.N.C. Guedes, Distribution of the related weevil species *Sitophilus oryzae* and *S. zeamais* in Brazil, *Insect Sci.* 20 (2013) 763–770.
- [16] C. E. Akunne, G. N. Chima, B. U. Ononye, K. P. Okafor. Comparative Efficacy of *Cymbopogon citratus* and *Psidium guajava* Powders as Poison against *Sitophilus zeamais* (Motschulsky) in Stored Maize Grains. *Science Journal of Bioscience and Bioengineering.* 2 (2015) 41-44.
- [17] F. C. Gómez, M. B. Ramírez, E. F. Gaona. Efecto insecticida del polvo de *Chenopodium ambrosioides* L. y carbonato de calcio en el control de *Sitophilus zeamais* en granos de maíz. *Investig. Agrar.* 18 (2016) 116-120.
- [18] C. Zhang, Z. Ma, X. Zhang, H. Wu. Transcriptomic alterations in *Sitophilus zeamais* in response to allyl isothiocyanate fumigation. *Pesticide Biochemistry and Physiology.* Article in press. (2016). <http://dx.doi.org/10.1016/j.pestbp.2016.10.001>.
- [19] T. Tefera, S. Mugo, P. Likhayo. Effects of insect population density and storage time on grain damage weight loss in maize due to the maize weevil *Sitophilus zeamais* and the larger grain borer *Prostephanus truncatus*. *African Journal of Agricultural Research* 6 (2011) 2249-2254.
- [20] C. Zhang, H. Wu, Y. Zhao, Z. Ma, X. Zhang. Comparative studies on mitochondrial electron transport chain complexes of *Sitophilus zeamais* treated with allyl isothiocyanate and calcium phosphide. *Pesticide Biochemistry and Physiology.* 126 (2016) 70- 75.
- [21] A. Termentzi, V. Ahluwalia, N. Tsafantakis, P. Milonas, A. Michaelakis, D. Papachristos, H. Karasali, N. Aligiannis, N. Fokialakis, A. L. Skaltsounis. Insecticidal plant extracts from the Greek biodiversity: Biological activity and phytochemical characterization. *Planta Med.* 81 (2015) 128. DOI: 10.1055/s-0035-1565505.
- [22] S. L. C. Silva, M. G. Carvalho, S. A. Gualberto, D. S. C. Torres, K. C. F. Vasconcelos, N. F. Oliveira. Bioactivity of ethanolic stem extract of *Croton linearifolius* Mull. Arg. (Euphorbiaceae) on *Cochliomyia macellaria* (Diptera: Calliphoridae). *Acta Veterinaria Brasilica.* 4 (2010) 252-258.
- [23] A. A. Rahuman, G. Gopalakrishnan, P. Venkatesan, K. Geetha. Atividade larvica de alguma planta Euphorbiaceae extraí contra o *Aedes aegypti* e *Culex quinquefasciatus* (Diptera: Culicidae). *Parasitol. Res.* 102 (2008) 867- 873. doi: 10.1007/s00436-007-0839-6.
- [24] U. P. J. Albuquerque. Re-examining hypotheses concerning the use and knowledge of medicinal plants: A study in the Caatinga vegetation of NE Brazil. *Ethnobiol. Ethnomed.* 2 (2006) 1–10.
- [25] U. P. Albuquerque, J. M. Monteiro, M. A. Ramos, E. L. C. Amorim. Medicinal and magic plants from a public market in northeastern Brazil. *J. Ethnopharmacol.* 110 (2007) 76–91.
- [26] Y. A. S. Menezes, J. F. Silva, A. A. Silva-Júnior, I. M. M. Rebecchi, A. S. Oliveira, A. F. Uchoa, M. F. F. Pedrosa. Protein-Rich Fraction of *Cnidoscolus urens* (L.) Arthur Leaves: Enzymatic Characterization and Procoagulant and Fibrinogenolytic Activities. *Molecules.* 19 (2014) 3552-3569; doi:10.3390/molecules19033552.
- [27] J.G. Melo, A. G. Santos, E. L. C. Amorim, S. C. Nascimento, U. P. Albuquerque. Medicinal plants used as antitumor agents in Brazil: An ethnobotanical approach. *Evid. Based Compl. Alt. Med.* (2011), 1–14.
- [28] M. F. Agra, K. N. Silva, I.J.L.D. Basílio, P. F. Freitas, J. M. Barbosa-Filho. Survey of medicinal plants used in the region Northeast of Brazil. *Rev. Bras. Farmacogn.* 18 (2008) 472–508.
- [29] T. J. S. Peixoto Sobrinho, V. T. N. A. Castro, A. M. Saraiva, D. M. Almeida, E. A. Tavares, M. N. C. Pisciotano, E. L. C. Amorim. Phytochemical screening and antibacterial activity

- of four *Cnidoscolus* species (Euphorbiaceae) against standard strains and clinical isolates. *J. Med. Plants Res.* 6 (2012) 3742-3748. DOI: 10.5897/JMPR11.1533.
- [30] B. A. Melo, A. J. M. Rugama, K. Haddi, D. T. Leite, E. E. Oliveira. Repellency and bioactivity of Caatinga biome plant powders against *Callosobruchus maculatus* (Coleoptera: Chrysomelidae: Bruchinae). *BioOne*. 98 (2015) 417- 423.
- [31] J. A. C. Alejo, J. M. T. Suárez, S. M. Catzín, N. M. Mendoza, L. M. Baizabal, P. S. Polanco, S. R. P. Sánchez, M. M. G. Angulo. In vitro sensitivity of *Meloidogyne incognita* to extracts from native Yucatecan plants. *Nematropica*. 36 (2006) 89-97.
- [32] Y. S. Xie, R. P. Bodnaryk, P.G. Fields. A rapid and simple flour-disk bioassay for testing substances active against stored-product insects. *Canadian Entomology* 128 (1996) 865-875.
- [33] M. B. Ismael, O. Koul, A. Luczynski, J. Kaminski. Insecticidal and antifeedant bioactivities of neem oils and their relationship to azadirachtin content. *Journal of Agricultural and Food Chemistry* 38 (1990) 1406-1411.
- [34] Z. L. Liu, S. H. Goh, S. H. Ho. Screening of Chinese medicinal herbs for bioactivity against *Sitophilus zeamais* Motschulsky and *Tribolium castaneum* (Herbst). *Journal of Stored Products Research* 43 (2007) 290-296.
- [35] Z. L. Liu, S. H. Ho. Bioactivity of the essential oil extracted from *Evodia rutaecarpa* Hook f. et Thomas against the grain storage insects, *Sitophilus zeamais* Motsch. and *Tribolium castaneum* (Herbst). *J. Stored Prod. Res.* 35 (1999) 317- 328.
- [36] D. J. Finney. Probit Analysis. A statistical treatment of the sigmoid response curve. Cambridge University Press, London. 3rdEd. (1971) 318.
- [37] P. B. B. M. Barbosa, J. M. de Oliveira, J. M. Chagas, L. M. A. Rabelo, G.F. de Medeiros, R. B. Giodani, E. A. Silva, A. F. Uchôa, M. D. D. M. Ximenes. Evaluation of seed extracts from plants found in the Caatinga biome for the control of *Aedes aegypti*. *Parasitology Research*. 113 (2014) 3565 – 3580.
- [38] M. C. C. Souza, M. B. M. Trovão. Bioatividade do extrato seco de plantas da Caatinga e do Nim (*Azadiractha indica*) sobre *Sitophilus zeamais* Mots em milho armazenado. *Revista Verde de Agroecologia e Desenvolvimento Sustentável* 4 (2009) 120–124.
- [39] C. S. A. Cruz, M. B. Medeiros, J. P. Gomes, F. C. Souza. Uso de plantas em pó seco com propriedades termiticida sobre a mortalidade de cupins arbóreos. *Revista Verde de Agroecologia e Desenvolvimento Sustentável* 7 (2013) 1 – 5.
- [40] A. A. Rajopadhye, A. S. Upadhye, S. P. Taware. Bioactivity of indigenous plant *Glossocardia bosvallia* (L. f.) DC. against insect pests of stored products. *Ind. Jour. Tradit. Knowledge*. 15 (2016) 260- 265.
- [41] Y. Dane, F. Mouhouche, R. C. garayoa, A. D. Rius. Phytochemical Analysis of Methanolic Extracts of *Artemisia absinthium* L. 1753 (Asteraceae), *Juniperus phoenicea* L., and *Tetraclinis articulata* (Vahl) Mast, 1892 (Cupressaceae) and evaluation of their biological activity for stored grain protection. *Árabe I. Sci. Eng.* 41 (2016) 2147- 2158. doi: 10.1007 / s13369-015-1977-2.
- [42] E. S. Autran, I. A. Neves, C. S. B. da Silva, G. K. N. Santos, C. A. G. D. Câmara, D. M. A. F. Navarro. Chemical composition, oviposition deterrent and larvicidal activities against *Aedes aegypti* of essential oils from *Piper marginatum* Jacq. (Piperaceae). *Bioresource Technology*. 100 (2009) 2284 – 2288.
- [43] S. Numa, L. Rodríguez, D. Rodríguez, E. Coy-Barrera. Susceptibility of *Tetranychus urticae* Koch to an ethanol extract of *Cnidoscolus aconitifolius* leaves under laboratory conditions. *SpringerPlus* 4 (2015) 338.

- [44] L. P. Candido, M. T. Cavalcanti, E. B. Beserra. Bioactivity of plant extracts on the larval and pupal stages of *Aedes aegypti* (Diptera, Culicidae). *Rev. Soc. Brasi. Medic. Tropical.* 46 (2013) 420-425.
- [45] C.-H. Lee, J. H. Jeon, S. G. Lee, H. S. Lee. Insecticidal Properties of Euphorbiaceae: *Sebastiania corniculata*-derived 8-Hydroxyquinoline and Its Derivatives against Three Planthopper Species (Hemiptera: Delphacidae). *J. Korean Soc. Appl. Biol. Chem.* 53(2010) 464-469.
- [46] F. Sievers, W. A. Archer, R. H. Moore, E. R. McGrovan. Insecticidal tests of plants from tropical America. *J. Economic Entomology.* 42 (1949) 549- 551.
- [47] A. S. Corrêa, L. O. de Oliveira, L. S. Braga, R. N. C. Guedes, Distribution of the related weevil species *Sitophilus oryzae* and *S. zeamais* in Brazil, *Insect Sci.* 20 (2013) 763–770.
- [48] D. P. Rees, Coleoptera, in: B.H. Subramanyam, D.W. Hagstrum (Eds.), *Integrated Management of Insects in Stored Products*, Marcel Dekker, New York, USA (1996) 1–40.
- [49] R. Taghizadeh, N. Mohammadkhani. Feeding deterency of two medicinal plant extracts on *Tribolium castaneum* (Coleoptera: Tenebrionidae). *J. Crop Prot.* 5 (2016) 529-539.
- [50] S. M. Upasani, H. M. Kotkar, P. S. Mendki, V. L. Maheshwari. Partial characterization and insecticidal properties of *Ricinus communis* L foliage flavonoids. *Pest. Manag. Sci.*, 59 (2003) 1349-1354. Doi: 10.1002 / ps.767.
- [51] C. P. Sánchez, P. V. Ayala, R. M. Belmont, R. F. Brito, A. J. Pérez. Repellency of Hydroethanolic Extracts of *Ricinus communis* (Euphorbiaceae) to *Scyphophorus acupunctatus* (Coleoptera: Curculionidae) in the Laboratory. *Florida Entomologist.* 95 (2012)706-710.
- [52] M. O. C. Rocha, R. I. S. Mariñez, S. G. García, M. M. I. Villaescusa, M. F. J. Cinco. Plant powders as stored grain protectants against *Zabrotes subfasciatus* (Boheman). *Southwestern Entomol.* 18 (1993) 73 - 75.
- [53] S. A. Babarinde, O. O. Oyegoke, A. E. Adekunle. Larvicidal and insecticidal properties of *Ricinus communis* seed extracts obtained by different methods against *Tribolium castaneum* Herbst (Coleoptera: Tenebrionidae). *Arch. Phytopathol. Plant Prot.* 44 (2011) 451- 459.
- [54] N. Chauhan, P. Kumar, S. Mishra, S. Verma, A. Malik, S. Sharma. Insecticidal activity of *Jatropha curcas* extracts against housefly, *Musca domestica*. *Sci Pollut Res.* 22 (2015)14793–14800. DOI 10.1007/s11356-015-4686-1
- [55] M. Khani, R. M. Awang, D. Omar, M. Rahmani, S. Rezazadeh. Tropical medicinal plant extracts against rice weevil, *Sitophilus oryzae* L. *J Med Plants Res.* 5 (2011) 259–265.
- [56] S. Verma, M. Verma, S. Sharma, A. Malik. Determination of phytocomponents of *Jatropha curcas* root by GC-MS analysis and their termiticidal activity. *Int J Ecol Environ Sci.* 39 (2013) 159–169.
- [57] G. N. Silva, L. R. A. Faroni, A. H. Sousa, R. S. Freitas. Bioactivity of *Jatropha curcas* L. to insect pests of stored products. *J. Stor. Prod. Res.* 48 (2012) 111- 113.
- [58] R. K. Devappa, H. P. S. Makkar, K. Becker. *Jatropha* toxicity - a Review. *Journal of Toxicology and Environmental Health, Part B* 13 (2010) 476- 507.
- [59] M. Govindarajan, A. Jebanesan, T. Pushpanathan, K. Samidurai. Studies on effect of *Acalypha indica* L. (Euphorbiaceae) leaf extracts on the malarial vector, *Anopheles stephensi* Liston (Diptera:Culicidae). *Parasitol Res* (2008) 103: 691. doi:10.1007/s00436-008-1032-2
- [60] E. M. Bashir, H. A.F. El Shafie. Insecticidal and Antifeedant Efficacy of *Jatropha* oil extract against the Desert Locust, *Schistocerca gregaria* (Forsk.) (Orthoptera: Acrididae) *Agric. Biol. J. N. Am.* 4 (2013) 260-267. doi:10.5251/abjna.2013.4.3.260.267.

- [61] T. A. Kodjo, M. Gbénonchi, A. Sadate, A. Komi, G. Y. M. Dieudonné, S. Komla. Bio-insecticidal effects of plant extracts and oil emulsions of *Ricinus communis* L. (Malpighiales: Euphorbiaceae) on the diamondback, *Plutella xylostella* L. (Lepidoptera: Plutellidae) under laboratory and semi-field conditions. J. Appl. Biosci. 43 (2011) 2899 – 2914.
- [62] T. T. Epidi, I. O. Udo, J. A. Osakwe. Susceptibility of *Sitophilus zeamais* mots. and *Callosobruchus maculatus* f. to plant parts of *Ricinodendron heudelotii*. J. Plant Protection Research 49 (2009) 411- 415.
- [63] Asmanizar, A. Djamin, A. B. Idris. Effect of selected plant extract on mortality of adult *sitophilus zeamais* motschulsky (coleoptera: curculionidae), a pest of stored rice grains. Malays. Appl. Biol. 37 (2008) 41–46.
- [64] P. Golob, G. Moss, M. Dalas, A. Fidgen, J. Evans. The use of spices and medicinals as bioactive protectants for grain. FAO Agricultural Services Bulletin. N°137. Nat. Res.Inst. Chathan. (1999). <http://www.fao.org/docrep/x2230e/x2230e04.htm>.
- [65] K. O. Adebawale, C. O. Adedire. Chemical composition and insecticidal properties of the underutilized *Jatropha curcas* seed oil. African Journal of Biotechnology, 5 (2006) 901-906.

4 Conclusão

- Os extratos de *C. urens* revelaram a presença de compostos majoritários tais como: Flavonóides, açúcares redutores e terpenos, além de outros metabólitos como: proantocianidinas, taninos e cumarinas, em menor quantidade.
- Os extratos de *C. urens* apresentaram uma ótima atividade antioxidante, mostrando ação significativa em todas as concentrações 50, 100, 200 e 500 µg/mL quando comparados ao controle.
- No entanto, os extratos aquoso e etanólico não apresentaram resultados satisfatórios quando foram testados contra células de linhagem HELA *in vitro*.
- Os extratos aquoso e etanólico de *C. urens* apresentaram ações antitumoral para o modelo experimental *in vivo* quando testado contra tumor sólido de carcinoma de Ehrlich, numa concentração de 200 mg/Kg, entretanto o extrato aquoso mostrou-se mais eficiente quando comparado com o extrato etanólico, sugerindo que os compostos presentes em extratos de *C. urens* desempenham um potencial inibitório contra células tumorais.
- Além da atuação da inibição do crescimento tumoral pode ser observado que os extratos aquoso e etanólico de *C. urens* também atuaram melhorando a resposta imunológica, bem como o perfil bioquímico dos grupos tratados.
- MeOHC.*urens* não interferiu na produção do número de fezes normais em camundongos por tratamento oral.
- O MeOHC.*urens* (200mg/kg; 400mg/kg) demonstrou ter uma eficiência em reduzir o percentual de produção de fezes diarreicas em camundongos com diarreia induzida por óleo de rícino.
- Além disso MeOHC.*urens*, também se mostrou eficiente em reduzir de forma significativa, o acúmulo e fluido intestinal induzido por óleo de rícino *in vivo*.
- Extratos de éter, clorofórmio e acetona de partes aéreas de *C. urens* foram testados quanto a sua ação inseticida, porém não demonstraram atividade significativa.
- Entretanto, extratos metanólicos bruto e fracionado de partes aéreas de *C. urens* (MeOHC.*urens* e MeOHFrac) demonstrou ser eficiente contra *S. zeamais* em baixas concentrações.

- Ambos os extratos metanólicos (0,18- 0,5 mg/g) foi eficiente em induzir efeito deterrente sobre *S. zeamais*.
- Alterações no perfil nutricional de insetos, pode ser verificado quando foram expostos a uma dieta impreguinada por MeOHC.*urens* e MeOHFrac.
- MeOHC.*urens* e MeOHFrac é capaz de induzir letalidade de 50% da população de *S. zeamais* em baixíssimas concentrações.

ANEXOS

ANEXO A - Carta de aprovação do comitê de ética (01)

Universidade Federal de Pernambuco
Centro de Ciências Biológicas
Av. Prof. Nelson Chaves, s/n
50670-420 / Recife - PE - Brasil
fones: (55 81) 2126 8840 / 2126 8351
fax: (55 81) 2126 8350
www.ccb.ufpe.br



Recife, 06 de agosto de 2012.

Ofício nº 458/12

Da Comissão de Ética no Uso de Animais (CEUA) da UFPE
Para: **Profª. Noêmia Pereira da Silva Santos**
Centro Acadêmico de Vitória
Universidade Federal de Pernambuco
Processo nº 23076.041082/2011-25

Os membros da Comissão de Ética no Uso de Animais do Centro de Ciências Biológicas da Universidade Federal de Pernambuco (CEUA-UFPE) avaliaram seu projeto de pesquisa intitulado, "**Avaliação da ação antitumoral de *Cnidoscolus urens* sobre tumores sólidos experimentais em camundongos Swiss**".


Concluímos que os procedimentos descritos para a utilização experimental dos animais encontram-se de acordo com as normas sugeridas pelo Colégio Brasileiro para Experimentação Animal e com as normas internacionais estabelecidas pelo National Institute of Health Guide for Care and Use of Laboratory Animals as quais são adotadas como critérios de avaliação e julgamento pela CEUA-UFPE.

Encontra-se de acordo com as normas vigentes no Brasil, especialmente a Lei 11.794 de 08 de outubro de 2008, que trata da questão do uso de animais para fins científicos e didáticos.

Diante do exposto, emitimos parecer favorável aos protocolos experimentais a serem realizados.

Origem dos animais: Biotério do LIKA - UFPE; Animais: Camundongos; Linhagem: Swiss; Sexo: machos; Peso: 30g; Idade: 40 a 60 dias; Número de animais previsto no protocolo: 100

Atenciosamente,


Noêmia Pereira da Silva Santos
Presidente do CEEA

CCB: Integrar para desenvolver

ANEXO B - Carta de aprovação do comitê de ética (02)

Universidade Federal de Pernambuco
Centro de Biociências
Av. Prof. Nelson Chaves, s/n
50670-420 / Recife - PE - Brasil
fones: (55 81) 2126 8840 | 2126 8351
fax: (55 81) 2126 8350
www.ccb.ufpe.br

Recife, 07 de julho de 2016.


Ofício nº 65/16

Da Comissão de Ética no Uso de Animais (CEUA) da UFPE
Para: **Prof. Nicácio Henrique da Silva**
Departamento de Bioquímica
Centro de Biociências
Universidade Federal de Pernambuco
Processo nº **23076.012693/2016-71**

Certificamos que a proposta intitulada “*Cnidoscolus sp* da caatinga: fitoquímica e atividades biológicas”, registrada com o nº **23076.012693/2016-71**, sob a responsabilidade de Prof. **Nicácio Henrique da Silva** - que envolve a produção, manutenção ou utilização de animais pertencentes ao filo Chordata, subfilo Vertebrata (exceto humanos), para fins de pesquisa científica (ou ensino) - encontra-se de acordo com os preceitos da Lei nº 11.794, de 8 de outubro de 2008, do Decreto nº 6.899, de 15 de julho de 2009, e com as normas editadas pelo CONSELHO NACIONAL DE CONTROLE DE EXPERIMENTAÇÃO ANIMAL (CONCEA), e foi aprovada pela COMISSÃO DE ÉTICA NO USO DE ANIMAIS (CEUA) DA UNIVERSIDADE FEDERAL DE PERNAMBUCO (UFPE), em reunião de 28/06/2016.

Finalidade	() Ensino (X) Pesquisa Científica
Vigência da autorização	Até 27/02/2020
Espécie/linhagem/raça	Camundongo albino <i>Swiss Mus musculus</i>
Nº de animais	138
Peso/Idade	30-35g/ 30-60 dias
Sexo	machos
Origem	Biotério do LIKA

Atenciosamente,


Prof. Dr. Pedro V. Carelli
Presidente da CEUA / CCB - UFPE
SIAPE 1801584

Anexo C - Guide for authors – JOURNAL OF ETHNOPHARMACOLOGY



JOURNAL OF ETHNOPHARMACOLOGY

An Interdisciplinary Journal Devoted to Indigenous Drugs

INFORMATION PACK

AUTHOR

CONTENTS

- Description p.1
- Audience p.2
- Impact Factor p.2
- Abstracting and Indexing p.2
- Editorial Board p.2 ● Guide for Authors p.4

ISSN: 0378-8741

TABLE OF



DESCRIPTION

The *Journal of Ethnopharmacology* is dedicated to the exchange of information and understandings about people's use of plants, fungi, animals, microorganisms and minerals and their **biological** and **pharmacological effects** based on the principles established through international conventions. Early people confronted with illness and disease, discovered a wealth of useful **therapeutic agents** in the plant and animal kingdoms. The empirical knowledge of these **medicinal substances** and their toxic potential was passed on by oral tradition and sometimes recorded in herbals and other texts on *materia medica*. Many valuable drugs of today (e.g., atropine, ephedrine, tubocurarine, digoxin, reserpine) came into use through the study of **indigenous remedies**. Chemists continue to use **plant-derived drugs** (e.g., morphine, taxol, physostigmine, quinidine, emetine) as prototypes in their attempts to develop more effective and less toxic medicinals.

In recent years the preservation of local knowledge, the promotion of indigenous medical systems in primary health care, and the conservation of biodiversity have become even more of a concern to all scientists working at the interface of social and natural sciences but especially to ethnopharmacologists. Recognizing the sovereign rights of States over their natural resources, ethnopharmacologists are particularly concerned with local people's rights to further use and develop their autochthonous resources.

Accordingly, today's ethnopharmacological research embraces the multidisciplinary effort in the:

- documentation of **indigenous medical knowledge**,
- scientific study of **indigenous medicines** in order to contribute in the long-run to improved health care in the regions of study, as well as
- search for pharmacologically unique principles from existing indigenous remedies.

The *Journal of Ethnopharmacology* publishes original articles concerned with the observation and experimental investigation of the biological activities of plant and animal substances used in the traditional medicine of past and present cultures. The journal will particularly welcome interdisciplinary papers with an **ethnopharmacological**, an **ethnobotanical** or an **ethnochemical** approach to the study of indigenous drugs. Reports of **anthropological** and **ethnobotanical** field studies fall within the journal's scope. Studies involving **pharmacological** and **toxicological** mechanisms of action are especially welcome. Clinical studies on efficacy will be considered if contributing to the understanding of specific ethnopharmacological problems. The journal welcomes review articles in the above mentioned fields especially those highlighting the multi-disciplinary nature of ethnopharmacology. Commentaries are by invitation only.

AUDIENCE

Ethnopharmacologists, Medicinal Chemists, Pharmacologists, Toxicologists, Anthropologists,
Pharmacognosists, Ethnobotanists, Economic Botanists, Ethnobiologists

IMPACT FACTOR

2015: 3.055 © Thomson Reuters Journal Citation Reports 2016

ABSTRACTING AND INDEXING

AGRICOLA

BIOSIS

Cambridge Scientific Abstracts

Chemical Abstracts

Current Contents/Life Sciences

MEDLINE®

International Pharmaceutical Abstracts

EMBASE

NAPRALERT (Natural Products Alert)

Science Citation Index

CAB Abstracts

Scopus

EMBiology

EDITORIAL BOARD

Editor-in-Chief:

R. Verpoorte, Institute of Biology, Natural Products Laboratory, Universiteit Leiden, Sylviusweg 72, 2333BE, Leiden, Netherlands

Deputy Editor-in-Chief

A.M. Viljoen, Tshwane University of Technology, Pretoria, South Africa

Associate Editor:

T. Efferth, Johannes Gutenberg Universität Mainz, Mainz, Germany

D. Guo, Chinese Academy of Sciences (CAS), Shanghai, China

A.K. Jäger, University of Copenhagen, Copenhagen O, Denmark

G. Lin, The Chinese University of Hong Kong, Hong Kong, Hong Kong

P.K. Mukherjee, Jadavpur University, Kolkata, India

G. Schmeda Hirschmann, Universidad de Talca, Talca, Chile

K. Shaari, University Putra Malaysia, Selangor, Malaysia

A. Shikov, Saint Petersburg Institute of Pharmacy, Kuzmolovo P 245, Russian Federation

E. Yesilada, Yeditepe University, Erenkoy-Istanbul, Turkey

Reviews Editor (including Commentaries and Book Reviews):

M. Heinrich, The School of Pharmacy, University of London, 29-39 Brunswick Square, London, WC1N 1AX, UK If you want to suggest a review, please provide a structured abstract and include an annotated table of contents and a short CV of the lead author(s).

Managing Editor:

B. Pomahacova, Leiden University, Leiden, Netherlands

I. Vermaak, Tshwane University of Technology, Pretoria, South Africa

M. Sandasi, Tshwane University of Technology, Pretoria, South Africa

L.J. McGaw, University of Pretoria, Pretoria, South Africa

Editorial Board:

S. Alban, Kiel, Germany

M.J. Balick, Bronx, New York, USA

R. Bauer

G. Bourdy, Cayenne, French Guiana

J.B. Calixto, Florianópolis, Brazil

C-T. Che, Hong Kong, Hong Kong

G.A. Cordell, Evanston, Illinois, USA

V.S. da Silva Bolzani, Araraquara, Brazil

J. Ding, Shanghai, China

V.M. Dirsch, Vienna, Austria

E. Elisabetsky, Porto Alegre, Brazil

J. Fleurentin, Metz, France
B.L. Furman, Glasgow, UK
M.P. Germano, Messina, Italy
J. Gertsch, Bern, Switzerland
A.H. Gilani, Karachi, Pakistan
M.P. Gupta, Panama City, Panama
A. Hensel, Münster, Germany
P.J. Houghton, London, UK
Z. Ismail, Penang, Malaysia
W. Jia, Kannapolis, North Carolina, USA
T. Johns, Ste. Anne de Bellevue, Quebec, Canada
A.K. Jäger, Copenhagen O, Denmark
G. Kavalali, Istanbul, Turkey
H-S. Kim, Cheongju, South Korea
J. Kim, Seoul, South Korea
Y. Kimura, Ehime, Japan
M.A. Lacaille-Dubois, Dijon, France
M. Leonti, Cagliari, Italy
E. Matteucci, Pisa, Italy
I. Merfort, Freiburg, Germany
J.J.M. Meyer, Pretoria, South Africa
D.E. Moerman
D.A. Mulholland, Guildford, England, UK
A. Panthong, Chiang Mai, Thailand
X. Peigen, Beijing, China
A. Pieroni, Pollenzo/Bra, Italy
D.D. Soejarto, Chicago, Illinois, USA
E. Speroni, Bologna, Italy
A.J. Vlietinck, Antwerpen, Belgium
H. Wagner, München, Germany
C.S. Weckerle, Zurich, Switzerland
C.W. Wright, Bradford, UK
S. Zacchino, Rosario, Argentina

Founding Editors:

J.G. Bruhn
L. Rivier, Lausanne, Switzerland

GUIDE FOR AUTHORS

INTRODUCTION

The *Journal of Ethnopharmacology* is dedicated to the exchange of information and understandings about people's use of plants, fungi, animals, microorganisms and minerals and their biological and pharmacological effects based on the principles established through international conventions. Early people, confronted with illness and disease, discovered a wealth of useful therapeutic agents in the plant and animal kingdoms. The empirical knowledge of these medicinal

substances and their toxic potential was passed on by oral tradition and sometimes recorded in herbals and other texts on *materia medica*. Many valuable drugs of today (e.g., atropine, ephedrine, tubocurarine, digoxin, reserpine) came into use through the study of indigenous remedies. Chemists continue to use plant-derived drugs (e.g., morphine, taxol, physostigmine, quinidine, emetine) as prototypes in their attempts to develop more effective and less toxic medicinals.

Please note that figures and tables should be embedded in the text as close as possible to where they are initially cited. It is also mandatory to upload separate graphic and table files as these will be required if your manuscript is accepted for publication.

Classification of your paper

Please note that upon submitting your article you will have to select **at least one classification** and **at least three of the given keywords**. You can preview the list of classifications and keywords ([here](#)). This information is needed by the Editors to more quickly process your article. In addition to this, you can submit free keywords as described below under "Keywords".

The "rules of 5"

The Editors and Editorial Board have developed the "Rules of 5" for publishing in JEP. We have produced five clear criteria that each author needs to think about before submitting a manuscript and setting the whole process of editing and reviewing at work. [Click here](#).

For more details on how to write a world class paper, please visit our [Pharmacology Author Resources](#) page.

Authors are encouraged to submit video material or animation sequences to support and enhance your scientific research. For more information please see the paragraph on video data below.

Types of paper

The *Journal of Ethnopharmacology* will accept the following contributions:

1. Original research articles - whose length is not limited and should include Title, Abstract, Methods and Materials, Results, Discussion, Conclusions, Acknowledgements and References. As a guideline, a full length paper normally occupies no more than 10 printed pages of the journal, including tables and illustrations.
2. Short Communications - whose average length is not more than 4 pages in print (approx. 2000-2300 words, including abstract and references). A maximum of 2 illustrations (figures or tables) is allowed. See paragraph below for description and format.
3. Letters to the Editors.
4. Reviews - Authors intending to write review articles should consult and send an outline to the Reviews Editor (see inside front cover for contact information) before preparing their manuscripts. The organization and subdivision of review articles can be arranged at the author's discretion. Authors should keep in mind that a good review sets the trend and direction of future research on the subject matter being reviewed. Tables, figures and references are to be arranged in the same way as research articles in the journal. Reviews on topics that address cutting-edge problems are particularly welcome. Outlines for potential reviews need to include: A detailed

abstract using the structure provided in the guidelines An annotated table of contents A short CV of the lead author 5. Book reviews - Books for review should be sent to the Reviews Editor.

6. Commentaries - *invited*, peer-reviewed, critical discussion about crucial aspects of the field but most importantly methodological and conceptual-theoretical developments in the field and should also provide a standard, for example, for pharmacological methods to be used in papers in the *Journal of Ethnopharmacology*. The scientific dialogue differs greatly in the social / cultural and natural sciences, the discussions about the common foundations of the field are ongoing and the papers published should contribute to a transdisciplinary and multidisciplinary discussion. The length should be a maximum of 2-3 printed pages or 2500 words. Please contact the Reviews Editor j.ethnopharmacol@pharmacy.ac.uk with an outline.

7. Conference announcements and news.

BEFORE YOU BEGIN

Ethics in publishing

Please see our information pages on [Ethics in publishing](#) and [Ethical guidelines for journal publication](#).

[Policy and ethics](#)

In the covering letter, the author must also declare that the study was performed according to the international, national and institutional rules considering animal experiments, clinical studies and biodiversity rights. See below for further information. The ethnopharmacological importance of the study must also be explained in the cover letter.

Animal and clinical studies - Investigations using experimental animals must state in the Methods section that the research was conducted in accordance with the internationally accepted principles for laboratory animal use and care as found in for example the European Community guidelines (EEC Directive of 1986; 86/609/EEC) or the US guidelines (NIH publication #85-23, revised in 1985). Investigations with human subjects must state in the Methods section that the research followed guidelines of the Declaration of Helsinki and Tokyo for humans, and was approved by the institutional human experimentation committee or equivalent, and that informed consent was obtained. The Editors will reject papers if there is any doubt about the suitability of the animal or human procedures used.

Biodiversity rights - Each country has its own rights on its biodiversity. Consequently for studying plants one needs to follow the international, national and institutional rules concerning the biodiversity rights.

Author contributions

For each author the contribution to the publication should be mentioned.

[Declaration of interest](#)

All authors are requested to disclose any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within three years of beginning the submitted work that could inappropriately influence, or be perceived to influence, their work. [More information](#).

[Submission declaration and verification](#)

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint,

see '[Multiple, redundant or concurrent publication](#)' section of our ethics policy for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service [CrossCheck](#).

[Changes to authorship](#)

Authors are expected to consider carefully the list and order of authors **before** submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only **before** the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the **corresponding author**: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.

Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors **after** the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

[Article transfer service](#)

This journal is part of our Article Transfer Service. This means that if the Editor feels your article is more suitable in one of our other participating journals, then you may be asked to consider transferring the article to one of those. If you agree, your article will be transferred automatically on your behalf with no need to reformat. Please note that your article will be reviewed again by the new journal. [More information](#).

[Copyright](#)

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see [more information](#) on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. [Permission](#) of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has [preprinted forms](#) for use by authors in these cases.

For open access articles: Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' ([more information](#)). Permitted third party reuse of open access articles is determined by the author's choice of [user license](#).

Author rights

As an author you (or your employer or institution) have certain rights to reuse your work. [More information](#).

Elsevier supports responsible sharing

Find out how you can [share your research](#) published in Elsevier journals.

Role of the funding source

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

Funding body agreements and policies

Elsevier has established a number of agreements with funding bodies which allow authors to comply with their funder's open access policies. Some funding bodies will reimburse the author for the Open Access Publication Fee. Details of [existing agreements](#) are available online.

Open access

This journal offers authors a choice in publishing their research:

Open access

- Articles are freely available to both subscribers and the wider public with permitted reuse.
- An open access publication fee is payable by authors or on their behalf, e.g. by their research funder or institution.

Subscription

- Articles are made available to subscribers as well as developing countries and patient groups throughout [universal access programs](#).
- No open access publication fee payable by authors.

Regardless of how you choose to publish your article, the journal will apply the same peer review criteria and acceptance standards.

For open access articles, permitted third party (re)use is defined by the following [Creative Commons user licenses](#):

Creative Commons Attribution (CC BY)

Lets others distribute and copy the article, create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), include in a collective work (such as an anthology), text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

The open access publication fee for this journal is **USD 3300**, excluding taxes. Learn more about Elsevier's pricing policy: <https://www.elsevier.com/openaccesspricing>.

Green open access

Authors can share their research in a variety of different ways and Elsevier has a number of green open access options available. We recommend authors see our [green open access page](#) for further information. Authors can also self-archive their manuscripts immediately and enable public access from their institution's repository after an embargo period. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and in editor-author communications. Embargo period: For subscription articles, an appropriate amount of time is needed for journals to deliver value to subscribing customers before an article becomes freely available to the public. This is the embargo period and it begins from the date the article is formally published online in its final and fully citable form.

This journal has an embargo period of 12 months.

Elsevier Publishing Campus

The Elsevier Publishing Campus (www.publishingcampus.com) is an online platform offering free lectures, interactive training and professional advice to support you in publishing your research. The College of Skills training offers modules on how to prepare, write and structure your article and explains how editors will look at your paper when it is submitted for publication. Use these resources, and more, to ensure that your submission will be the best that you can make it.

Language (usage and editing services)

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the [English Language Editing service](#) available from Elsevier's WebShop.

Submission

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

Additional information

Authors who want to submit a manuscript should consult and peruse carefully recent issues of the journal for format and style. Authors must include the following contact details on the title page of their submitted manuscript: full postal address; fax; e-mail. All manuscripts submitted are subject to peer review. The minimum requirements for a manuscript to qualify for peer review are that it has been prepared by strictly following the format and style of the journal as mentioned, that it is written in good English, and that it is complete. Manuscripts that have not fulfilled these requirements will be returned to the author(s).

In addition, you are recommended to adhere to the research standards described in the following articles:

Cos P., Vlietinck A.J., Berghe D.V., et al. (2006) Anti-infective potential of natural products: how to develop a stronger in vitro 'proof-of-concept'. *Journal of Ethnopharmacology*, 106: 290-302.

Matteucci, E., Giampietro, O. (2008) Proposal open for discussion: defining agreed diagnostic procedures in experimental diabetes research. *Journal of Ethnopharmacology*, 115: 163-172.

Froede, T.S.A. and Y.S. Medeiros, Y.S. (2008) Animal models to test drugs with potential antidiabetic activity. *Journal of Ethnopharmacology* 115: 173-183. Gertsch J. (2009) How scientific is the science in ethnopharmacology? Historical perspectives and epistemological problems. *Journal of Ethnopharmacology*, 122: 177-183.

Chan K., et al. (2012) Good practice in reviewing and publishing studies on herbal medicine, with special emphasis on traditional Chinese medicine and Chinese Materia Medica. *Journal of Ethnopharmacology* 140: 469-475.

Heinrich, M., Edwards. S., Moerman. D.E.. and Leonti. M. (2009), Ethnopharmacological field studies: a critical assessment of their conceptual basis and methods. *J. Ethnopharmacol*, 124: 1-17.

PREPARATION

Use of word processing software

It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the [Guide to Publishing with Elsevier](#)). Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

Article structure

Subdivision - numbered sections

Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be given a brief heading. Each heading should appear on its own separate line.

Introduction

State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

Material and methods

Provide sufficient detail to allow the work to be reproduced. Methods already published should be indicated by a reference: only relevant modifications should be described.

Theory/calculation

A Theory section should extend, not repeat, the background to the article already dealt with in the Introduction and lay the foundation for further work. In contrast, a Calculation section represents a practical development from a theoretical basis.

Results

Results should be clear and concise.

Discussion

This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

Conclusions

The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

Glossary

Please supply, as a separate list, the definitions of field-specific terms used in your article.

Appendices

If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.

Essential title page information

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations.** Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lowercase superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. **Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.**
- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

Abstract

A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

The author should divide the abstract with the headings **Ethnopharmacological relevance, Aim of the study, Materials and Methods, Results, and Conclusions**. Click [here](#) to see an example.

Graphical abstract

A Graphical abstract is mandatory for this journal. It should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership online. Authors must provide images that clearly represent the work described in the article. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. You can view [Example Graphical Abstracts](#) on our information site.

Authors can make use of Elsevier's Illustration and Enhancement service to ensure the best presentation of their images also in accordance with all technical requirements: [Illustration Service](#).

Keywords

After having selected a classification in the submission system, authors must in the same step select 5 keywords. These keywords will help the Editors to categorize your article accurately and process it more quickly. A list of the classifications and set keywords can be found [here](#).

In addition, you can provide a maximum of 6 specific keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, "and", "of"). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

Chemical compounds

You can enrich your article by providing a list of chemical compounds studied in the article. The list of compounds will be used to extract relevant information from the NCBI PubChem Compound database and display it next to the online version of the article on ScienceDirect. You can include up to 10 names of chemical compounds in the article. For each compound, please provide the [PubChem CID](#) of the most relevant record as in the following example: Glutamic acid (PubChem CID:611). Please position the list of compounds immediately below the 'Keywords' section. It is strongly recommended to follow the exact text formatting as in the example below: Chemical compounds studied in this article

Ethylene glycol (PubChem CID: 174); Plitidepsin (PubChem CID: 44152164); Benzalkonium chloride (PubChem CID: 15865) [More information](#).

Plant names

In the Materials and Methods section there must be a separate heading for describing the material used. That includes official name, local name, English name (if known), GPS position in case of collection in the wild or cultivation, a voucher specimen must be deposited in an official herbarium for possible future comparison. In the text it should be stated that the plant name has been checked with www.theplantlist.org mentioning the data of accessing that website.

In case of commercially procured material should mention the source, batch number, quality control data. Data on chemical characterization (metabolomics, chromatographic methods) should also be presented, in case of known active compounds their quantitative analysis should be presented.

Acknowledgements

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

Formatting of funding sources

List funding sources in this standard way to facilitate compliance to funder's requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, please include the following sentence:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Math formulae

Please submit math equations as editable text and not as images. Present simple formulae in line with normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

Footnotes

Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate the position of footnotes in the text and list the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.

Artwork

Electronic artwork General points

- Make sure you use uniform lettering and sizing of your original artwork.
- Embed the used fonts if the application provides that option.
- Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Provide captions to illustrations separately.
- Size the illustrations close to the desired dimensions of the published version.
- Submit each illustration as a separate file.

A detailed [guide on electronic artwork](#) is available.

You are urged to visit this site; some excerpts from the detailed information are given here.

Formats

If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format.

Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings, embed all used fonts.

TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.

TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.

TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.

Please do not:

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
- Supply files that are too low in resolution;
- Submit graphics that are disproportionately large for the content.

Please note that figures and tables should be embedded in the text as close as possible to where they are initially cited. It is also mandatory to upload separate graphic and table files as these will be required if your manuscript is accepted for publication.

Color artwork

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. **For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article.** Please indicate your preference for color: in print or online only. [Further information on the preparation of electronic artwork.](#)

Figure captions

Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

Tables

Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules.

References

Citation in text

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these

references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with "Unpublished results". "*Personal communication*" will not be accepted as a reference. Citation of a reference as "in press" implies that the item has been accepted for publication.

Reference links

Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is encouraged.

A DOI can be used to cite and link to electronic articles where an article is in-press and full citation details are not yet known, but the article is available online. A DOI is guaranteed never to change, so you can use it as a permanent link to any electronic article. An example of a citation using DOI for an article not yet in an issue is: VanDecar J.C., Russo R.M., James D.E., Ambeh W.B., Franke M. (2003). Aseismic continuation of the Lesser Antilles slab beneath northeastern Venezuela. *Journal of Geophysical Research*, <http://dx.doi.org/10.1029/2001JB000884i>. Please note the format of such citations should be in the same style as all other references in the paper.

Reference management software

Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support [Citation Style Language styles](#), such as [Mendeley](#) and [Zotero](#), as well as [EndNote](#). Using the word processor plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide.

Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following link:

<http://open.mendeley.com/use-citation-style/journal-of-ethnopharmacology>

When preparing your manuscript, you will then be able to select this style using the Mendeley plugins for Microsoft Word or LibreOffice.

Reference style

Text: All citations in the text should refer to:

1. **Single author:** the author's name (without initials, unless there is ambiguity) and the year of publication;
2. **Two authors:** both authors' names and the year of publication;
3. **Three or more authors:** first author's name followed by 'et al.' and the year of publication. Citations may be made directly (or parenthetically). Groups of references should be listed first alphabetically, then chronologically.

Examples: 'as demonstrated (Allan, 2000a, 2000b, 1999; Allan and Jones, 1999). Kramer et al. (2010) have recently shown'

List: References should be arranged first alphabetically and then further sorted chronologically if necessary. More than one reference from the same author(s) in the same year must be identified by the letters 'a', 'b', 'c', etc., placed after the year of publication.

Examples:

Reference to a journal publication:

Van der Geer, J., Hanraads, J.A.J., Lupton, R.A., 2010. The art of writing a scientific article. *J. Sci. Commun.* 163, 51–59.

Reference to a book:

Strunk Jr., W., White, E.B., 2000. *The Elements of Style*, fourth ed. Longman, New York.

Reference to a chapter in an edited book:

Mettam, G.R., Adams, L.B., 2009. How to prepare an electronic version of your article, in: Jones, B.S., Smith, R.Z. (Eds.), *Introduction to the Electronic Age*. E-Publishing Inc., New York, pp. 281–304.

Reference to a website:

Cancer Research UK, 1975. Cancer statistics reports for the UK. <http://www.cancerresearchuk.org/aboutcancer/statistics/cancerstatsreport/> (accessed 13.03.03).

Video

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats with a preferred maximum size of 150 MB. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including [ScienceDirect](#). Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our [video instruction pages](#). Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

Supplementary material

Supplementary material can support and enhance your scientific research. Supplementary files offer the author additional possibilities to publish supporting applications, high-resolution images, background datasets, sound clips and more. Please note that such items are published online exactly as they are submitted; there is no typesetting involved (supplementary data supplied as an Excel file or as a PowerPoint slide will appear as such online). Please submit the material together with the article and supply a concise and descriptive caption for each file. If you wish to make any changes to supplementary data during any stage of the process, then please make sure to provide an updated file, and do not annotate any corrections on a previous version. Please also make sure to switch off the

'Track Changes' option in any Microsoft Office files as these will appear in the published supplementary file(s). For more detailed instructions please visit our [artwork instruction pages](#).

Data in Brief

Authors have the option of converting any or all parts of their supplementary or additional raw data into one or multiple Data in Brief articles, a new kind of article that houses and describes their data. Data in Brief articles ensure that your data, which is normally buried in supplementary material, is actively reviewed, curated, formatted, indexed, given a DOI and publicly available to all upon publication. Authors are encouraged to submit their Data in Brief article as an additional item directly alongside the revised version of their manuscript. If your research article is accepted, your Data in Brief article will automatically be transferred over to *Data in Brief* where it will be editorially reviewed and published in the new, open access journal, *Data in Brief*. Please note an open access fee is payable for publication in *Data in Brief*. Full details can be found on the [Data in Brief website](#). Please use [this template](#) to write your Data in Brief.

Database linking

Elsevier encourages authors to connect articles with external databases, giving readers access to relevant databases that help to build a better understanding of the described research. Please refer to relevant database identifiers using the following format in your article: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN). [More information and a full list of supported databases](#).

AudioSlides

The journal encourages authors to create an AudioSlides presentation with their published article. AudioSlides are brief, webinar-style presentations that are shown next to the online article on ScienceDirect. This gives authors the opportunity to summarize their research in their own words and to help readers understand what the paper is about. [More information and examples are available](#). Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides presentation after acceptance of their paper.

Interactive plots

This journal enables you to show an Interactive Plot with your article by simply submitting a data file. [Full instructions](#).

Submission checklist

The following list will be useful during the final checking of an article prior to sending it to the journal for review. Please consult this Guide for Authors for further details of any item.

Ensure that the following items are present:

One author has been designated as the corresponding author with contact details:

- E-mail address
- Full postal address

All necessary files have been uploaded, and contain:

- Keywords
- All figure captions
- All tables (including title, description, footnotes)

Further considerations

- Manuscript has been 'spell-checked' and 'grammar-checked'

- References are in the correct format for this journal
- All references mentioned in the Reference list are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Internet)

Printed version of figures (if applicable) in color or black-and-white

- Indicate clearly whether or not color or black-and-white in print is required. For any further information please visit our [Support Center](#).

AFTER ACCEPTANCE

Online proof correction

Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

Offprints

The corresponding author will, at no cost, receive a customized [Share Link](#) providing 50 days free access to the final published version of the article on [ScienceDirect](#). The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's [Webshop](#). Corresponding authors who have published their article open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

AUTHOR INQUIRIES

[Track your submitted article](#)

Anexo D: Guide for Authors- PESTICIDE BIOCHEMISTRY AND PHYSIOLOGY

PESTICIDE BIOCHEMISTRY AND PHYSIOLOGY

INFORMATION PACK

AUTHOR

CONTENTS

- **Description** p.1
- **Audience** p.1
- **Impact Factor** p.1
- **Abstracting and Indexing** p.2
- **Editorial Board** p.2 • **Guide for Authors** p.4

ISSN: 0048-3575

TABLE OF



DESCRIPTION

Pesticide Biochemistry and Physiology publishes original scientific articles pertaining to the mode of action of **plant protection agents** such as insecticides, fungicides, herbicides, and similar compounds, including nonlethal pest control agents, biosynthesis of pheromones, hormones, and plant resistance agents. Manuscripts may include a biochemical, physiological, or molecular study for an understanding of **comparative toxicology** or **selective toxicity** of both target and nontarget organisms. Particular interest will be given to studies on the molecular biology of **pest control**, toxicology, and **pesticide resistance**.

Research Areas Emphasized Include the Biochemistry and Physiology of:

- Comparative toxicity
- Mode of action
- Pathophysiology
- Plant growth regulators
- Resistance
- Other effects of pesticides on both parasites and hosts

Benefits to authors

We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our [author services](#).

Please see our [Guide for Authors](#) for information on article submission. If you require any further information or help, please visit our [Support Center](#)

AUDIENCE

Pesticide scientists, agricultural scientists, entomologists, plant scientists

IMPACT FACTOR

2015: 2.388 © Thomson Reuters Journal Citation Reports 2016

ABSTRACTING AND INDEXING

Scopus

EMBiology

EDITORIAL BOARD

Editor:

J.M. Clark, Dept. of Veterinary and Animal Sciences, University of Massachusetts, 311B Morrill 1 N, Amherst, Massachusetts, MA 01003, USA

Associate Editors:

C. Preston, School of Agriculture, Food & Wine, University of Adelaide, PMB 1, Glen Osmond, SA 5064, Australia **K.Y. Zhu**, Dept. of Entomology, Kansas State University, 123 Waters Hall, Manhattan, Kansas, KS 66506, USA

Editorial Board:

M.J. Adang, Dept. of Entomology, 413 Biological Sciences Bldg., University of Georgia, 120 Cedar Street, Athens, Georgia, GA 30602-2606, USA

K.A. Aliferis, Macdonald Campus; Fac. of Agricultural & Environmental Sciences, McGill University, 2111 Lakeshore Road, Ste. Anne de Bellevue, H9X 3V9, Canada

T. Arie, Fac. of Agriculture, Tokyo University of Agriculture and Technology, 3-5-8 Saiwaicho, Fuchu, 183, Tokyo, Japan

J.R. Bloomquist, Dept. of Entomology and Nematology, Emerging Pathogens Institute, University of Florida, 2055 Mowry Road, Gainesville, Florida, FL 32610-0009, USA

D. Cordova, Stine-Haskell Research Center, Dupont Crop Protection, 1090 Elkton Road, Newark, Delaware, DE 19711-0030, USA

F.E. Dayan, Thad Cochran Research Center, U.S. Department of Agriculture (USDA), Agricultural Research Service (ARS), P.O. Box 8048, University, Mississippi, MS 38677, USA

K. Dong, Dept. of Entomology and Neuroscience Program, Michigan State University, Rm 106, CIPS, East Lansing, Michigan, MI 48824, USA

S.O. Duke, NPURU, U.S. Department of Agriculture (USDA), Agricultural Research Service (ARS), University, Mississippi, MS 38677, USA

R.H. Ffrench-Constant, Daphne du Maurier School of Biosciences, Cornwall Campus, University of Exeter, TR10 9EZ, Penryn, Cornwall, England, UK

M. Fujimura, Life Sciences, University of Tokyo, 1-1-1 Izunimo, Itakura, Oura, 374-0193, Gunma, Japan

B.D. Hammock, Entomology & Cancer Research Center, University of California, Davis, Davis, California, CA 95616, USA

S.H. Lee, Dept. of Agricultural Biotechnology, Seoul National University (SNU), 151-742, Seoul, South Korea

Z. Ma, Institute of Biotechnology, Zhejiang University, 866 Yuhangtang Road, 310058, Hanzhou, China

H. Matsumoto, School of Life & Environmental Sciences, University of Tsukuba, 305-8572, Tsukuba, Ibaraki, Japan

R. Nauen, Research Insecticides, Bayer CropScience, D-40789, Monheim, Germany

W.J. Owen, Discovery Research, Dow AgroSciences, 9330 Zionsville Road, Indianapolis, Indiana, IN 46268, USA **B.R.**

Pittendrigh, Dept. of Entomology, University of Illinois at Urbana-Champaign, 1101 Peabody, Urbana, Illinois, IL 61801, USA

X. Qian, Dept. of Pesticides and Pharmaceuticals, East China University of Science and Technology, 130 Meilong Road, 200237, Shanghai, China

S. Qiang, Weed Research Laboratory, Nanjing Agricultural University, 210095, Nanjing, China

D. Sammons, Monsanto Company, 800 North Lindbergh Blvd., St. Louis, Missouri, 63167, USA

J.G. Scott, Dept. of Entomology, Barton Lab., Cornell University, Geneva Nyu 14456 E 25th St, New York, New York, NY 10010-2545, USA

D.L. Shaner, U.S. Department of Agriculture (USDA), Agricultural Research Service (ARS), 2150 Centre Ave, Fort Collins, Colorado, CO 80526, USA

G. Smagghe, Faculty of Bioscience Engineering, Department of Crop Protection, Ghent University, Coupure Links 653, B-9000, Ghent, Belgium

T.C. Sparks, Discovery Research, Dow AgroSciences, 9330 Zionsville Road, Indianapolis, Indiana, IN 46268, USA **D.M.**

Söderlund, Dept. of Entomology, Barton Lab., Cornell University, Geneva Nyu 14456 E 25th St, New York, New York, NY 10010-2545, USA

P.J. Tranel, Dept. of Crop Sciences, University of Illinois at Urbana-Champaign, 1201 West Gregory Drive, Urbana, Illinois, IL 61801, USA

T. Van Leeuwen, Dept. of Crop Protection, Fac. of Bioscience, Universiteit Gent, Coupure Links 653, B-9000, Gent, Belgium

J. Vontas, Inst. of Molecular Biology and Biotechnology, Foundation for Research & Technology - FORTH, Hellas Nikolaou Plastira 100, GR 70013, Heraklion, Crete, Greece

M.S. Williamson, Insect Molecular Biology Group, IACR-Rothamsted Experimental Station, AL5 2JQ, Harpenden, Hertfordshire, UK

GUIDE FOR AUTHORS

INTRODUCTION

Pesticide Biochemistry and Physiology will publish original research papers in English, dealing with the biochemistry and physiology of insecticides, herbicides fungicides, acaricides, nematocides, rodenticides and similar compounds, including nonlethal pest control agents such as antifeeding compounds and chemosterilants as well as, for example, the biosynthesis of pheromones, hormones and plant resistance agents. Topics of interest include the effects of these agents on the biochemistry and physiology of both target and non-target organisms, and the biochemical transformations of the agents themselves. The mechanisms of resistance, and interactions such as synergism and antagonism, are also suitable topics.

The journal does not encourage papers devoid of biochemical or physiological content, e.g., reports of toxicity testing, or chemical synthesis, or analysis of residues (except when used as a tool for

elucidation of metabolic pathways), or of the efficacy of pesticide treatments. Nevertheless, suitability is based on the purpose or rationale of the study, and not only upon the technique used.

In addition to full-length manuscripts containing original data, the Editor will consider occasional publication of concise reviews describing up-to-date and timely analysis of specific research areas of interest to readers of the journal. The recommended length of each "minireview" is four to seven published pages, including references, presented in a format identical to that used in regular contributions. They will be reviewed for their scientific merit in the same manner as full-length articles.

Contact details for submission

All new manuscripts must be submitted through the *Pesticide Biochemistry and Physiology* online submission and review Web site (<http://www.evis.com/evis/jrnl/PESTBIO>). Authors are requested to submit the text, tables, and artwork in electronic form to this address. Authors are highly encouraged to include a list of three or more potential reviewers for their manuscript, with complete contact information.

Submission checklist

You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.

Ensure that the following items are present:

One author has been designated as the corresponding author with contact details:

- E-mail address
- Full postal address

All necessary files have been uploaded:

Manuscript:

- Include keywords
- All figures (include relevant captions)
- All tables (including titles, description, footnotes)
- Ensure all figure and table citations in the text match the files provided
- Indicate clearly if color should be used for any figures in print

Graphical Abstracts / Highlights files (where applicable)

Supplemental files (where applicable)

Further considerations

- Manuscript has been 'spell checked' and 'grammar checked'
- All references mentioned in the Reference List are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Internet)
- Relevant declarations of interest have been made
- Journal policies detailed in this guide have been reviewed
- Referee suggestions and contact details provided, based on journal requirements

For further information, visit our [Support Center](#).

BEFORE YOU BEGIN

Human and animal rights

If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with [The Code of Ethics of the World Medical Association](#) (Declaration of Helsinki) for experiments involving humans; [Uniform Requirements for manuscripts submitted to Biomedical journals](#). Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

All animal experiments should comply with the [ARRIVE guidelines](#) and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, [EU Directive 2010/63/EU for animal experiments](#), or the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and the authors should clearly indicate in the manuscript that such guidelines have been followed.

Declaration of interest

All authors are requested to disclose any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within three years of beginning the submitted work that could inappropriately influence, or be perceived to influence, their work. [More information](#).

Submission declaration

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see '[Multiple, redundant or concurrent publication](#)' section of our ethics policy for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere including electronically in the same form, in English or in any other language, without the written consent of the copyright-holder.

Changes to authorship

Authors are expected to consider carefully the list and order of authors **before** submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only **before** the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the **corresponding author**: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.

Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors **after** the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

Copyright

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see [more information](#) on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. [Permission](#) of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has [preprinted forms](#) for use by authors in these cases.

For open access articles: Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' ([more information](#)). Permitted third party reuse of open access articles is determined by the author's choice of [user license](#).

Author rights

As an author you (or your employer or institution) have certain rights to reuse your work. [More information](#).

Elsevier supports responsible sharing

Find out how you can [share your research](#) published in Elsevier journals.

Role of the funding source

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

Funding body agreements and policies

Elsevier has established a number of agreements with funding bodies which allow authors to comply with their funder's open access policies. Some funding bodies will reimburse the author for the Open Access Publication Fee. Details of [existing agreements](#) are available online.

Open access

This journal offers authors a choice in publishing their research:

Open access

- Articles are freely available to both subscribers and the wider public with permitted reuse.
- An open access publication fee is payable by authors or on their behalf, e.g. by their research funder or institution.

Subscription

- Articles are made available to subscribers as well as developing countries and patient groups throughout [universal access programs](#).
- No open access publication fee payable by authors.

Regardless of how you choose to publish your article, the journal will apply the same peer review criteria and acceptance standards.

For open access articles, permitted third party (re)use is defined by the following [Creative Commons user licenses](#):

[Creative Commons Attribution \(CC BY\)](#)

Lets others distribute and copy the article, create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), include in a collective work (such as an anthology), text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

[Creative Commons Attribution-NonCommercial-NoDerivs \(CC BY-NC-ND\)](#)

For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

The open access publication fee for this journal is **USD 3000**, excluding taxes. Learn more about Elsevier's pricing policy: <http://www.elsevier.com/openaccesspricing>.

[Green open access](#)

Authors can share their research in a variety of different ways and Elsevier has a number of green open access options available. We recommend authors see our [green open access page](#) for further information. Authors can also self-archive their manuscripts immediately and enable public access from their institution's repository after an embargo period. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and in editor-author communications. Embargo period: For subscription articles, an appropriate amount of time is needed for journals to deliver value to subscribing customers before an article becomes freely available to the public. This is the embargo period and it begins from the date the article is formally published online in its final and fully citable form. [Find out more](#).

This journal has an embargo period of 12 months.

[Elsevier Publishing Campus](#)

The Elsevier Publishing Campus (www.publishingcampus.com) is an online platform offering free lectures, interactive training and professional advice to support you in publishing your research. The College of Skills training offers modules on how to prepare, write and structure your article and explains how editors will look at your paper when it is submitted for publication. Use these resources, and more, to ensure that your submission will be the best that you can make it.

[Language \(usage and editing services\)](#)

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the [English Language Editing service](#) available from Elsevier's WebShop.

[Submission](#)

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

PREPARATION

Use of word processing software

It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the [Guide to Publishing with Elsevier](#)). Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

Line number

Include line numbers in the source file as it is mandatory for submission.

Article structure

Subdivision - numbered sections

Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be given a brief heading. Each heading should appear on its own separate line.

Introduction

State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

Material and methods

Provide sufficient detail to allow the work to be reproduced. Methods already published should be indicated by a reference: only relevant modifications should be described.

Theory/calculation

A Theory section should extend, not repeat, the background to the article already dealt with in the Introduction and lay the foundation for further work. In contrast, a Calculation section represents a practical development from a theoretical basis.

Results

Results should be clear and concise.

Discussion

This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

Conclusions

The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

Appendices

If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.

Essential title page information

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations.** Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lowercase superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. **Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.**
- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

Abstract

A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

Graphical abstract

A Graphical abstract is mandatory for this journal. It should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership online. Authors must provide images that clearly represent the work described in the article. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. You can view [Example Graphical Abstracts](#) on our information site.

Authors can make use of Elsevier's Illustration and Enhancement service to ensure the best presentation of their images also in accordance with all technical requirements: [Illustration Service](#).

Highlights

Highlights are mandatory for this journal. They consist of a short collection of bullet points that convey the core findings of the article and should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point). You can view [example Highlights](#) on our information site.

Keywords

Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

Abbreviations

Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

Acknowledgements

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

Formatting of funding sources

List funding sources in this standard way to facilitate compliance to funder's requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, please include the following sentence:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Units

Follow internationally accepted rules and conventions: use the international system of units (SI). If other units are mentioned, please give their equivalent in SI.

Math formulae

Please submit math equations as editable text and not as images. Present simple formulae in line with normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

Footnotes

Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate the position of footnotes in the text and list the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.

Artwork

Electronic artwork General points

- Make sure you use uniform lettering and sizing of your original artwork.
- Embed the used fonts if the application provides that option.
- Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Provide captions to illustrations separately.
- Size the illustrations close to the desired dimensions of the published version.
- Submit each illustration as a separate file.

A detailed [guide on electronic artwork](#) is available.

You are urged to visit this site; some excerpts from the detailed information are given here. *Formats*

If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format.

Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings, embed all used fonts.

TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.

TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.

TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.

Please do not:

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
- Supply files that are too low in resolution;
- Submit graphics that are disproportionately large for the content.

Color artwork

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. **For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article.** Please indicate your preference for color: in print or online only. [Further information on the preparation of electronic artwork.](#)

Illustration services

[Elsevier's WebShop](#) offers Illustration Services to authors preparing to submit a manuscript but concerned about the quality of the images accompanying their article. Elsevier's expert illustrators can

produce scientific, technical and medical-style images, as well as a full range of charts, tables and graphs. Image 'polishing' is also available, where our illustrators take your image(s) and improve them to a professional standard. Please visit the website to find out more.

Figure captions

Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

Tables

Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules.

References

Citation in text

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

Reference links

Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is encouraged.

A DOI can be used to cite and link to electronic articles where an article is in-press and full citation details are not yet known, but the article is available online. A DOI is guaranteed never to change, so you can use it as a permanent link to any electronic article. An example of a citation using DOI for an article not yet in an issue is: VanDecar J.C., Russo R.M., James D.E., Ambek W.B., Franke M. (2003). Aseismic continuation of the Lesser Antilles slab beneath northeastern Venezuela. *Journal of Geophysical Research*, <http://dx.doi.org/10.1029/2001JB000884i>. Please note the format of such citations should be in the same style as all other references in the paper.

Web references

As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

Data references

This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

References in a special issue

Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

Reference management software

Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support [Citation Style Language styles](#), such as [Mendeley](#) and [Zotero](#), as well as [EndNote](#). Using the word processor plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide.

Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following link:

<http://open.mendeley.com/use-citation-style/pesticide-biochemistry-and-physiology>

When preparing your manuscript, you will then be able to select this style using the Mendeley plugins for Microsoft Word or LibreOffice.

Reference formatting

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:

Reference style

Text: Indicate references by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s) must always be given.

Example: '..... as demonstrated [3,6]. Barnaby and Jones [8] obtained a different result' **List:** Number the references (numbers in square brackets) in the list in the order in which they appear in the text.

Examples:

Reference to a journal publication:

[1] J. van der Geer, J.A.J. Hanraads, R.A. Lupton, The art of writing a scientific article, J. Sci. Commun.163 (2010) 51–59.

Reference to a book:

[2] W. Strunk Jr., E.B. White, *The Elements of Style*, fourth ed., Longman, New York, 2000.

Reference to a chapter in an edited book:

[3] G.R. Mettam, L.B. Adams, How to prepare an electronic version of your article, in: B.S. Jones, R.Z. Smith (Eds.), *Introduction to the Electronic Age*, E-Publishing Inc., New York, 2009, pp. 281–304.

Reference to a website:

[4] Cancer Research UK, Cancer statistics reports for the UK. <http://www.cancerresearchuk.org/aboutcancer/statistics/cancerstatsreport/>, 2003 (accessed 13.03.03).

Reference to a dataset:

[dataset] [5] M. Oguro, S. Imahiro, S. Saito, T. Nakashizuka, Mortality data for Japanese oak wilt disease and surrounding forest compositions, Mendeley Data, v1, 2015. <http://dx.doi.org/10.17632/xwj98nb39r.1>.

Journal abbreviations source

Journal names should be abbreviated according to the [List of Title Word Abbreviations](#).

Video

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats with a preferred maximum size of 150 MB. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including [ScienceDirect](#). Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our [video instruction pages](#). Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

Supplementary material

Supplementary material can support and enhance your scientific research. Supplementary files offer the author additional possibilities to publish supporting applications, high-resolution images, background datasets, sound clips and more. Please note that such items are published online exactly as they are submitted; there is no typesetting involved (supplementary data supplied as an Excel file or as a PowerPoint slide will appear as such online). Please submit the material together with the article and supply a concise and descriptive caption for each file. If you wish to make any changes to supplementary data during any stage of the process, then please make sure to provide an updated file, and do not annotate any corrections on a previous version. Please also make sure to switch off the 'Track Changes' option in any Microsoft Office files as these will appear in the published supplementary file(s). For more detailed instructions please visit our [artwork instruction pages](#).

RESEARCH DATA Data in Brief

Authors have the option of converting any or all parts of their supplementary or additional raw data into one or multiple Data in Brief articles, a new kind of article that houses and describes their data. Data in Brief articles ensure that your data, which is normally buried in supplementary material, is actively reviewed, curated, formatted, indexed, given a DOI and publicly available to all upon publication. Authors are encouraged to submit their Data in Brief article as an additional item directly alongside the revised version of their manuscript. If your research article is accepted, your Data in Brief article will automatically be transferred over to *Data in Brief* where it will be editorially reviewed and published in the new, open access journal, *Data in Brief*. Please note an open access fee is payable for publication in *Data in Brief*. Full details can be found on the [Data in Brief website](#). Please use [this template](#) to write your Data in Brief.

Database linking

Elsevier encourages authors to connect articles with external databases, giving readers access to relevant databases that help to build a better understanding of the described research. Please refer to relevant database identifiers using the following format in your article: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN). [More information and a full list of supported databases](#).

AudioSlides

The journal encourages authors to create an AudioSlides presentation with their published article. AudioSlides are brief, webinar-style presentations that are shown next to the online article on ScienceDirect. This gives authors the opportunity to summarize their research in their own words and to help readers understand what the paper is about. [More information and examples are available](#). Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides presentation after acceptance of their paper.

Interactive plots

This journal enables you to show an Interactive Plot with your article by simply submitting a data file. [Full instructions](#).

AFTER ACCEPTANCE

Online proof correction

Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us

in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

Offprints

The corresponding author will, at no cost, receive a customized [Share Link](#) providing 50 days free access to the final published version of the article on [ScienceDirect](#). The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's [Webshop](#). Corresponding authors who have published their article open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

AUTHOR INQUIRIES

Visit the [Elsevier Support Center](#) to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.

You can also [check the status of your submitted article](#) or find out [when your accepted article will be published](#).

Anexo E: Ficha de identificação botânica- Instituto Agrônomo de Pernambuco (IPA)**HERBÁRIO IPA – DÁRDANO DE ANDRADE LIMA
FICHA DE IDENTIFICAÇÃO BOTÂNICA**

FIB Nº. 06/2013

Nº	Família	Nº IPA	Nome Científico
01	Euphorbiaceae.	84.190	<i>Cnidoscolus urens</i> (L.) Arthur

Material identificado por A.G.Silva.

Dr^a Rita de Cássia Pereira
Curadora do Herbário IPA

Procedência: PE – Caruaru.

Determinada em: Setembro de 2012.

Instituto Agrônomo de Pernambuco - IPA
Vinculado à Secretaria de Agricultura e Reforma Agrária
Av. Gal. San Martin, 1371 – Bongi – 50761-000 – Recife – PE – C.P. 1022
CNPJ 10.912.293/0001-37 – PABX: (81) 3184-7200 – Fax: (81) 3184-7211
Home Page: www.ipa.br / E-mail: ipa@ipa.br

IPA – 77 anos semeando conhecimento